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Combination therapy of multiple drugs with different mechanisms can overcome drug 
resistance, improve safety and efficacy, and thus becomes a promising strategy in cancer 
treatment. However, the difference of physiochemical and pharmacokinetic properties of the 
combined drugs might lead to suboptimal uptake and biodistribution of two drugs at the tumor 
sites. Multifunctional nanocarriers merge as an ideal strategy to circumvent these limitations and 
improve the therapeutic effect of anticancer agents.  
A dual-functional nanocarrier was first developed based on the PEG-conjugated S-trans, 
trans-farnesylthiosalicylic acid (FTS) for delivery of paclitaxel (PTX). FTS is a potent nontoxic 
RAS antagonist. To facilitate the release of FTS from the carrier and improve the drug loading 
capacity and formulation stability, both disulfide linkage and Fluorenylmethyloxycarbonyl 
(Fmoc) group were incorporated to PEG5k-FTS2 to form a PEG5k-Fmoc-S-S-FTS2 micellar 
system. PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles exhibited a superior synergistic therapeutic 
effect in vitro and in vivo. 
Despite the potent therapeutic effect, the drug content from PEG-conjugated prodrug 
nanocarriers is relatively low. In order to solve this problem, drug-based monomer was 
polymerized to increase the number of drug units in each polymer molecule. Here a PPMP-based 
prodrug copolymer micelle (POEG15-b-PPPMP7), in which each carrier molecule contains 7 
units of PPMP, was developed. PPMP is a potent inhibitor of glucosylceramide synthase (GCS), 
the major catabolic enzyme of ceramide. Doxorubicin (DOX)/POEG-b-PPPMP micellar system 
exhibited significantly improved antitumor response in vitro and in vivo. 
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The polymeric prodrug-based carrier strategy was also applied to another drug, 
suberoylanilide hydroxamic acid (SAHA), and developed a well-characterized POEG15-b-
PSAHA12 nanocarrier. SAHA is a histone deacetylase inhibitor (HDACI) approved by FDA. In 
vivo delivery of DOX via POEG-b-PSAHA led to significant inhibition of 4T1.2 tumor growth. 
However, not all targets have small molecule drugs. Better synergism would be achieved 
through the combination of small molecule drugs (for known targets) and gene therapeutics for 
“undruggable” targets. This inspired us to develop a creatine-based polymer (POEG-PCre) for 
the co-delivery of nucleic acids and chemodrugs. POEG-PCre carrier is effective in co-delivery 
of DOX and bioengineered miR-34a to tumor cells and specific accumulation to lung tissue for 
the treatment of breast cancer lung metastasis. 
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1.0 Introduction 
1.1 Combination Therapy for Cancer Treatment 
Cancer is defined as a disease involving abnormal cell growth with the potential to invade 
or spread to other parts of the body. Cancer is among the leading causes of death worldwide 
(World Cancer Report 2019 from the World Health Organization). In 2018, an estimated 1.7 
million new cases will be diagnosed and 0.6 million cancer-related deaths in United States. The 
economic and financial burden for cancer is increasing, with the $147.3 billion national 
expenditures for cancer care in United States in 2017 (date reported by National Cancer 
Institute). Age-standard cancer mortality rates for all types of malignancies have decreased, but 
newer drugs only contribute to a small percentage of this improvement[1]. This is primarily 
because the development of new pharmaceutical anti-cancer agents is laborious and expensive, 
requiring initial in vitro and in vivo experimentation, and subsequent clinical trials before 
receiving FDA approval[2]. It is estimated that a newly designed drug takes 15 years to enter the 
pharmaceutical market[3]. Consequently, it is important to find more efficient methodical 
approaches that are also economically feasible.  
 Owing to the intrinsic heterogeneity and complexity of tumor cells, they have tendency 
to spread beyond its original site and become resistant to certain drugs, and its genetic diversity–
underscores the need for a variety of approaches to attack it[4]. Monotherapy based on a single 
drug has some limitations in cancer treatments, such as limited efficacies, poor tolerability and 
drug resistance[5]. Combination therapy of two or more drugs with different mechanisms can 
overcome these limitations, and thus becomes a cornerstone and standard clinical practice for 
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cancer therapy[6]. Combination therapy targets key pathways in a synergistic or an additive 
manner. This approach potentially reduces drug resistance, while simultaneously providing 
therapeutic anti-cancer benefits, such as reducing tumor growth and metastatic potential, 
arresting mitotically active cells, reducing cancer stem cell populations, and inducing 
apoptosis[2].  
It is well known that the success of combination therapy is largely dependent on the 
choice of drugs. Recently, the focus of drug screening has shifted from traditional 
chemotherapeutic agents to molecular targeted therapeutics, including monoclonal antibodies 
and small molecule inhibitors[7, 8]. Different from traditional chemotherapy acting on all rapidly 
dividing cells, targeted therapy blocks the growth and spread of cancer through interfering with 
specific molecular targets involved in the tumor development and metastasis. The combination 
of targeted therapy and traditional chemotherapy drugs might represent a promising strategy 
against cancers. In this thesis, chemotherapy would be combined with several targeted therapies, 
including RAS inhibitor (FTS), GCS inhibitor (PPMP), HDAC inhibitor (SAHA) and miRNA-
34a. The rational of each combinational regimen will be discussed in the background information 
of each chapter. 
1.2 Nanoparticles for Combination Therapy in Combating Cancer 
1.2.1  Nanomedicine in Cancer Therapy 
Since the last century, tremendous efforts have been made to circumvent the limitations 
of anticancer drugs and maximize its clinical outcomes in cancer treatment. Among them, 
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nanomedicine has gained popularity as an attractive strategy to improve 
physiochemical/pharmacokinetic properties, enhance therapeutic efficacy, and reduce the 
systemic toxicity of a broad variety of anticancer agents[9]. A number of nanocarriers, such as 
polymeric conjugates, liposomes, micelles, dendrimers, nanocrystals, and many others, have 
been developed, and some of them have already been successfully put into market or are under 
clinic trials[10, 11].  
The advantages of nanomedicine over the administration of free anticancer agents include 
enhanced water solubility of hydrophobic agents, increased absorption and bioavailability, 
protection from degradation by the degrading enzymes before reaching the target area, and 
prolonged blood circulation allowing increased accumulation in the tumor site. It has been well-
established that newly formed vasculatures at a tumor site are usually leaky and abnormal in 
architecture. At the same time, lymphatic drainage is usually ineffectively developed in solid 
tumor. Therefore, nanoparticles with a size of 20~200 nm, given adequate circulating time, 
preferentially extravasate into solid tumor tissues, and are retained in tumor at a higher 
concentration over normal tissues. This phenomenon, first discovered by Maeda and 
Matsumura[12], is well known as the enhanced permeability and retention effect (EPR effect) 
and is the physiological basis of the preferential accumulation of nanoparticles in the tumor site 
or “passive targeting.” In addition to passive targeting, the efficiency of selective delivery can be 
further enhanced by attaching a targeting ligand, such as an antibody, small peptide, aptamer, or 
others, onto the surface of nanoparticles. Based on the high affinity between ligands and 
receptors highly expressed on target cells, this “active targeting” strategy further enhances 
recognition and uptake of drug-loaded particles by cancer cells[13, 14]. 
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1.2.2  Nanoparticles for Combination Therapy  
Nanoparticles have recently emerged as a promising class of carriers for the co-delivery 
of multiple drugs. Nanoparticle formulations offer several advantages for multidrug delivery 
compared with administration of free drugs. The low solubility and different pharmacokinetic 
properties of combined drugs will lead to poor uptake and suboptimal dose ratio of the two drugs 
at the tumor sites[15]. Besides, direct use of these drugs via systemic administration might result 
in poor biodistribution and severe systemic toxicities. On the contrary, packing multiple drugs 
into single nanocarriers will enable controlled release of multiple drugs in precisely balanced 
ratios, which can normalize the pharmacokinetics, biodistribution, and stability of chemically 
dissimilar drugs that independently have disparate pharmacological behaviors[16]. In addition, 
stimulus-responsive, targeted carriers in development can co-release drugs in the same organ, 
tissue, or cell, to increase efficacy and to reduce toxicity from off-target exposure.  
 
1.2.3  Polymeric Micelles as an Attractive Approach for Cancer Therapy 
Among a variety of nanocarriers developed in recent decades, micelles are unique and 
appealing due to their high capability to solubilize hydrophobic agents and ease of manipulation. 
More importantly, the small size of micelles, typically below 100 nm, allows for preferential 
accumulation in solid tumor through passive targeting. Micellar systems are usually formed by 
amphipathic molecules, or surfactants, composed of two distinct domains, one being hydrophilic 
and the other hydrophobic. Upon exposure to an aqueous environment, the hydrophobic 
segments are self-assembled into a hydrophobic inner core, surrounded by a corona formed by 
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hydrated hydrophilic domains. This unique core-shell architecture of micelles provides both a 
hydrophobic loading zone for the encapsulation of hydrophobic drugs as well as a hydrophilic 
outer layer to effectively diminish the binding of plasma proteins, nonspecific uptake by the 
reticuloendothelial system (RES), and unwanted self-aggregation with other micelles[17, 18]. A 
minimum concentration of micelle-forming surfactants is required for micelle formation in an 
aqueous medium, which is called the critical micelle concentration (CMC). Micelle-forming 
amphipathic molecules remain as monomers in solution when below the CMC; while above the 
CMC, they are self-assembled into micelles. The CMC is an important parameter of the stability 
of micelles upon dilution. Generally, larger hydrophobic segments lead to a lower CMC value.  
For most of the current micellar systems, drug-loading largely relies on hydrophobic 
interactions between their core-forming hydrophobic segments and the poorly water-soluble 
drugs. Commonly used hydrophobic segments include hydrophobic copolymers, lipids, or other 
small hydrophobic molecules. Polyester and polyamide are two widely used copolymers in 
micelle formulation, such as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and 
poly(L-lysine) (PLL)[19-21]. These materials are able to be gradually degraded in vivo through 
enzyme-assisted hydrolysis of ester or amide bond, and finally excreted out of the body without 
causing toxicity. Besides copolymers, lipids are also used as hydrophobic segments in micelle 
formation. Torchilin’s group has developed a lipid-core micellar system using PEG-
phosphatidylethanolamine (PE) conjugate as surfactant[22-24]. In these systems, a strong 
hydrophobic interaction provided by double acyl chains of PE facilitated the formation of stable 
micelles and encapsulation of a broad spectrum of anticancer agents including paclitaxel (PTX), 
tamoxifen, and camptothecin (CPT)[25, 26]. As for cases of using small molecules as 
hydrophobic segments of surfactants, the PEG-dendritic oligo-cholic acid system would be an 
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excellent example. This so-called amphiphilic telodendrimer system was first developed by 
Lam’s group[27]. In their studies, multiple cholic acids (CA), one of the major bile acids 
produced in the human liver, were conjugated to the terminal of the PEG chain to construct a 
biocompatible copolymer with linear-dendritic architecture. Distinct from other hydrophobic 
molecules, CA has unique facial amphiphilicity, making it an efficient functional building block 
for caging other hydrophobic molecules[28, 29]. Combined with its small particle size (20~60 
nm) and superior stability, this micellar system acts as a promising delivery vector for PTX with 
specific tumor accumulation, low toxicity profiles, and excellent therapeutic efficacy in a nude 
mice model with human ovarian cancer xenograft[30-32]. 
Poly(ethylene glycol) (PEG) is the most commonly utilized hydrophilic segment to 
construct micelle-forming surfactants. The advantages of PEG in pharmaceutical applications 
include high water solubility, neutral charge, low polydispersity index, nontoxicity, low 
immunogenicity, commercial availability, high solubility in most organic solvents, and ease to 
conjugate with other segments[33]. It has been demonstrated that PEGylation effectively 
stabilizes micellar systems, diminishes undesired binding with blood components, and prolongs 
circulation time. Besides micelles, PEG is also widely applied to other delivery systems as 
liposomes, polymer drug conjugates, and PEGylated proteins/peptides[34, 35]. 
1.3 Prodrug-based Dual-functional Nanocarriers for Combination Therapy 
As discussed above, micelles are usually formed by amphipathic molecules composed of 
both a hydrophilic segment, usually PEG, and one or more hydrophobic segments. These 
hydrophobic segments can be hydrophobic copolymers, lipids, or small molecules. Despite the 
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high efficiency in encapsulation of hydrophobic agents, most of the segments are “inert” 
molecules that lack therapeutic effect and potentially impose safety issues[36]. To overcome 
these important obstacles, we developed prodrug-based dual-functional nanocarriers, in which 
the carrier itself is a prodrug exhibits favorable biological activity, at the same time, it could 
serve as the carrier for other hydrophobic anticancer drugs. In our case, the hydrophobic small 
molecule drugs were covalently linked to PEG chain to construct prodrug. This strategy 
improves water solubility, prolonged circulation time, improved pharmacokinetic profile, 
preferential accumulation based on passive targeting or active targeting and reduces adverse 
effects. More interestingly, besides being an effective strategy to improve the performance of 
hydrophobic anticancer agents, the prodrug polymer may also be developed as a potential 
nanocarrier for encapsulation of other chemotherapeutic agents. This dual-function nanocarrier 
not only acts as an efficient delivery system for anticancer agents, but also exhibits anticancer 
activity by itself and, more importantly, synergizes with loaded agents for improved therapeutic 
efficacy and/or reduced side effects.  
1.3.1  PEG-conjugated Prodrug-based Carriers 
One strategy to develop prodrug polymer is conjugating selected numbers of hydrophobic 
anticancer drugs to PEG. In our lab, several PEG-conjugated prodrug-based carriers have been 
developed, such as PEG-vitamin E, PEG-Embelin and PEG-FTS[37-39]. FTS is a potent and 
nontoxic RAS antagonist, leading to RAS dependent tumor regression[40]. Based on its 
hydrophobic nature and a free carboxyl group in its structure, FTS can be easily conjugated to a 
PEG to construct a micelle-forming amphipathic molecule. We first developed a PEG-FTS 
conjugate that consists of a molecule of PEG and two molecules of FTS (PEG5K-FTS2). PEG5K-
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FTS2 conjugates dramatically increased the water solubility of FTS, and self-assembled to nano-
sized (20~30nm) spherical micelles that effectively solubilized other hydrophobic agents as 
PTX[39]. Besides PTX, PEG5K-FTS2 also demonstrated synergistic action with other anticancer 
agents in tumor growth inhibition, such as DOX or curcumin[41]. For further optimization of 
PEG-FTS systems, four different PEG-FTS conjugates were developed and characterized. They 
differed in the molecular weight of PEG (PEG2K vs PEG5K) and the number of FTS molecules 
(FTS2 vs FTS4). The data demonstrated that PEG-FTS conjugates equipped with four FTS 
molecules formed more stable micelles with PTX compared to those with two FTS, and that 
PTX-loaded micelles formed by PEG5K exhibited improved stability over counterparts with 
PEG2K. It is likely that more FTS motifs formed an increased hydrophobic space for 
accommodation of PTX, and a longer chain of PEG more efficiently stabilized these drug-loaded 
nanoparticles. Consistent with these data, PTX/PEG5K-FTS4 micelles showed the slowest 
kinetics of PTX release and were the most potent in inhibiting the tumor cell growth in vitro and 
in vivo[42].  
1.3.2  Polymeric Prodrug-based Carriers 
Despite the potent therapeutic effect, the PEG-conjugated prodrug-based carriers showed 
relatively low drug content in each carrier molecule (PEG5K-FTS2 or PEG5K-FTS4), therefore the 
amounts of drug that can be delivered to tumor tissues are limited, which confines the 
contribution of carrier-associated biological activity to the over-all activity of drug-loaded 
micelles[43]. In addition, recent studies reported that the hydrophobic cores were essential to 
improve the drug loading capacity, formulation stability and slower the drug release[44-46]. 
These inspired us to explore new prodrug micellar systems with increased units of drug per 
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prodrug molecule and larger hydrophobic core.  Generally, the post-modification method was the 
most widely applied approach, by which drugs was chemically attached to a polymer backbone 
to construct prodrug micelles[47, 48]. However, this method often involves additional steps 
which complicated the synthetic process. In addition, due to the steric hindrance, some reactive 
groups might remain in the polymers following conjugation, which might cause the destruction 
of micelle structure or side effects through reacting with bioactive molecules in vivo[49]. 
Recently, polymerization of drug-based monomer has been developed as a facile strategy to 
obtain well-defined prodrug amphiphilic polymers[50, 51].  
We applied this strategy of the polymerization of drug-based monomer to other two 
targeted drugs: PPMP (a GCS inhibitor) and SAHA (a HDAC inhibitor). The drug-based 
monomer with olefin was easily synthesized by conjugating the drug with methacryloyl chloride 
or vinyl benzyl chloride to form a hydrolysable ester linkage. Meanwhile, the macro-chain 
transfer agent POEG was then synthesized by reversible addition-fragmentation transfer (RAFT) 
polymerization of hydrophilic OEGMA monomer, which was further used to initiate the 
polymerization of hydrophobic drug-based monomer and give a well-defined diblock co-
polymers with a hydrophilic POEG block and a hydrophobic drug block. These amphiphilic 
polymers could self-assemble into prodrug micelles and act as the nanocarrier for other 
hydrophobic anticancer drugs. The POEG15-b-PPPMP7 and POEG15-b-PSAHA12 prodrug 
polymers contain 7 units of PPMP and 12 units of SAHA respectively. The increased units of 
hydrophobic drugs in each prodrug polymer could not only decrease the amounts of carrier 
materials in in vivo application by increase the drug loading capacity and micelle stability, but 
also provide better synergistic effect with loaded anticancer drugs. The physiochemical 
properties of two polymeric prodrug-based micelles including size, structure, drug loading and 
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release were evaluated. Moreover, the antitumor activity of carrier alone and drug-loaded 
micelles were investigated in vitro and in vivo.  
1.4 Multi-functional Nanocarriers for Co-delivery of Gene/drug Combination 
Tremendous progress in sequencing thousands of cancer genomes through The Cancer 
Genome Atlas (TCGA) and advances in cancer biology have uncovered many drivers of 
tumorigenesis. Many of the drivers, particularly kinases, have provided druggable targets that 
have yielded significant clinical benefits over the past several decades. However, not all proteins 
are suitable for drug interactions and even fewer are appropriate drug targets, owing to large 
protein–protein interaction (PPI) interfaces or their lack of deep protein pockets. In this situation, 
gene therapy may play more important role in drugging the “undruggable” targets. 
Gene therapy involves the delivery of plasmid DNA (pDNA), small interfering RNA 
(siRNA), short hairpin RNA (shRNA) or micro RNA (miRNA) to modulate the expression of 
specific gene or proteins, which has the potential advantages to target any disease related gene.  
Cancer gene therapy usually works through either upregulating tumor suppressor gene and 
cytotoxic immune cytokines or downregulating the oncogenes and genes involved in tumor cell 
drug resistance. The use of combination therapy involving both gene therapy and chemotherapy 
has resulted in combinational effect and has become an increasingly important strategy for the 
future.  
However, the physiochemical properties of chemotherapeutic agents and nucleic acids 
are totally different: most anticancer drugs are small molecule with poor water solubility, while 
nucleic acids are polyanionic molecules with high molecular weight, high water solubility and 
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low stability. It is significantly challenging to develop a dependable system to co-deliver both 
therapeutics to the target organs, tissues and cells. Most carriers reported so far are designed for 
the separate delivery of small molecule drugs or nucleic acid therapeutics, which would have 
different pharmacokinetics and pharmacodynamics properties and can hardly achieve 
combinational effects[52, 53] Some carriers such as liposomes, polymeric nanoparticles and 
micelles were developed for codelivery of the two different types of therapeutics but they often 
involved complicated preparation process[54]. Herein, we report a novel nanocarrier (POEG-
PCre) for co-delivery DOX and bioengineered miR-34a prodrug, based on the built-in blocks of 
naturally occurring cationic molecule—creatine. Stable and nanosized micelles co-loaded with 
DOX and tRNA-mir-34a could be simply prepared and were highly effective in targeted delivery 
of payloads to lungs. Significantly improved antitumor activity was demonstrated with 
codelivery of DOX and miR-34a prodrug in comparison with other control groups in a 4T1.2 
lung metastasis model. POEG-PCre may represent a simple and effective delivery system for an 
optimal chemo-gene combination therapy. 
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2.0 An Improved PEG-FTS Conjugate as a Dual Functional Nanocarrier for Enhanced 
Delivery of Paclitaxel 
2.1 Abstract 
We have previously improved the bioactivity of PEG5k-FTS2 system by incorporating 
disulfide bond (PEG5k-S-S-FTS2) to facilitate the release of Farnesyl thiosalicylic acid 
(FTS)[55]. Later, Fluorenylmethyloxycarbonyl (Fmoc) moiety has been introduced to PEG5k-
FTS2 system (PEG5k-Fmoc-FTS2) in order to enhance drug loading capacity (DLC) and 
formulation stability[56]. In this study, we have brought in both disulfide linkage and Fmoc 
group to PEG5k-FTS2 to form a simple PEG5k-Fmoc-S-S-FTS2 micellar system. PEG5k-Fmoc-S-
S-FTS2 conjugate formed filamentous micelles with a ~ ten-fold decrease in critical micellar 
concentration (CMC). Compared with PEG5k-Fmoc-FTS2, our novel system exhibited further 
strengthened DLC and colloidal stability. More FTS was freed from PEG5k-Fmoc-S-S-FTS2 in 
treated tumor cells compared to PEG5k-Fmoc-FTS2, which was correlated to an increased 
cytotoxicity of our new carrier in these cancer cells. After loading Paclitaxel (PTX) into PEG5k-
Fmoc-S-S-FTS2 micelles, it showed more potent efficiency in inhibition of tumor cell 
proliferation than Taxol® and PTX-loaded PEG5k-Fmoc-FTS2. PTX release kinetics of 
PTX/PEG5k-Fmoc-S-S-FTS2 was much slower than that of Taxol® and PTX/PEG5k-Fmoc-FTS2 
in normal release medium. In contrast, in glutathione (GSH)-containing medium, PTX in PEG5k-
Fmoc-S-S-FTS2 micelles revealed faster and more complete release. Pharmacokinetics and tissue 
distribution study showed that our PEG5k-Fmoc-S-S-FTS2 system maintained PTX in circulation 
for a longer time and delivered more PTX to tumor sites with less accumulation in major organs. 
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Finally, PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles resulted in a superior therapeutic effect in 
vivo compared to Taxol® and PTX formulated in PEG5k-Fmoc-FTS2 micelles. 
2.2 Background 
Micelles are a promising delivery system for anticancer drugs due to their ability to solubilize 
hydrophobic drugs[57], small size[58], prolonged retention in the blood[59], enhanced tumor 
penetration[60] and ease in preparation[61].  Among all micellar systems, PEG-derivatized 
micellar systems impede the recognition and binding of plasma proteins, further preventing 
reticuloendothelial system (RES) surveillance and rapid elimination of nanoparticles[34, 62, 63]. 
Biologically active carrier, in which small molecules with therapeutic effect are conjugated with 
PEG, is an attractive and unique strategy since these bioactive molecules could achieve the 
additive or synergistic effect with co-delivered anticancer drugs[64-66]. Our group previously 
developed PEG5k-FTS2 to load Paclitaxel (PTX), which exhibited enhanced antitumor efficiency 
compared to Taxol® formulation in vitro and in vivo[39]. FTS is a farnesyl mimic and an 
antagonist of RAS protein[67]. Mutations of the K-Ras gene occur in over 90% of pancreatic 
carcinomas and 20 to 25% of all human tumors[68, 69]. FTS competes with active RAS for 
binding to the docking protein on the cell membrane, leading to RAS dislodgement from the cell 
membrane and degradation[70]. FTS has shown promising results in clinical trials for several 
types of cancers, including phase I studies in refractory hematologic malignancies and 
elapsed/refractory solid tumors as well as phase II studies in pancreatic cancer and KRAS mutant 
lung adenocarcinoma. The results of most clinical trials showed that FTS was well tolerated and 
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showed insufficient or modest activity in those patients as a single therapy, and therefore 
suggested FTS to be utilized in combination therapy[71-74]. 
 
To facilitate the effective release of FTS from the carrier, PEG5K-S-S-FTS2 was then 
developed in our group[55]. Disulfide bond could be readily reduced by the glutathione[75, 76]. 
It has been reported that the GSH concentration in tumor tissue was four times higher than that in 
normal tissue[77]. In addition, the intra-cellular concentration of GSH (2-10 mM) is a thousand-
fold higher than that in blood or extra-cellular matrix (2-20 µM)[78, 79]. Hence, PEG5K-S-S-
FTS2 micelles possess a unique advantage that they are stable in the circulation but rapidly 
release FTS and loaded PTX upon reaching the tumor tissue/cells. Our data showed that the 
incorporation of a disulfide bond into PEG5k-FTS2 resulted in an improved FTS release in 
cultured tumor cells, and enhanced inhibition of the proliferation of these tumor cells. More 
importantly, PTX-loaded PEG5K-S-S-FTS2 formulation revealed a significantly enhanced 
inhibition of tumor growth than the PEG5k-FTS2 formulation in a murine breast cancer model 
(4T1.2)[55]. 
 
Another independent strategy to improve the formulation stability and loading capacity of 
PEG5k-FTS2 micelles was to incorporate a 9-fluorenylmethoxycarbony (Fmoc) moiety at the 
interfacial region between hydrophilic PEG segment and hydrophobic FTS domain[56]. The 
Fmoc carbamate, with an aromatic ring, is often used as an amine protecting group in peptide 
synthesis[80]. By including Fmoc moiety in PEG5k-FTS2 conjugate, we provided an additional 
mechanism of drug/carrier interaction (π-π stacking interaction) besides hydrophobic interaction 
between hydrophobic FTS and loaded hydrophobic anticancer drugs[81, 82]. The enhancement 
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of drug/carrier interaction shall enable the carrier more effective in loading more drugs (higher 
drug loading capacity) and in stabilizing loaded drugs in circulation (excellent colloidal 
stability)[83]. Indeed, DOX loaded in PEG5k-Fmoc-FTS2 showed sustained release kinetics, 
which was slower than that of PEG5k-FTS2 formulation. In addition, pharmacokinetics and 
biodistribution study exhibited prolonged circulation of DOX/PEG5k-Fmoc-FTS2 in the blood 
and enhanced DOX accumulation at tumor sites. More importantly, PTX or DOX formulated in 
PEG5k-Fmoc-FTS2 led to significantly improved antitumor activities over those drugs formulated 
in PEG5k-FTS2 in a breast cancer or prostate cancer model[56]. 
 
In this study, we incorporated both disulfide and Fmoc into PEG5k-FTS2 system to gather 
the merits from both of them but overcome the demerits from each of them. Our data showed 
that PEG5k-Fmoc-S-S-FTS2 exhibited a further decrease of CMC and an improvement in both 
drug loading capacity and formulation stability compared to PEG5k-Fmoc-FTS2. PEG5k-Fmoc-S-
S-FTS2 was more effective in FTS release inside tumor cells than PEG5k-Fmoc-FTS2, which 
likely contributed to the increased cytotoxicity of the new carrier. Pharmacokinetics and 
biodistribution study showed that PTX/PEG5k-Fmoc-S-S-FTS2 was stable in the blood and was 
more effective than PTX/PEG5k-Fmoc-FTS2 in mediating selective delivery of PTX to tumor 
tissues. More importantly, PTX/PEG5k-Fmoc-S-S-FTS2 was significantly more effective than 
PTX/PEG5k-Fmoc-FTS2 and Taxol® in antitumor activity in a murine breast cancer model. 
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2.3 Experiment Procedures 
2.3.1  Materials 





-(tert-butoxycarbonyl)-L-lysine (Fmoc-lysine(Boc)-OH) were 
purchased from GL Biochem (Shanghai, China). Poly (ethylene glycol) methyl ether 
(MeO−PEG−OH, MW = 5000kDa), dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-
2,5- diphenyl tetrazolium bromide (MTT), and Dulbecco’s Modified Eagle’s Medium (DMEM) 
were all purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) and 
penicillin−streptomycin solution were purchased from Thermo Fisher Scientific (Waltham, MA). 
Dicyclohexylcarbodiimide (DCC) was purchased from Alfa Aesar (Ward Hill, MA). 4- 
(dimethylamino) pyridine (DMAP) was purchased from Calbiochem-Novabiochem Corporation 
(San Diego, CA). Paclitaxel (98%) was purchased from AK Scientific Inc. (Union City, CA).  
All solvents used in this study were of HPLC grade. 
2.3.2  Synthesis of PEG5k-Fmoc-S-S-FTS2 Conjugate 
PEG5k-Fmoc-S-S-FTS2 conjugates were synthesized via solution phase condensation 
reaction as shown in Figure 2-1. 
Compound 1: MeO-PEG5k-OH (5g, 1.0 mmol, 1.0 eq), Fmoc-Lys (Boc)-OH (1.2g, 2.5 
mmol, 2.5 eq), DCC (515 mg, 2.5 mmol, 2.5 eq) and DMAP (37mg, 0.3 mmol, 0.3 eq) were 
dissolved in DCM and stirred at room temperature for two days. The mixture was filtered 
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through cotton and then purified through two cycles of dissolution/precipitation with DCM/ether 
and DCM/ethanol respectively to afford Compound 1 (4.5 g, 0.82 mmol, 82% yield). 
Compound 2: Compound 1 (MeO-PEG5k-Fmoc-lysine-Boc) (4.5g, 0.8 mmol) was 
dissolved in 20 mL mixture of trifluoroacetic acid (TFA)/DCM (1:1, v/v). The mixture was 
stirred for 2 hours at room temperature and purified through two cycles of 
dissolution/precipitation with DCM/ether to give Compound 2 (4.0 g, 0.75 mmol, 91% yield). 
Compound 3: Compound 2 (MeO-PEG5k-Fmoc-lysine) (4.0 g, 0.8 mmol), Boc-Lys 
(Boc)-OH (692 mg, 2.0 mmol, 2.5 eq), DCC (412 mg, 2.0 mmol, 2.5 eq) and DMAP (29 mg, 
0.24 mmol, 0.3 eq) were dissolved in DCM and stirred at room temperature for two days. The 
mixture was filtered through cotton and then purified through two cycles of 
dissolution/precipitation with DCM/ether and DCM/ethanol respectively to afford Compound 3 
(4.5 g, 0.79 mmol, 84% yield). 
Compound 4: Compound 3 (MeO-PEG5k-Fmoc-lysine-lysine-diBoc) was dissolved in 20 
mL mixture of trifluoroacetic acid (TFA)/DCM (1:1, v/v). The mixture was stirred for 2 hours at 
room temperature and purified through similar steps as described above to afford Compound 4 
(3.8g, 0.69 mmol, 87% yield). 
Compound 5: Compound 5 was synthesized following a published method.[39] 
Compound 6: Compound 5 (FTS) (3.6 g, 10 mmol), Bis(2-hydroxyethyl) disulfide (1.5 
g, 10 mmol, 1.0 eq), DCC (3.1 g, 15 mmol, 1.5 eq) and DMAP (122 mg, 1 mmol, 0.1 eq) were 
dissolved in DCM and stirred at room temperature until TLC showed completion of the reaction. 
The mixture was filtered through cotton and the filtrate was concentrated on a rotary evaporator. 
The residue was chromatographed (1:4 EtOAC/PE) on silica gel to afford Compound 6 (3.2 g, 
6.5 mmol, 65% yield). 
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Compound 7: Compound 6 (FTS-S-S-OH) (3.2 g, 6.5 mmol), succinic anhydride (1.3 g, 
13.0 mmol) and DMAP (1.6 g, 13.0 mmol) was dissolved in DCM and refluxed at 50 °C until 
TLC showed completion of the reaction. The mixture was concentrated on a rotary evaporator 
and the residue was chromatographed (1:1 EtOAc/PE) on silica gel to afford the Compound 7 
(5.8 g, 6.5 mmol, 97% yield). 
Compound 8: Compound 4, Compound 7, DCC and DMAP were dissolved in DCM 
with a molar ratio of 1:6:6:0.3 and stirred at room temperature for two days. The mixture was 
filtered through cotton and then purified through two cycles of dissolution/precipitation with 
DCM/ether and DCM/ethanol respectively to afford Compound 8 (3.90g, 0.59 mmol, 85% 
yield).  
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Figure 2-1. Synthesis of PEG5K-Fmoc-S-S-FTS2 conjugate 
2.3.3  Preparation and Characterization of PTX-Loaded PEG5k-Fmoc-S-S-FTS2 Micelles 
PTX (10 mM in chloroform) was mixed with PEG5k-Fmoc-S-S-FTS2 (10 mM in 
chloroform) at various carrier/drug molar ratios. The chloroform was removed by nitrogen flow 
to produce a thin film of drug/carrier, which was further dried under high vacuum for 2 h to 
remove any trace of remaining solvent. Then, the thin film was hydrated and vortexed in saline 
to form PTX-loaded micelles. The PTX-free micelles were prepared similarly as described 
above. 
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The particle size and the size distribution of micelles were examined via a Zetasizer 
(DLS). The morphology of drug-free or PTX-loaded PEG5k-Fmoc-S-S-FTS2 was observed using 
transmission electron microscopy (TEM). The drug loading efficiency was examined by high-
performance liquid chromatography (HPLC) as described in a previous publication[65]. DLC 
and drug loading efficiency (DLE) were calculated according to the following equation[65]: 
DLC %= [weight of drug loaded/(weight of carrier used + weight of drug used)]×100%, DLE 
%= (weight of loaded drug/weight of input drug)×100 %. The colloidal stability of drug-loaded 
micelles with various carrier/drug molar ratios was evaluated by following the changes in sizes 
of the particles or visible precipitates every hour in the first 12 h and daily after 12 h following 
sample preparation at room temperature. CMC of PEG5k-Fmoc-S-S-FTS2 was determined using 
pyrene as a fluorescence probe as described[84]. 




 cells/well), PC-3 (5×10
3
 cells/well) or 4T1.2 (1×10
3
 cells/well) cells were 
seeded in 96-well plates followed by 24 h of incubation in DMEM with 10% FBS and 1% 
streptomycin/penicillin. For drug-free micelles, after removing old medium, various 
concentrations of PEG5k-Fmoc-S-S-FTS2, PEG5k-Fmoc-FTS2 and free FTS were added in 
triplicate and cells were incubated for another 72h. The medium was then removed and 100 μL 
of MTT in PBS (0.5 mg/mL) was added. Four h later, the medium was removed and the MTT 
formazan was solubilized by DMSO. The absorbance of each well was measured by a 
microplate-reader, with wavelength at 550 nm and reference wavelength at 630 nm. Untreated 
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groups were included as controls. Cell viability was calculated as [ODtreat-ODblank)/(ODuntreat-
ODblank) ×100%]. The cytotoxicity of PTX/PEG5k-Fmoc-S-S-FTS2, PTX/PEG5k-Fmoc-FTS2 and 
Taxol® was also similarly tested. 
2.3.5  Release of FTS from PEG5k-Fmoc-S-S-FTS2 inside Tumor Cells 
DU-145 (1.6×104 cells/well), PC-3 (4×104 cells/well) or 4T1.2 (8×103 cells/well) cells 
were seeded in 6-well plates followed by 24 h of incubation in DMEM with 10% FBS and 1% 
streptomycin/penicillin. After removing the old medium, PEG5k-Fmoc-S-S-FTS2 and PEG5k-
Fmoc-FTS2 were added to tumor cells in triplicate and cells were incubated for 72h. Then, iced-
cold PBS was added to wash the cells for three times and a mixture of MeOH/H2O (1:1) was 
added to solubilize those cells. The lysates were collected and centrifuged at 14,000 rpm for 10 
min at 4 °C. Supernatant was harvested for UPLC/MS analysis as described before[55]. 
2.3.6  In Vitro PTX Release from PTX/PEG5k-Fmoc-S-S-FTS2  
One mL of PTX/PEG5k-Fmoc-S-S-FTS2, PTX/PEG5k-Fmoc-FTS2 and Taxol® at a PTX 
concentration of 1mg/mL were placed into dialysis bags (MWCO=12 kDa) in triplicate and 
incubated in 200 mL release medium at 37 °C with gentle shaking. Both normal release medium 
(DPBS containing 0.5% (w/v) Tween 80) and GSH-containing release medium (normal release 
medium with 10 mM GSH) were used. Twenty μL of liquids were taken from dialysis bags at 
0.5, 1, 2, 4, 6, 8, 12, 24 and 48h. After lyophilization, methanol was added to each tube to 
solubilize PTX and the concentration of PTX was measured by HPLC with the detection 
wavelength at 227 nm.  
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2.3.7  Plasma Pharmacokinetics and Tissue Distribution of PTX-loaded PEG5k-Fmoc-S-S-
FTS2 
For plasma pharmacokinetics, PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles, PTX-loaded 
PEG5k-Fmoc-FTS2 micelles or Taxol® were injected into tumor-free female BALB/c mice via 
tail-vein at a PTX dose of 10 mg/kg. Five mice were used in each group. Blood samples were 
collected in heparinized tubes at designated time points (3min, 10min, 30min, 1h, 2h, 4h, 8h and 
12h post injection). Samples were centrifuged at 12,500 rpm for 10min at 4 °C and 20 μL of the 
supernatant were collected. Then 350 μL acetonitrile was added and samples were centrifuged at 
12,500 rpm for 5 min at 4 °C. The supernatant was transferred to clean tubes and dried under 
nitrogen flow. Then the residue was dissolved in 200 μL methanol and centrifuged at 12,500 rpm 
for 5 min at 4 °C. Fifty μL of the clear supernatant was collected and injected into HPLC for 
PTX analysis. Noncompartmental pharmacokinetic analysis was executed by WinNonlin.  
 
For tissue distribution study, PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles, PTX-loaded 
PEG5k-Fmoc-FTS2 micelles or Taxol® were i.v. injected into mice bearing 4T1.2 tumors of 400–
600 mm
3
 at a PTX dose of 10 mg/kg. Mice were sacrificed 24 h post injection. Major organs 
(including heart, liver, spleen, lung and kidney) and tumors were harvested, weighed, and stored 
at -80°C. The samples were similarly processed for PTX assays as described above. 
  40 
2.3.8  In Vivo Therapeutic Study 
An aggressive murine breast cancer model (4T1.2) was used to evaluate the antitumor 
efficacy of PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles. 4T1.2 cells (2×10
5
 in 200 μL PBS) 
were inoculated s.c. at the right flank of female BALB/c mice. Once tumor volume reached 
~50mm
3
, treatments were initiated and this day was marked as day 1. On this day, mice were 
randomly divided into six groups with five mice in each group, and treated via tail vein injection 
with PBS, drug-free PEG5k-Fmoc-S-S-FTS2 micelles, drug-free PEG5k-Fmoc-FTS2 micelles, 
PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles, PTX-loaded PEG5k-Fmoc-FTS2 micelles or 
Taxol® at a PTX dose of 10 mg/kg respectively. The treatment was performed on days 1, 3, 5, 7, 
10 and 13. Tumor size was measured with the digital caliper three times a week and calculated 
by the formula: (L×W
2
)/2, where L is the longest and W is the shortest in tumor diameters (mm). 
The body weights of all mice from each group were measured at the day of each treatment. Mice 
were sacrificed when the ulceration developed or the tumor size reached ~2000 mm
3
. Tumors 
were weighed at the end of experiment. 
2.4 Results 
2.4.1  Synthesis and Biophysical Characterization of PEG5k-Fmoc-S-S-FTS2 
PEG5k-Fmoc-S-S-FTS2 was synthesized by conjugating FTS-S-S-COOH with a 
PEG5K-Fmoc scaffold (Figure 2-1). Briefly, Fmoc-lys-(Boc) and Boc-lys-(Boc) were 
sequentially linked   to PEG5K by the condensation reaction to afford PEG5k-Fmoc-lysine. At 
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the same time, FTS-S-S-COOH was synthesized via the reaction of FTS with 2,2'-
disulfanediylbis(ethan-1-ol) followed by the reaction with succinic anhydride. The synthetic 
route is shown in Scheme 1. The structure of PEG5k-Fmoc-S-S-FTS2 was confirmed by 1H-
NMR (Figure 2-2). The peaks at 3.3 ppm were assigned to the methoxy group on the end of 
PEG, and the intense peaks at 3.5 ppm were attributed to the methane protons of PEG chain. The 
peaks between 7.0 and 8.0 ppm corresponded to the aromatic rings of Fmoc group and benzyl 




H-NMR of PEG5k-Fmoc-S-S-FTS2 conjugate 
 
PEG5k-Fmoc-S-S-FTS2 readily formed a transparent dispersion in water. The 
hydrodynamic size of drug-free (Figure 2-3A) and PTX-loaded (Figure 2-3C) PEG5k-Fmoc-S-S-
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FTS2 examined by DLS was around 60 nm. TEM showed elongated, wormlike structure with a 
uniform size distribution, which was consistent with DLS (Figure 2-3B and C), whereas PEG5k-
FTS2 micelles[39] and PEG5k-Fmoc-FTS2 micelles[56] listed in Table 1 possessed spherical 
structures. The size, DLC and formulation stability of PTX-loaded PEG5k-Fmoc-S-S-FTS2 
micelles were then examined and compared to those of PEG5k-Fmoc-FTS2 and PEG5k-FTS2 
formulations (Table 2-1). PTX could be loaded into PEG5k-Fmoc-S-S-FTS2 micelles at a 
carrier/drug ratio as low as 0.25:1. On the contrary, PEG5k-Fmoc-FTS2 could only load PTX at a 
carrier/drug ratio of 0.5:1 or higher. For PEG5k-FTS2, an even higher carrier/drug ratio (2.5:1) 
was needed to formulate PTX (Table 1). Incorporation of PTX into micelles only resulted in a 
slight increase in particle sizes for all of the three formulations (Table 2-1). The colloidal 
stability of PTX-loaded micelles was examined by following the changes in sizes at different 
times after preparation. With an increase in the carrier/drug ratio, the stability was also 
significantly improved for all of the three formulations. Overall, the stability of the three 
formulations follow the order of PTX/PEG5k-Fmoc-S-S-FTS2 > PTX/PEG5k-Fmoc-FTS2 > 
PTX/PEG5k-FTS2 under all carrier/drug ratios examined (Table 2-1). A carrier/drug molar ratio 
of 5:1 was used for all subsequent study. 
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Figure 2-3. Particle size distribution of drug-free PEG5k-Fmoc-S-S-FTS2 micelles (A) and PTX-loaded PEG5k-
Fmoc-S-S-FTS2 micelles (C). TEM images of drug-free PEG5k-Fmoc-S-S-FTS2 micelles (B) and PTX-loaded 
PEG5k-Fmoc-S-S-FTS2 micelles (D). 
 
Table 2-1 Characterization of drug-free and PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles 
Micelles Molar 
ratio 
   Conc.of         




















PEG5K-FTS2  - - 17.6±0.2 0.20 - - - 
PEG5K-FTS2: PTX 2.5:1 1 24.9±0.7 0.35 4.5 81.2 2 
PEG5K-FTS2: PTX 5:1 1 25.6±0.4 0.23 2.8 97.6 20 
PEG5K-Fmoc-FTS2  - - 24.8±0.5 0.22   - 
PEG5K-Fmoc-FTS2: 
PTX 
0.5:1 1 36.2±0.6 0.19 12.1 55.4 12 
PEG5K-Fmoc-FTS2: 
PTX 
1:1 1 29.4±0.7 0.11 9.0 73.2 15 
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PEG5K-Fmoc-FTS2: 
PTX 
2.5:1 1 29.7±0.9 0.12 4.6 87.3 17 
PEG5K-Fmoc-FTS2: 
PTX 
5:1 1 25.0±0.3 0.27 2.6 96.0 48 
PEG5K-Fmoc-S-S-
FTS2 
- - 94.5±2.8 0.20 - -  
PEG5K-Fmoc-S-S-
FTS2: PTX 
0.25:1 1 108.1±5.4 0.26 34.0 53.5 3 
PEG5K-Fmoc-S-S-
FTS2: PTX 
0.5:1 1 116.7±6.2 0.26 20.5 67.6 12 
PEG5K-Fmoc-S-S-
FTS2: PTX 
1:1 1 112.3±4.7 0.24 11.4 86.3 18 
PEG5K-Fmoc-S-S-
FTS2: PTX 
2.5:1 1 117.0±6.1 0.23 4.9 90.2 24 
PEG5K-Fmoc-S-S-
FTS2: PTX 
5:1 1 105.6±4.3 0.23 2.5 98.8 72 
a
PTX concentration in micelle was kept at 1 mg/mL. Blank micelle concentration was 20 mg/mL. 
b
The size of drug-
free or PTX-loaded PEG5K-FTS2 and PEG5K-Fmoc-FTS2 was measured directly by Zetasizer. The size of drug-free 
or PTX-loaded PEG5K-Fmoc-S-S-FTS2 were calculated according to Stokes-Einstein equation: Leff= kT/(2πηD), 
where k is the Boltzmann constant (1.38 *10
-23
 J/K), T is the temperature (298.15 K), η is the viscosity of the 
solution (0.8872 mPaIs from DLS), D is the diffusion coefficient examined by DLS. 
c
PDI = polydispersity index. 
d)
DLC = drug loading capacity. 
e
DLE = drug loading efficiency. 
f
Data mean there was no noticeable size change and 
visible precipitates during the follow-up period at room temperature. 
The CMC of PEG5k-Fmoc-S-S-FTS2 micelles was determined by a rapid change of fluorescence 
intensity of loaded pyrene probe during serial dilution. Compared to that of PEG5k-Fmoc-FTS2 
(0.001 mg/mL, 0.17 μM) and PEG5k-S-S-FTS2 (0.0007 mg/mL, 0.20 μM), PEG5k-Fmoc-S-S-
FTS2 showed a 10-fold decrease in its CMC (0.0002 mg/mL, 0.02 μM) (Figure 2-4).  
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Figure 2-4. CMC of PEG5k-Fmoc-S-S-FTS2 (A), PEG5k-Fmoc-FTS2 (B), PEG5k-S-S-FTS2 (C) and PEG5k-FTS2 
(D) micelles. 
2.4.2  In Vitro Cytotoxicity Assay of Drug-free Micelles  
The cytotoxicity of drug-free PEG5k-Fmoc-S-S-FTS2 micelles was tested in DU-145, PC-
3 or 4T1.2 cancer cells and compared to that of free FTS and PEG5k-Fmoc-FTS2 (Figure 2-5A, B 
and C). Compared to free FTS, both PEG5k-Fmoc-FTS2 and PEG5k-Fmoc-S-S-FTS2 showed less 
cytotoxicity. It was also apparent that PEG5k-Fmoc-S-S-FTS2 was more active than PEG5k-
Fmoc-FTS2 in cytotoxicity in all of three cell lines tested. The improvement of cytotoxicity of 
PEG5k-Fmoc-S-S-FTS2 may be ascribed to the more effective cleavage of disulfide bond and the 
release of more FTS in treated tumor cells. 
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Figure 2-5. Cytotoxicity of drug-free PEG5k-Fmoc-S-S-FTS2 and PEG5k−Fmoc−FTS2 micelles compared to 
free FTS against human prostate cancer cell lines DU-145 (A), PC-3 (B) and mouse breast cancer cell line 
4T1.2 (C). 
2.4.3  Release of FTS from PEG5k-Fmoc-S-S-FTS2 Inside tumor cells 
To examine if the enhanced cytotoxicity of PEG5k-Fmoc-S-S-FTS2 is attributed to a more 
effective FTS release, we examined the amount of free FTS in PC-3, DU145 and 4T1.2 cancer 
cells by UPLC-MS, 72h following treatment with PEG5k-Fmoc-S-S-FTS2. As shown in Figure 5, 
the FTS signals in PEG5k-Fmoc-S-S-FTS2-treated cells were 2-3 times of that in PEG5k-Fmoc-
FTS2-treated DU-145 (Figure 2-6A) and PC-3 (Figure 2-6B) cells. In murine breast cancer cells 
4T1.2 (Figure 2-6C), the amount of FTS released from PEG5k-Fmoc-S-S-FTS2 was about 1.6 
times of that released from PEG5k-Fmoc-FTS2.  
 
Figure 2-6. UPLC/MS analysis of the amounts of released parent FTS from tumor cells. 
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Human prostate cancer cell lines DU-145 (A), PC-3 (B) and mouse breast cancer cell line 4T1.2 (C) were treated 
with PEG5k-Fmoc-S-S-FTS2 or PEG5k−Fmoc−FTS2 micelles at a FTS concentration of 20 μM for 72 h. Values 
reported are the means ± SD for triplicate samples. Significance was determined by one-way ANOVA with Fisher’s 
post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001 (PTX/PEG5k-Fmoc-S-S-FTS2 vs. PTX/PEG5k-Fmoc-FTS2). 
2.4.4  In Vitro Cytotoxicity of Drug-Loaded Micelles 
The in vitro cytotoxicity of PTX loaded in PEG5k-Fmoc-S-S-FTS2 and PEG5k-Fmoc-FTS2 
micelles was tested in comparison with Taxol® formulation in DU-145 (Figure 2-7A), PC-3 
(Figure 2-7B) and 4T1.2 (Figure 2-7C) cells. Taxol® inhibited the cell proliferation in a dose-
dependent manner. PTX formulated in PEG5k-Fmoc-FTS2 exhibited increased cytotoxicity over 
Taxol®. More importantly, PTX loaded in PEG5k-Fmoc-S-S-FTS2 was more potent in killing 
tumor cells than both Taxol® and PTX-loaded PEG5k-Fmoc-FTS2 micelles in PC-3, DU-145 and 
4T1.2 cells, especially at low PTX doses. Both PEG5k-Fmoc-FTS2 and PEG5k-Fmoc-S-S-FTS2 
blank micelles showed minimal cytotoxicity at the same carrier concentrations as those used in 
drug-loaded micelles. 
 
Figure 2-7. Cytotoxicity of drug-free PEG5k-Fmoc-FTS2, drug-free PEG5k-Fmoc-S-S-FTS2, PTX-loaded 
PEG5k-Fmoc-FTS2 and PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles compared to Taxol® formulation against 
human prostate cancer cell lines DU-145 (A), PC-3 (B) and mouse breast cancer cell line 4T1.2 (C). 
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Values reported are the means ± SD for triplicate samples. Significance was determined by one-way ANOVA with 
Fisher’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001 (PTX/PEG5k-Fmoc-S-S-FTS2 vs. PTX/PEG5k-Fmoc-
FTS2). #P< 0.05, ##P < 0.01, ###P < 0.001 (PTX/PEG5k-Fmoc-S-S-FTS2 vs. Taxol®). &P< 0.05, &&P < 0.01, 
&&&P < 0.001 (PTX/PEG5k-Fmoc-FTS2 vs. Taxol®). 
2.4.5  In Vitro PTX Release from PEG5k-Fmoc-S-S-FTS2  
The in vitro PTX release from PEG5k-Fmoc-S-S-FTS2 in PBS with or without GSH was 
examined by a dialysis method and compared to that of PTX-loaded PEG5k-Fmoc-FTS2 and 
Taxol®. In the normal release medium (Figure 2-8A), PTX release from PEG5k-Fmoc-S-S-
FTS2/PTX was slower than that from PEG5k-Fmoc-FTS2 /PTX and Taxol®. After 8 hours, 40.6% 
of PTX was released from PEG5k-Fmoc-FTS2 formulation, while only 24.0% of PTX was 
released from PEG5k-Fmoc-S-S-FTS2 micelles. In a separate experiment, in order to simulate the 
tumor microenvironment, GSH was added to the release medium to a final concentration of 10 
mM. Under this condition, the release of PTX from PEG5k-Fmoc-S-S-FTS2 formulation was 
faster than that from PEG5k-Fmoc-FTS2 and Taxol® formulations (Figure 2-8B). For the initial 8 
hours, 74.0% of PTX has already been released from PEG5k-Fmoc-S-S-FTS2, a 28% increase 
over PEG5k-Fmoc-FTS2 formulation. It was also noted that the release of PTX from PEG5k-
Fmoc-FTS2 and Taxol® was not significantly affected by the GSH in release medium. 
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Figure 2-8. Cumulative PTX release profile from Taxol®, PTX-loaded PEG5k-Fmoc-FTS2 and PTX-loaded 
PEG5k-Fmoc-S-S-FTS2 micelles in the normal release medium (A) and the GSH-containing medium (B). 
DPBS (pH = 7.4) containing 0.5% (w/v) Tween 80 was used as the normal release medium. Values reported are the 
means ± SD for triplicate samples.  
2.4.6  Plasma Pharmacokinetics and Tissue Distribution 
PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles, PTX-loaded PEG5k-Fmoc-FTS2 micelles or 
Taxol® were injected into tumor-free mice at a PTX dose of 10 mg/kg. The plasma 
concentrations of PTX were examined at different time points. The initial concentration of 
PEG5k-Fmoc-S-S-FTS2 at this dose was around 0.7 μM, which was 35-fold higher than its CMC 
(0.02 μM). The concentrations of PTX in the blood following intravenous injection are shown in 
Figure 2-9A. Compared to Taxol®, the plasma concentrations of PTX for both PTX-loaded 
PEG5k-Fmoc-S-S-FTS2 and PTX-loaded PEG5k-Fmoc-FTS2 micelles at early time points were 
significantly higher. Until 12 h, the plasma concentrations of both micellar groups still 
maintained at relatively high levels. PTX/PEG5k-Fmoc-FTS2 and PTX/PEG5k-Fmoc-S-S-FTS2 
showed a similar profile with respect to the kinetics of PTX in the blood. 
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The biodistribution of PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles was investigated in 
female BALB/c mice bearing 4T1.2 breast tumor. Taxol®, PTX-loaded PEG5k-Fmoc-FTS2 and 
PTX-loaded PEG5k-Fmoc-S-S-FTS2 were injected at a same PTX dose of 10 mg/kg. After 24 
hours, both tumors and major organs including heart, liver, spleen, lung and kidney were excised 
and homogenized for PTX determination. As shown in Figure 2-9B, compared to Taxol® group, 
PTX/PEG5k-Fmoc-S-S-FTS2 showed more PTX accumulation at tumor site over normal tissues 
including heart, liver, spleen, lung and kidney. In addition, the tumor uptake of PTX was higher 
for PTX/PEG5k-Fmoc-FTS2 and PTX/PEG5k-Fmoc-S-S-FTS2 compared to Taxol® group. The 
amounts of PTX accumulated at tumor tissues were also significantly higher in PTX/PEG5k-
Fmoc-S-S-FTS2 treated mice than those in PTX/PEG5k-Fmoc-FTS2 treated mice. The 
PTX/PEG5k-Fmoc-S-S-FTS2 group also showed significant amount of PTX accumulated in the 
liver and heart, however, there was no significant difference compared to Taxol® or PTX/PEG5k-
Fmoc-FTS2. 
 
Figure 2-9. Pharmacokenetics and biodistribution of PTX-loaded PEG5k−Fmoc−S-S-FTS2 micelles 
compared to Taxol® and PTX-loaded PEG5k−Fmoc−FTS2 micelles. 
(A) Pharmacokinetics of Taxol®, PTX-loaded PEG5k−Fmoc−FTS2 and PTX-loaded PEG5k−Fmoc−S-S-FTS2 
micelles in tumor-free female BALB/c mice. (B) Tissue distribution of PTX 24 h post-injection in tumor-bearing 
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FTS2 micelles. Taxol®, PTX-loaded PEG5k−Fmoc−FTS2 and PTX-loaded PEG5k−Fmoc−S-S-FTS2 micelles were 
given at the dose of 10 mg PTX/kg, respectively. Values reported are the means ± SEM, n=5.  
2.4.7  In Vivo Therapeutic Study 
The in vivo tumor growth inhibitory effect of PTX-loaded PEG5k-Fmoc-S-S-FTS2 
micelles was investigated in a highly metastatic syngeneic murine breast cancer mode (4T1.2, 
s.c.). PEG5K-Fmoc-FTS2 and PEG5K-Fmoc-S-S-FTS2 alone showed a comparable but low level 
of antitumor activity (Figure 2-10A). Taxol® group exhibited modest antitumor activity 
compared to the control group (Figure 2-10A). PTX/PEG5k-Fmoc-FTS2 was more effective than 
Taxol® in antitumor activity (Figure 2-10A). At the same dose of PTX, PTX/PEG5k-Fmoc-S-S-
FTS2 was most effective in inhibiting the tumor growth (Figure 2-10A).  Figure 2-10B and 9D 
show the images and weights of tumor tissues that were collected at the end of the experiment, 
which were consistent with data of tumor growth curves (Figure 2-10A). There were slight 
increases in body weights in all groups over the period of study, suggesting the negligible 
toxicity of PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles in vivo (Figure 2-10C). 
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Figure 2-10. Antitumor activity of PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles in 4T1.2 breast tumor model. 
(A) Antitumor activity of drug-free PEG5k-Fmoc-FTS2, drug-free PEG5k-Fmoc-S-S-FTS2 micelles, Taxol®, PTX-
loaded PEG5k-Fmoc-FTS2 and PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles in female BALB/c mice bearing 4T1.2 
breast tumor. (B) Weights of tumors collected from different groups at the end of experiment.  (C) Changes of body 
weight in mice receiving different treatments. (D) Photographs of tumors collected from different treatment groups 
at the end of experiment. Values reported are the means ± SEM, n=5.  Significance was determined by one-way 
ANOVA with Fisher’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001 (vs. control). 
2.5 Discussion 
We previously improved PEG5k-FTS2 system either by incorporating disulfide bond 
(PEG5k-S-S-FTS2) to facilitate drug release at tumor sites[55], or by introducing Fmoc motif 
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(PEG5k-Fmoc-FTS2) to enhance the drug loading capacity and the formulation stability[56]. In 
this study, we combined both disulfide bond and Fmoc group in PEG5k-FTS2 system and 
synthesized a novel compound PEG5k-Fmoc-S-S-FTS2. We hypothesized that our novel PEG5k-
Fmoc-S-S-FTS2 assimilated the advantages from the previous two carriers, while minimizing 
their potential drawbacks. Our data suggested that PTX loaded in PEG5k-Fmoc-S-S-FTS2 
exhibited superior performance over PTX formulated in PEG5k-Fmoc-FTS2 in vitro and in vivo. 
 
In contrast to PEG5k-S-S-FTS2[55] and PEG5k-Fmoc-FTS2[56] micelles that formed 
typical spherical structures, PEG5k-Fmoc-S-S-FTS2 micelles showed predominantly tubular 
morphology. We have previously shown that PEG5K-(Fmoc-OA)2 conjugates[85] also exhibited 
a filamentous structure. Fmoc is known to promote parallel interactions of individual short 
peptides carrying the same group, which often leads to the formation of elongated 
nanoassemblies[81]. However, the lipid chain also played a role in the formation of the 
filamentous structure, as PEG5K-Fmoc[82] conjugate possessed a spherical structure. Moreover, 
it has been reported that the morphology of the crystalline-coil micelles of block copolymers 
strongly depended on the lengths of both blocks and composition[86]. As the length of the 
hydrophobic block increases, micellar morphology is inclined to turn into cylindrical and 
wormlike. Compared to PEG5k-Fmoc-FTS2 molecule, PEG5k-Fmoc-S-S-FTS2 possessed longer 
lipid chains as well as hydrophobic disulfide bond, which likely contributed to the tubular 
structures of PEG5k-Fmoc-S-S-FTS2 micelles. Interestingly, it has been reported that compared 
to the sphere counterparts, the filomicelles were more resistant to the clearance by macrophages 
and persisted in circulation for a longer time[87]. The filamentous morphology of PEG5k-Fmoc-
S-S-FTS2 might contribute to its improved performance in vivo. 
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In addition to its unique structure, PEG5k-Fmoc-S-S-FTS2 had a CMC that was ~ 10 
times lower than that of the counterparts without disulfide bond or Fmoc. The CMC of micellar 
carriers is known to be controlled by the hydrophilic/hydrophobic ratio[88]. Compared to 
PEG5K-Fmoc-FTS2, we introduced additional 16 -C- in addition to two highly hydrophobic 
disulfide bonds in our PEG5K-Fmoc-S-S-FTS2 system. The increase of hydrophobic chain could 
improve carrier/carrier interaction, and further reduce CMC. The reduced CMC shall ensure an 
improved stability of PEG5k-Fmoc-S-S-FTS2 micellar system upon the dilution after intravenous 
injection.  
 
One of the potential concerns over a disulfide-containing carrier is the premature 
cleavage by the reducing components in the blood such as GSH before it reaches the tumor 
tissue[89]. However, this is unlikely to happen, as the blood concentrations of GSH are 
significantly lower than those in the tumor tissues/cells. This concern might be further minimized 
following the incorporation of a neighboring Fmoc group. Due to its bulky structure, Fmoc may 
provide a steric hindrance for the attack of the disulfide bond by the relatively low 
concentrations of GSH. Furthermore, the overall stability of the PEG-Fmoc-S-S-FTS2 micelles in 
the blood can be improved by their unique filamentous structures and/or significantly reduced 
CMC. This is supported by the data that PEG5k-Fmoc-S-S-FTS2 micelles were even more 
effective than their counterpart without a disulfide (PEG5k-Fmoc-FTS2) in mediating selective 
delivery of PTX to tumor tissues (Figure 2-9B). However, we also observed significant amount 
of PTX accumulation in the heart and the liver. The mechanism was not clear, which required 
more studies in the future.  
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Despite the excellent stability in the blood, PEG5k-Fmoc-S-S-FTS2 well retained its 
cleavability by relatively high concentrations of GSH as those seen inside tumor tissues/cells. As 
shown in Figure 2-6, more free FTS were detected in the tumor cells treated with PEG5k-Fmoc-
S-S-FTS2 compared to PEG5k-Fmoc-FTS2-treated cells, which was correlated with the improved 
cytotoxicity of carrier alone for PEG5k-Fmoc-S-S-FTS2 (Figure 2-5). In addition, PTX/PEG5k-
Fmoc-S-S-FTS2 demonstrated accelerated release of PTX following the addition of GSH into the 
release medium (Figure 2-8B). The cleavage of the disulfide linkage and then a facilitated 
release of PTX following disruption of carrier in the tumor tissues/cells shall promote a 
synergistic action between FTS and PTX as demonstrated by the enhanced cytotoxicity of 
PTX/PEG5k-Fmoc-S-S-FTS2 in cultured cancer cells (Figure 2-7).   
  
A highly metastatic murine breast cancer cell line 4T1.2 was selected to investigate the in 
vivo therapeutic efficacy of PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles. PTX/PEG5k-Fmoc-
FTS2 was more effective than Taxol® as we reported before[56]. Importantly, PTX/PEG5k-
Fmoc-S-S-FTS2 was even more effective than the PEG5k-Fmoc-FTS2 formulation in inhibiting 
the tumor growth. Meanwhile, no decrease of body weight and no noticeable activity change 
were found, demonstrating the excellent safety profile of our system. The superior antitumor 
efficacy along with the minimal toxicity of the PTX/PEG5k-Fmoc-S-S-FTS2 system could be 
ascribed to the improved stability in circulation, increased PTX delivery to tumor sites and 
enhanced drug release inside tumor cells. In addition, the increased delivery of FTS and thus an 
enhanced synergy with PTX may also contribute to the overall antitumor activity of PTX-loaded 
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PEG5k-Fmoc-S-S-FTS2 micelles. Lack of significant antitumor activity by carrier alone is likely 
due to the low concentrations of FTS at tumor site. 
In summary, we have further improved PEG5k-FTS2 based system via incorporating both 
disulfide linkage and Fmoc group, forming a simple PEG5k-Fmoc-S-S-FTS2 micellar system. 
These filamentous micelles showed enhanced drug loading capacity and formulation stability, 
along with decreased CMC. PEG5k-Fmoc-S-S-FTS2 well retained the biological activity of FTS 
and effectively release FTS at tumor cells. PTX-loaded PEG5k-Fmoc-S-S-FTS2 showed more 
potent cytotoxicity in tested tumor cells. Pharmacokinetics and biodistribution studies showed 
that PTX-loaded PEG5k-Fmoc-S-S-FTS2 micelles were able to retain PTX in the bloodstream for 
a prolonged period of time and were highly effective in targeted delivery of PTX to tumors with 
less accumulation in major organs. More importantly, PTX-loaded PEG5k-Fmoc-S-S-FTS2 
micelles demonstrated more potent antitumor activity over Taxol® formulation and PTX-loaded 
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3.0 Novel Glucosylceramide Synthase Inhibitor Based Prodrug Copolymer Micelles for 
Delivery of Anticancer Agents 
3.1 Abstract 
In order to improve the efficacy of chemotherapy for cancers, we have developed a novel 
prodrug micellar formulation to co-deliver ceramide-generating anticancer agents and ceramide 
degradation inhibitor (PPMP). The prodrug nanocarrier is based on a well-defined POEG-b-
PPPMP diblock copolymer. The hydrophilic block of POEG-b-PPPMP is POEG, and the 
hydrophobic block is composed of a number of PPMP units, which could work synergistically 
with loaded anticancer drugs. POEG-b-PPPMP was readily synthesized via a one-step reversible 
addition-fragment transfer (RAFT) polymerization from a PPMP monomer. The newly 
synthesized polymers were self-assembled into micelles and served as a carrier for several 
hydrophobic anticancer drugs including DOX, PTX and C6-ceramide. POEG-b-PPPMP prodrug 
polymer exhibited intrinsic antitumor activity in vitro and in vivo. In addition, POEG-b-PPPMP 
prodrug polymer was comparable to free PPMP in selectively enhancing the production of pro-
apoptotic ceramide species as well as down-regulating the mRNA expression of GCS. DOX-
loaded POEG-b-PPPMP micelles exhibited an excellent stability of 42 days at 4 °C. Moreover, 
DOX loaded in POEG-b-PPPMP micelles showed higher levels of cytotoxicity than DOX loaded 
in a pharmacologically inert polymer (POEG-b-POM) and Doxil formulation in several tumor 
cell lines. Consistently, in a 4T1.2 murine breast cancer model, the tumor inhibition followed the 
order of DOX/POEG-b-PPPMP > DOX/POEG-b-POM ≥ Doxil > POEG-b-PPPMP> POEG-b-
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POM. Our data suggest that POEG-b-PPPMP micelles are a promising dual-functional carrier 
that warrants more studies in the future.  
3.2 Background 
Ceramides are not only essential structural components of cell membranes regulating 
fluidity and subdomain stucture of lipid bilayer, but also have crucial and specific links to 
various aspects of cancer initiation, progression and response to chemotherapies[90, 91]. As 
tumor suppressor lipids, ceramides have important messenger functions mediating cell 
differentiation, cell cycle arrest, senescence and apoptosis[92]. Mounting evidence shows that 
ceramides are intimately involved in those pathways by regulating specific protein targets such 
as phosphatases and kinases[93]. Ceramides activate the ceramide-activated protein phosphatases 
(CAPPs), which comprise the serine/threonine protein phosphatases PP1 and PP2A. PP1 gives 
rise to the dephosphorylation of SR proteins that mediate the alternative splicing of BCL-X, 
while PP2A dephosphorylates and inactivates anti-apoptotic proteins such as BCL2 and AKT[94, 
95]. Moreover, cathepsin D is activated by ceramides, leading to activation of the pro-apoptotic 
protein BID and the subsequent activation of caspase-9 and caspase-3[96]. Ceramides also 
activate the kinase suppressor of RAS (KSR)[97]. Proteins modulated by these pathways include 
telomerase, c-MYC, caspases and cyclin-dependent kinases (CDKs)[90]. All of these 
downstream effects can lead to changes in growth arrest, apoptosis and/or senescence. Therefore, 
manipulating the generation and/or accumulation of the ceramides could disarm a key 
mechanism for tumour viability and growth. Several ceramide mimetics and delivery systems 
have been developed to increase the solubility, specificity and efficacy of ceramides[98]. For 
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example, analogues and mimics of ceramides such as C2- and C6-ceramides, which are similar 
to the natural metabolites of ceramides, are capable of direct activation of ceramide targets, 
inducing cell death in a myriad of cancer types[99]. B13, another ceramide analogue, inhibits 
acid CDase, inducing accumulation of ceramide and increasing apoptosis in an in vivo model of 
metastatic human colon cancer and in a prostate cancer xenograft model[100]. In addition, 
several delivery systems have been empolyed for systemic delivery of ceramides including 
liposomes[101], calcium phosphate nanocomposite particles (CPNPs)[102], linear dentritic 
nanoparticles[103], nanoemulsions[104] and others. For instance, delivery of ceramides via 
pegylated liposomes, which are generally more effective at crossing the cell membrane, increase 
accumulation of ceramides and their ability to kill cancer cells[105].  
 
Recently it has been shown that ceramide metalolism can also be modulated by 
chemotherapy or radiotherapy[106]. Despite the differences in their chemical structures and the 
postulated major mechanisms of action, many chemotherapeutic agents are all capable of 
inducing ceramide generation through enhanced de novo synthesis, catabolism of sphingomyelin, 
or both, suggesting a role of ceramide metabolism in the overall antitumor activity of these 
agents [107]. Doxorubicin, etoposide, camptothecin, 4-HPR, fludarabine, cisplatin, gemcitabine, 
irinotican, vorinostat or radiation induces de novo ceramide genration[108, 109]. A-SMase has 
been implicated in mediating apoptosis-induced by paclitaxel (PTX), 5-FU, daunorubicin and 
radiation[106]. Cytosine arabinoside (Ara-C) triggers ceramide generation through the activation 
of N-SMase[98]. In each case, the result is an enhanced ceramide-governed cytotoxic response. 
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However, the accumulation of ceramides in tumor cells could simultaneously initiate 
and/or up-regulate the catabolic pathways towards themselves. Glucosylceramide synthase 
(GCS) is one of the most pivotal metabolic enzymes to clear ceramides. GCS catalyzes ceramide 
glycosylation, transferring a glucose residue from UDP-glucose to ceramide for the synthesis of 
glucosylceramide; this process facilitates ceramide clearance and limits ceramide-induced 
apoptosis[110-112]. Emerging evidence shows that ceramides increase GCS enzyme activity and 
GCS mRNA level[113, 114]. More importantly, chemotherapeutic agents, such as DOX,  which 
increase endogenous ceramide levels, have been demonstrated to activate GCS promoter and 
induce GCS gene expression[115]. Therefore, inhibition of GCS would diminish the ablility of 
tumor cells to detoxify ceramide and restore the sensitivity of tumor cells to anticancer drugs. 
PPMP (1-phenyl-2-palmitoylamino-3-morpholino-1- propanol) is a potent inhibitor of GCS and 
can help sustain a high level of ceramide inside tumor cells through inhibiting its conversion to 
bio-inactive glycosylated ceramide[116]. PPMP also inhibits l-O-acylceramide synthase, another 
minor ceramide metabolizing enzyme[117]. Like other inhibitors of GCS, PPMP can both induce 
cell death by itself and synergize with classical chemotherapeutic agents. The combination of 
PPMP with anticancer drugs such as PTX[118], 4-HPR[119], irinotican[118] has been reported 
to cause increased ceramide levels and cytotoxicity on tumor cells, such as those derived from 
neuroblastoma, melanoma, prostate, lung, colon, breast and pancreatic cancers. 
 
One of the issues for the clinical translation of the combination therapy is lack of an 
effective strategy for selective codelivery of PPMP and the chemotherapeutic agents. In this 
study, we developed a PPMP prodrug-based polymeric nanocarrier (POEG-b-PPPMP) to 
overcome this limitation.  POEG-b-PPPMP could serve as a depot system allowing the release of 
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active PPMP over a prolonged period of time. More importantly, POEG-b-PPPMP could self-
assemble to form micelles to achieve synergistic codelivery with other anticancer drugs 
including DOX, PTX and C6-ceramide. We systematically evaluated the sizes, structures and 
drug loading efficiency of POEG-b-PPPMP-based nanocarrier. The antitumor activity of drug-
free POEG-b-PPPMP and DOX-loaded POEG-b-PPPMP was also investigated in vitro and in 
vivo. 
3.3 Experiment Procedures 
3.3.1  Materials 
PPMP·HCl was synthesized and purified following a published patent (WO 2005/049827 
A2). Methacryl chloride, triethylamine, 4-Cyano-4-
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid, oligo(ethylene glycol) methacrylate 
OEGMA (average Mn = 500), 2,2-Azobis (isobutyronitrile)(AIBN), Dulbecco’s Modified 
Eagle’s Medium (DMEM), trypsin-EDTA solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (MO, U.S.A). DOX·HCl was 
purchased from LC Laboratories (MA, U.S.A). PTX was purchased from AK Scientific Inc. 
(CA, U.S.A.). Fetal bovine serum (FBS), penicillin-streptomycin solution and TRIzol lysis 
reagent were purchased from Invitrogen (NY, U.S.A.). QuantiTect Reverse Transcription Kit 
was purchased from Qiagen (MD, U.S.A). 
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3.3.2  Synthesis of PPMP-monomer 
Methacryloyl chloride (209 uL, 2 mmol) was added to the solution of PPMP·HCl salt 
(511 mg, 1 mmol) in 5 mL DCM, followed by triethylamine (689 uL, 5mmol) at 0 °C. The 
reaction mixture was stirred at 0 °C for 1 h and then kept at room temperature overnight. The 
completion of reaction was monitored by TLC (Petroleum ether/EtOAc = 9:1). The reaction 
mixture was quenched by the addition of saturated NaHCO3, and the product was extracted with 
DCM (3×15 mL). The organic phase was collected and washed by water and brine, dried over 
Na2SO4, filtered, and the solvent was then evaporated. The crude product was purified by 
column chromatography on silica gel eluted with petroleum ether/EtOAc (12: 1) to give the oil 
product PPMP monomer (450 mg, 90%).  
3.3.3  Synthesis of POEG macroCTA 
POEG macroCTA was synthesized and purified following a published protocol [43]. 
3.3.4  Synthesis of POEG-b-PPPMP 
POEG macroCTA (390 mg, 0.052 mmol), PPMP-monomer (225 mg, 0.415 mmol), 
AIBN (4.5 mg, 0.027 mmol), and 2 mL dried 1, 4-Dioxane and THF (V/V=1/1) were added in a 
Schlenk tube and deoxygenated by free-pump-thawing for three times. Under N2 protection, the 
mixture was kept in an oil bath thermostated at 90°C for 24 h, and then quenched by cooling the 
tube in liquid nitrogen. The mixture was precipitated in hexane for 3 times and dried in vacuum. 
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3.3.5  Preparation and Characterization of Blank or Drug-loaded POEG-b-PPPMP 
micelles 
DOX solution was first prepared by dissolving DOX·HCl in a mixture of 
chloroform/methanol (1:1, v/v) containing triethylamine (5 equiv) to remove HCl. Then DOX 
(5mg/mL in chloroform/methanol) was mixed with POEG-b-PPPMP polymers (50 mg/mL in 
chloroform) at different carrier/drug ratios. The solvent was removed by nitrogen flow to 
produce a thin film of carrier/drug mixture, which was further dried in vacuum for 2 h to remove 
any remaining solvent. Then the thin film was hydrated and gently vortexed in Dulbecco’s 
phosphate-buffered saline (DPBS) to form DOX-loaded micelles. PTX-loaded, C6-ceramide-
loaded POEG-b-PPPMP micelles and drug-free micelles were prepared similarly as described 
above.  
 
The average diameter and the size distribution of POEG-b-PPPMP micelles were 
assessed via a Zetasizer (DLS). The morphology of POEG-b-PPPMP blank micelles and drug-
loaded micelles was observed by transmission electron microscopy (TEM). The drug loading 
efficiency of DOX and PTX was examined by Waters Alliance 2695 Separations Module 
combined with Waters 2475 Fluorescence Detector (excitation, 490 nm; emission, 590 nm; gain, 
3; sensitivity (FUFS), 10,000) and high performance liquid chromatography (HPLC) respectively 
as described previously [120]. Drug loading capacity (DLC) and drug loading efficiency (DLE) 
were calculated according to the following equation: DLC %= [weight of drug loaded/(weight of 
polymer used + weight of drug used)]×100%, DLE %= (weight of loaded drug/weight of input 
drug)×100 %. The colloidal stability of drug-loaded micelles with various carrier/drug molar 
ratios at room temperature and 4°C was evaluated by following the changes in sizes of the 
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particles or visible precipitates every hour in the first 12 h and daily after 12 h following sample 
preparation. 
 
The CMC of POEG-b-PPPMP micelles was determined by using nile red as a 
fluorescence probe as described previously[121].  
 
The kinetics of DOX release from DOX/ POEG-b-PPPMP was performed according to a 




3.3.6  In Vitro Cytotoxicity Assay 
Cytotoxicity assay was performed on 4T1.2 mouse breast cancer cells, MCF-7 human 
breast cancer cells and PC-3 human prostate cancer cells. 4T1.2 (1×10
3
 cells/well), MCF-7 
(5×10
3
 cells/well) or PC-3 (3×10
3
 cells/well) cells were seeded in 96-well plates followed by 24 
h of incubation in DMEM with 10% FBS and 1% streptomycin/penicillin.  
 
To evaluate the combinational effect of PPMP with other anticancer drugs, cells were 
treated with various concentrations of free PPMP, free DOX·HCl, and the combination of both 
respectively for 48 h. The combination of PPMP and PTX or C6-ceramide was evaluated 
similarly. To measure the cytotoxicity of blank POEG-b-PPPMP micelles, cells were challenged 
with various concentrations of blank POEG-b-PPPMP micelles or free PPMP at equivalent 
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PPMP concentrations for 48 h. To explore the cytotoxicity of drug-loaded POEG-b-PPPMP 
micelles, a pharmacologically inert polymer, POEG-b-POM, was served as a control carrier for 
anticancer drugs. Six groups were tested in this experiment, including free anticancer drug, 
commercial formulation of anticancer drug, drug-loaded POEG-b-PPPMP micelles, drug-loaded 
POEG-b-POM micelles, drug-free POEG-b-PPPMP micelles and drug-free POEG-b-POM 
micelles. The former four drug-containing groups were compared at the same concentration of 
anticancer drugs. The concentrations of last two drug-free micelles were same as those of the 
carrier in drug-loaded groups respectively. Specifically, for testing of DOX-loaded micelles, 
tumor cells were challenged with various concentrations of free DOX·HCl, Doxil, POEG-b-
PPPMP/DOX micelles, POEG-b-POM/DOX micelles, POEG-b-PPPMP micelles and POEG-b-
POM micelles. For testing of PTX-loaded micelles, cells were incubated with PTX, Taxol®, 
POEG-b-PPPMP/PTX micelles, POEG-b-POM/PTX micelles, POEG-b-PPPMP micelles and 
POEG-b-POM micelles for 48 h.  
 
MTT assay and the calculation of cell viability were performed as described before[122]. 
The anti-proliferation data for single drug and combination treatment was fitted to an inhibitory, 
normalized dose-response model with variable slope (Y = 100/(1 + 10^((LogEC50-X) 
*HillSlope); (GraphPad Prism, San Diego, CA) 
3.3.7  Real-time PCR 
Real-time PCR studies were performed on 4T1.2 mouse breast cancer cells and MCF-7 
human breast cancer cells. 4T1.2 (2×10
4 
cells/well) or MCF-7 (6×10
4 
cells/well) cells were 
seeded in 6-well plates followed by 24 h of incubation in DMEM containing 10% FBS and 1% 
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streptomycin/penicillin. After 24 hours, medium was replaced with 2% FBS medium containing 
free PPMP, blank POEG-b-PPPMP, DOXHCl, free PPMP + free DOX or POEG-b-
PPPMP/DOX. Free PPMP, blank POEG-b-PPPMP and POEG-b-PPPMP/DOX were examined 
at the same concentration of PPMP (1.7 M), while free DOX and POEG-b-PPPMP/DOX were 
compared at the same concentration of DOX (100 nM). After 48 hours, total cellular RNA was 
extracted using the TRIzol lysis reagent. cDNA was generated from the purified RNA using 
QuantiTect Reverse Transcription Kit according to the manufacturer’s instructions. The cDNAs 
corresponding to GCS were amplified by PCR using the specific primers (mouse GCS forward 
5’-CCAGGAGGGAATGGCCTTGT-3’, mouse GCS reverse 5’-
AGAGACACCAGGGAGCTTGC-3’; human GCS forward 5’- CCACCCTGTCCTCCTCCTG-
3’, human GCS reverse 5’- GAAGACGGCCATTCCCTCCA-3’). Quantitative real-time PCR 
was performed using SYBR Green Mix on a 7900HT Fast Real-time PCR System. Relative 
target mRNA levels were analyzed using delta-delta-Ct calculations and normalized to GAPDH. 
3.3.8  Analysis of lipids 
Ceramides measurements were also carried out on 4T1.2 cells or MCF-7 cells. All cells 
were similarly treated as described above. After 48 h treatment, cells were washed twice with 
ice-cold DPBS and lysed in 60 L 0.2% sodium dodecyl sulfate (SDS). An aliquot (30 L) of 
the cell lysates was taken for protein determination. For another aliquot (30 L) of the cell 
lysates, 0.5 g of C6-ceramide was added as the internal standard. Lipids were extracted using 
400 L of chloroform/methanol (3:1, v/v). After gentle vortex and centrifugation at 3,000 rpm at 
RT for 10 min, the resulting organic lower phase was collected and evaporated under a stream of 
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nitrogen. Lipids were resuspended in 200 L ACN/IPA/H2O (1:1:1, v/v/v) and centrifuged at 
12,500 rpm for 10 min at 4 °C and 150 μL of the clear supernatant was collected in UPLC 
injection vials. Sphingolipids were separated on an Agilent 1200 high performance liquid 
chromatography system (Agilent Technologies, CA, U.S.A) and analyzed by electrospray 
ionization-tandem mass spectrometry on a 400 QTRAP (AB Sciex, MA, U.S.A). The peak areas 
for different sphingolipid subspecies (C16-ceramide, C18-ceramide, C20-ceramide, C22-
ceramide and C24-ceramide) were quantified by internal standards (C6-ceramide) and then 
normalized to protein concentrations.  
3.3.9  Plasma Pharmacokinetics and Tissue Distribution 
For plasma pharmacokinetics, POEG-b-PPPMP/DOX micelles, POEG-b-POM/DOX and 
DOX·HCl were injected intravenously into groups of 5 tumor-free female CD1 mice at a DOX 
dose of 5 mg/kg, respectively. Blood samples were collected in heparinized tubes at designated 
time points (3min, 10 min, 30 min, 1 h, 2 h, 4 h, 8 h and 12 h) post injection. The samples were 
centrifuged at 12,500 rpm for 10 min at 4 °C and 20 μL of the supernatant was collected. Then 
200 μL acetonitrile was added and the samples were vortexed for 1 min. The samples were 
centrifuged at 12,500 rpm for 10 min at 4 °C and 150 μL of the clear supernatant was collected 
and injected into HPLC for DOX analysis. Noncompartmental pharmacokinetic analysis was 
executed by WinNonlin. 
 
For tissue distribution study, POEG-b-PPPMP/DOX micelles, POEG-b-POM/DOX and 
DOX·HCl were i.v. injected into female BALB/c mice bearing 4T1.2 tumors of 400–600 mm3 (n 
= 5) at a DOX dose of 5 mg/kg, respectively. Mice were sacrificed 24 h post injection. Major 
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organs (including heart, liver, spleen, lung and kidney) and tumors were harvested, weighed, and 
stored at -80°C. One hundred mg of each organ was weighed and homogenized in 500 μL PBS 
on ice. Five hundred μL methanol/acetonitrile (1/1, v/v) was then added and vortexed for 3 min. 
The samples were centrifuged at 12,500 rpm for 10 min at 4 °C and the supernatant was 
transferred to clean tubes and dried under nitrogen flow. Two-hundred μL acetonitrile was added 
and vortexed to dissolve samples, which were then centrifuged at 12,500 rpm for 10 min at 4 °C. 
One hundred and fifty μL of the clear supernatant was collected and injected into HPLC for 
DOX analysis. 
3.3.10  In Vivo Therapeutic Study 
The in vivo antitumor efficacy of the DOX-loaded POEG-b-PPPMP micelles was tested 
in a syngeneic 4T1.2 mouse breast cancer model. 4T1.2 cells (2×105 in 20 μL DPBS) were 
inoculated s.c. at the right mammary fat pad of female BALB/c mice. When the tumor volume 
reached ~ 50 mm3, mice were randomly divided into six groups (n=5), and treated via tail vein 
injection with DPBS, blank POEG-b-PPPMP micelles, blank POEG-b-POM micelles, DOX-
loaded POEG-b-PPPMP micelles, DOX-loaded POEG-b-POM or Doxil, respectively, at a DOX 
dose of 5 mg/kg. The treatments were conducted every three days for a total of 3 times. Tumor 
sizes were measured with the digital caliper every three days following the initiation of the 
treatment and calculated by the formula: (L×W2)/2, where L is the longest and W is the shortest 
in tumor diameters (mm). Body weights were also monitored for the indication of toxicity. On 23 
days post injection, all mice were sacrificed and tumor tissues were collected for weight, 
photography and H&E staining.   
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3.3.11  Histochemical Staining 
The H&E staining was similarly conducted as described before[123]. 
3.3.12  Statistical Analysis 
In vitro or in vivo data are presented as mean ± standard deviation (SD) or 
mean± standard error of mean (SEM), respectively. Two-tailed Student’s T test or analysis of 
variance (ANOVA) was used to compare two groups or multiple groups, respectively. 
Significance was determined with Tukey simultaneous post hoc test. In all statistical analyses, 
P < 0.05 is considered statistically significant.  
3.4 Results 
3.4.1  Effect of Anticancer Drugs on GCS mRNA Expression 
To evaluate the effect of DOX, PTX, or C6-ceramide on GCS expression, we treated 
MCF-7 cells with various concentrations of DOX, PTX and C6-ceramide, respectively. The 
expression of GCS mRNA was examined by RT-qPCR 48 h following the drug treatment. As 
shown in Figure 3-1A, treatment of MCF-7 cells with either DOX or C6-ceramide led to 
significant increases in the mRNA expression levels of GCS in a dose-dependent manner. At a 
DOX concentration of 200 nM and a C6-ceramide concentration of 2 μM, the GCS mRNA 
expression levels in MCF-7 cells were increased by 4.2 and 6.5-fold respectively. Induction of 
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GCS mRNA expression by DOX or C6-ceramide was similarly observed in 4T1.2 cells (Figure 
3-1B). However, induction of GCS expression by DOX or C6-ceramide was less dramatic in 
4T1.2 cells compared to that in MCF-7 cells. Treatment with PTX also led to significant 
induction of GCS expression in MCF-7 cells but not in 4T1.2 cells. These results suggest that 
ceramides generated in tumor cells in response to chemotherapeutic stress upregulate GCS 
expression to detoxify ceramides and prevent cell death. 
 
 
Figure 3-1. Effects of chemotherapies on GCS mRNA expression in MCF-7 (A) and 4T1.2 (B) cell after 48 h 
treatment. 
Data are presented as the means ± SD for triplicate samples. P values were generated by one-way ANOVA using the 
Dunnett test for multiple comparisons to one control (*P < 0.05, **P < 0.01, *** P < 0.001).  
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3.4.2  Effect of Combination of PPMP and Other Chemotherapeutic Drugs on Tumor Cell 
Proliferation 
To assess whether GCS inhibitor PPMP could further enhance the cytotoxicity and/or 
restore sensitivity of tumor cells to the action of anticancer drugs, we evaluated the growth 
inhibitory activity of combination treament of PPMP with other anticancer drugs in MCF-7, 
4T1.2 and PC-3 cell lines.  As shown in Figure 3-2A, PPMP or DOX alone caused a 
concentration-dependent inhibition of MCF-7 cell proliferation. It is also apparent that 
combination of the two led to a significant improvement in the level of cytotoxicity. Similar 
synergistic effects between PPMP and DOX were found in 4T1.2 (Figure 3-2B) and PC-3 
(Figure 3-2C) cells. PPMP also synergized with PTX or C6-ceramide in inhibiting the tumor cell 
proliferation in all tumor cell lines tested (Figure 3-2D~J). Combination index (CI) was then 
calculated to assess a potential synergy between PPMP and other anticancer drugs, by the 
equation CI=(d1/IC501)+ (d2/IC502), with d1 or d2 being the concentration of PPMP or other 
anticancer agent (DOX, PTX or C6-ceramide) required to achieve 50% killing effect in co-
treatment, while IC501 or IC502 being IC50 of PPMP or other anticancer agents in single 
treatment, respectively. All of CI values listed in Table 3-1 were less than 1, indicating the 
synergy between PPMP and DOX, PTX or C6-ceramide in all of the examined cancer cell lines.  
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Figure 3-2. Synergistic effect between PPMP and other anticancer drugs in inhibiting the proliferation of 
tumor cells. 
(A-C) MCF-7, 4T1.2 or PC-3 cells were treated with various concentrations of free PPMP, free DOX or the 
combination of PPMP and DOX. (D-F) MCF-7, 4T1.2 or PC-3 cells were treated with various concentrations of free 
PPMP, free PTX or the combination of PPMP and PTX.  (G-I) MCF-7, 4T1.2 or PC-3 cells were treated with 
various concentrations of free PPMP, free C6-ceramide or the combination of PPMP and C6-ceramide. After 48 h, 
the cytotoxicity was determined by MTT assay. The experiments was performed in triplicate and repeated three 




Table 3-1. Synergistic Antiproliferative Activity of PPMP and Other Anticancer Drugs in Cancer Cells 
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PPMP DOX MCF-7 3.8±0.6 5.7±0.4 250 964.3±106.6 0.93 
PPMP DOX 4T1.2 1.8±0.3 2.2±0.1 10 272.0±62.1 0.85 
PPMP DOX PC-3 1.5±0.3 3.4±0.1 250 629.4±33.6 0.84 
PPMP PTX MCF-7 4.1±0.5 5.7±0.4 250 7143.0±1866.0 0.75 
PPMP PTX 4T1.2 1.0±0.3 2.2±0.1 25 108.1±18.1 0.69 
PPMP PTX PC-3 1.5±0.4 3.4±0.1 2 4.3±0.2 0.91 
PPMP Ceramide MCF-7 3.6±0.1 5.7±0.4 1 6.2±0.2 0.79 
PPMP Ceramide 4T1.2 1.1±0.2 2.2±0.1 1 2.8±0.2 0.86 
PPMP Ceramide PC-3 1.1±0.4 3.4±0.1 1 1.6±0.1 0.95 
a) Unit of DOX and PTX. b) Unit of C6-ceramide. Combination Index (CI) of co-treatment of PPMP with DOX, 
PTX and C6-ceramide in MCF-7, 4T1.2 and PC-3 cells. The cell viability was determined by MTT assay. The anti-
proliferation data for single drug and combination treatment was fitted to an inhibitory, normalized dose-response 
model with variable slope (Y = 100/(1 + 10^((LogEC50-X) *HillSlope); (GraphPad Prism, San Diego, CA). The CI 
was calculated by the formula: CI=(d1/D501)+(d2/D502), where D501 is the IC50 of PPMP in single treatment, and d1 
is the concentration of PPMP required to achieve 50% inhibition effect with d2 in co-treatment. Similarly, D502 is 
IC50 of DOX, PTX or C6-ceramide in single treatment, and d2 is the concentration of DOX, PTX or C6-ceramide 
required to obtain the same 50% cell-killing effect in combination with d1. The CI values are interpreted as follows: 
<1.0, synergism; 1.0, additive; and >1.0, antagonism. The experiments was performed in triplicate and repeated 
three times. 
 
3.4.3  Synthesis and Characterization of the POEG-b-PPPMP Polymers 
First, PPMP·HCl was synthesized following a published patent (WO 2005/049827 A2) 
and its chemical identity was confirmed by 
1
H-NMR (Figure 3-3). Then PPMP was conjugated 
with methacryloyl chloride through a hydrolyzable ester linkage as shown in Figure 3-4. The 
structure of PPMP monomer was confirmed by 
1
H-NMR (Figure 3-5). Meanwhile, the macro-
chain transfer agent POEG was synthesized by RAFT polymerization of hydrophilic OEGMA 
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monomer according to a published method [43]. POEG (MW=7500) was then used to initiate the 
polymerization of hydrophobic PPMP monomer, yielding the amphiphilic POEG-b-PPPMP 
block copolymer. The structure of POEG-b-PPPMP was confirmed by 
1
H-NMR (Figure 3-6), 
and the average degree of polymerization of the PPMP monomers was calculated by comparing 
the intensity of Ib and Ia. The calculated molecular weight by 
1
H-NMR was Mn=11700. The 
molecular weight detected by gel permeation chromatography (GPC)  was Mn=12100 with 
narrow polydispersity (PDI) of 1.3, which was consistent with molecular weight calculated by 
1
H-NMR. Therefore, each POEG-b-PPPMP molecule contained 15 units of OEGMA and 7 units 




H-NMR of PPMP in CDCl3. 
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H-NMR of PPMP monomer in CDCl3. 




H-NMR of POEG-b-PPPMP polymers in CDCl3. 
3.4.4  Biophysical Characterization of Blank and Drug-loaded POEG-b-PPPMP micelles 
POEG-b-PPPMP alone or POEG-b-PPPMP/drug mixture readily formed transparent 
micellar solution in DPBS by a simple film hydration method. Figure 3-7 showed that the CMC 
of POEG-b-PPPMP micelles was around 0.03 mg/mL (2.4 μM). The low CMC of POEG-b-
PPPMP shall provide a good stability for micelles upon dilution in blood stream after 
intravenous administration. The hydrodynamic sizes of blank and drug-loaded POEG-b-PPPMP 
micelles were examined by DLS and the data are shown in Figure 3-8. POEG-b-PPPMP formed 
micelles with a diameter of 105 nm (Figure 3-8A). Interestingly, incorporation of a drug into 
micelles at a carrier/drug ratio of 20:1 (mg/mg) resulted in a slight decrease in particle sizes 
(80~100 nm) (Figure 3-8B-D). This is likely due to an enhanced interaction between the carrier 
and loaded drugs, leading to the formation of a more compact structure. TEM images further 
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confirmed the spherical morphology of blank and drug-loaded POEG-b-PPPMP micelles with a 
uniform size distribution (Figure 3-8). The size, DLC, and formulation stability of drug-loaded 
POEG-b-PPPMP micelles were then examined (Table 3-2). DOX could be loaded into POEG-b-
PPPMP micelles at a carrier/drug ratio as low as 10/1 (mg/mg), at which ratio DOX was 
incorporated into the carrier at a DLC of 6.5 % and DOX-loaded micelles were stable with no 
obvious changes in size or precipitation for 6 days at 4 °C. In addition, with an increase in the 
carrier/drug ratio, the drug encapsulation efficiency and colloidal stability were further 
improved. As shown in Table 2, at a carrier/drug ratio of 50:1, DOX-loaded micelles were stable 
for 42 days in solution at 4 °C. In order to deliver more PPMP as well as provide good stability, 
a carrier/drug mass ratio of 50:1 was used for all subsequent studies. In addition to DOX, other 
chemotherapeutic agents such as PTX and C6-ceramide, could be effectively loaded into POEG-
b-PPPMP nanocarrier. Therefore, POEG-b-PPPMP might serve as a carrier for the delivery of 
different types of anticancer drugs. 
 
Figure 3-7. Plot of fluorescence intensity at 641 nm versus concentrations of POEG-b-PPPMP copolymers. 
  78 
 
Figure 3-8. TEM images of drug-free POEG-b-PPPMP micelles (A), DOX-loaded POEG-b-PPPMP micelles 
(B), PTX-loaded POEG-b-PPPMP micelles (C) and ceramide-loaded POEG-b-PPPMP micelles (D) using 
negative staining. 
DOX, PTX or ceramide were loaded in to POEG-b-PPPMP micelles at carrier/drug ratio of 20/1 (mg/mg). Scale bar 
is 100 nm. 
 
































POEG15-b-PPPMP7   105.0 0.179     
POEG15-b-PPPMP7: 
DOX 
10:1 87.58 0.221 6.5 68.9 48 h 6 d 
POEG15-b-PPPMP7: 20:1 82.46 0.214 3.8 79.7 4 d 25 d 




30:1 79.77 0.196 2.8 86.7 7 d 37 d 
POEG15-b-PPPMP7: 
DOX 
50:1 89.34 0.193 1.9 96.0 12 d 42 d 
POEG15-b-PPPMP7: 
PTX 
10: 1 107.1 0.205 8.2 90.4 24 h 51 h 
POEG15-b-PPPMP7: 
PTX 
20: 1 97.7 0.212 4.4 92.5 45 h  6 d 
POEG15-b-PPPMP7: 
PTX 
30: 1 95.8 0.217 3.1 95.2 53 h 17 d 
POEG15-b-PPPMP7: 
PTX 
50:1 93.2 0.205 1.9 95.6 7 d 21 d 
a) DOX or PTX concentration in micelles was kept at 0.5 or 1 mg/mL respectively. b) Measured by dynamic light 
scattering particle sizer. c) PDI = polydispersity index. d) DLC = drug loading capacity. e) DLE = drug loading 
efficiency. f) Data mean there was no noticeable size change and visible precipitates during the follow-up period. 
 
3.4.5  In Vitro Drug Release 
The release profile of DOX from DOX-loaded POEG-b-PPPMP micelles was 
investigated by a dialysis method in DPBS and compared to that of free DOX and DOX-loaded 
POEG-b-POM micelles. As shown in Figure 3-9, DOX release from two micellar formulations 
was significantly slower than that from free DOX. Forty eight percent of DOX was rapidly 
released from free DOX in 2 h and around 83% of total drug was released within 12 h. In 
contrast, less than 10% DOX was released from POEG-b-PPPMP formulation in 2 h and the 
slow release kinetics extended for 72 h. The performance of DOX cumulative release followed 
the order of DOX/POEG-b-PPPMP > DOX/POEG-b-POM > free DOX.  
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Figure 3-9. Cumulative DOX release profile from POEG-b-PPPMP micelles with free DOX and POEG-b-
POM micelles as control. 
DOX concentration was fixed at 0.5 mg/mL. DPBS was used as the release medium. Values reported are the means 
± SD for triplicate samples. Statistical significance was determined by two-way ANOVA using the Tukey test for 
multiple comparisons. *P < 0.05, **P < 0.01, *** P < 0.001 (POEG-b-PPPMP/DOX vs free DOX); 
#





P < 0.001 (POEG-b-PPPMP/DOX vs POEG-b-POM/DOX). 
 
3.4.6  In vitro Cytotoxicity of Prodrug Micelles and PTX/DOX/Ceramide-loaded Micelles 
The in vitro cytotoxicity of POEG-b-PPPMP blank micelles was tested in 4T1.2, PC-3 
and MCF-7 cancer cells and compared to that of free PPMP. As shown in Figure 3-10A, free 
PPMP inhibited the proliferation of 4T1.2 tumor cells in a dose-dependent manner. Compared to 
free PPMP, POEG-b-PPPMP prodrug micelles showed less cytotoxicity at equivalent amounts of 
PPMP in 4T1.2 cells. Similar results were shown in PC-3 and MCF-7 tumor cells (Figure 3-10B 
& C). The cytotoxicity of POEG-b-PPPMP shall likely come from the PPMP cleaved from the 
prodrug polymer following the intracellular uptake. The less effectiveness of POEG-b-PPPMP 
was likely due to the limited PPMP cleavage and release in a relatively short period of treatment.  
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Figure 3-10. Cytotoxicity of POEG-b-PPPMP prodrug micelles in 4T1.2 mouse breast cancer cell line (A), 
PC-3 human prostate cancer cell line (B) and MCF-7 human breast cancer cell line (C) with free PPMP as the 
control. 
Cells were treated with different micelles for 48 h and values reported are the means ± SD for triplicate samples. P 
values were determined by two-tailed Student’s T test. *P < 0.05, **P < 0.01, *** P < 0.001 (POEG-b-PPPMP vs 
PPMP). 
 
The cytotoxicity of DOX-loaded POEG-b-PPPMP micelles was also investigated in 
4T1.2 (Figure 3-11A), PC-3 (Figure 3-11B) and MCF-7 (Figure 3-11C) cells. DOX-loaded 
POEG-b-POM, DOX·HCl and Doxil were included as controls.  At all doses that were used for 
loading DOX, POEG-b-POM showed minimal impact on the proliferation of 4T1.2 cells (Figure 
3-11A). POEG-b-PPPMP alone showed modest effects on tumor cell proliferation at higher 
doses. DOX formulated in POEG-b-PPPMP was more effective than DOX·HCl and Doxil in 
inhibiting the proliferation of 4T1.2 cancer cells. More importantly, DOX-loaded POEG-b-
PPPMP was more potent than DOX-loaded POEG-b-POM in inhibiting the proliferation of 
4T1.2 cells. The improved cytotoxicity was likely due to the released PPMP from POEG-b-
PPPMP prodrug copolymer, via the cleavage of the hydrolyzable ester bond by the esterase in 
tumor cells, resulting in synergistic action with codelivered DOX. A trend of synergistic action 
between POEG-b-PPPMP-based carrier and codelivered DOX was also shown in PC-3 (Figure 
  82 
3-11B) and MCF-7 (Figure 3-11C) cells.   We have further shown a synergy between POEG-b-
PPPMP and codelivered PTX (Figure 3-11 D-F) or C6-ceramide (Figure 3-11 G-I). 
 
 
Figure 3-11. Cytotoxicity of DOX-loaded POEG-b-PPPMP micelles in 4T1.2 (A), PC-3 (B) and MCF-7 (C) 
cell lines, PTX-loaded POEG-b-PPPMP micelles in 4T1.2 (D), PC-3 (E) and MCF-7 (F) cell lines, and C6-
ceramide-loaded POEG-b-PPPMP micelles in 4T1.2 (G), PC-3 (H) and MCF-7 (I) cell lines after 48 h 
treatment. 
Data are presented as the means ± SD for triplicate samples. P values were determined by two-way ANOVA using 
the Tukey test for multiple comparisons.  *P < 0.05, **P < 0.01, *** P < 0.001 (POEG-b-PPPMP/DOX vs 
-b-PPPMP/PTX vs PTX, POEG-b-PPPMP/ceramide vs ceramide); &P < 0.05, &P < 0.01, 
&&&P < 0.001 (POEG-b-PPPMP/DOX vs DOXIL, POEG-b-PPPMP/PTX vs Taxol®); #P < 0.05, ##P < 0.01, 
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###P < 0.001 (POEG-b-PPPMP/DOX vs POEG-b-POM/DOX, POEG-b-PPPMP/PTX vs POEG-b-POM/PTX), 
POEG-b-PPPMP/ceramide vs POEG-b-POM/ceramide).  
3.4.7  Effect of POEG-b-PPPMP on Regulation of Ceramides Production  
As a prodrug of PPMP, the ability of POEG-b-PPPMP in regulating ceramides 
production was investigated in 4T1.2 and MCF-7 cells. The peak areas for different sphingolipid 
subspecies (C16-ceramide, C18-ceramide, C20-ceramide, C22-ceramide and C24-ceramide) 
were quantified using a non-naturally occurring C6-ceramide as an internal standard and then 
normalized to protein concentrations. We focused on these species as long-chain ceramides 
(C16-C20) are known to have anti-proliferative and pro-apoptotic effects[124]. It has been 
reported that the levels of C16, C24:0 or C24:1 ceramides are significantly increased in breast 
cancer tissues [125]. Especially, evidence is mounting that the endogenous levels of C16:0 
ceramide were increased under pro-apoptotic conditions, which played a decisive role in 
regulating apoptosis[126-128] As shown in Figure 3-12A & G, treatment with PPMP as well as 
the POEG-b-PPPMP-based prodrug led to a modest increase in the amounts of C16 ceramide. As 
a ceramide-generating anticancer agent, DOX significantly induced C16 ceramide production in 
both tested cell lines, while free drug combination (DOX·HCl+PPMP) or POEG-b-PPPMP/DOX 
mixed micelles were most effective in promoting ceramide accumulation. Unlike its effect on 
C16 ceramide, our POEG-b-PPPMP/DOX formulation caused negligible changes in the amounts 
of C24 ceramides (Figure 3-12 E, F, K & L). Interestingly C24:0 or C24:1 has been reported to 
have minimal effect in promoting apoptosis and could even promote the proliferation of tumor 
cells [129, 130]. Therefore, our POEG-b-PPPMP/DOX system appears to selectively promote 
the accumulation of pro-apoptotic ceramide species.  
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Figure 3-12. Different species of relative ceramide level in 4T1.2 or MCF-7 cells measured by LC/MS 48 h 
after POEG-b-PPPMP or POEG-b-PPPMP/DOX treatments compared to free drug alone or combination. 
Tumor cells were treated with PPMP, POEG-b-PPPMP, DOX·HCl +PPMP or POEG-b-PPPMP/DOX at the same 
PPMP concentration of 1.7 μM; DOX·HCl, DOX·HCl +PPMP or POEG-b-PPPMP/DOX at the same DOX 
concentration of 100 nM. Data are presented as the means ± SD for triplicate samples. P values were generated by 
one-way ANOVA using the Tukey test for multiple comparisons. *P < 0.05, **P < 0.01, *** P < 0.001. 
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3.4.8  Effect of POEG-b-PPPMP on GCS mRNA Expression 
In addition to direct inhibition of GCS enzymatic activity, PPMP has been shown to 
downregulate the mRNA expression of GCS in tumor cells. PPMP treatment was shown to cause 
decreases in GCS mRNA levels in drug-resistant cell lines with high endogenous GCS mRNA 
expression, including head and neck cancer (AMC-HN2, relative resistance to cisplatin) [131] 
and leukemia cell lines (K562/AO2, multidrug resistance)[132]. Accordingly, we examined the 
efficacy of POEG-b-PPPMP in downregulating GCS mRNA expression in both MCF-7 and 
4T1.2 cells and compare to that of free PPMP. As shown in Figure 3-13, treatment with free 
PPMP led to significant decreases in the basal levels of GCS mRNA in both cancer cell lines. 
Free PPMP was also effective in inhibiting the DOX-induced upregulation of GCS mRNA 
expression. POEG-b-PPPMP was comparable to free PPMP in inhibiting both basal and DOX-
induced expression of GCS mRNA. 
 
Figure 3-13. Effects of POEG-b-PPPMP and POEG-b-PPPMP/DOX on GCS mRNA expression in MCF-7 (A) 
or 4T1.2 (B) cells after 48 h treatment compared to free drug alone or combination. 
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Tumor cells were treated with PPMP, POEG-b-PPPMP, DOX·HCl+PPMP or POEG-b-PPPMP/DOX at the same 
PPMP concentration of 1.7 μM; DOX·HCl, DOX·HCl+PPMP or POEG-b-PPPMP/DOX at the same DOX 
concentration of 100 nM. Data are presented as the means ± SD for triplicate samples. P values were generated by 
one-way ANOVA using the Tukey test for multiple comparisons.  *P < 0.05, **P < 0.01, *** P < 0.001. 
3.4.9  Plasma Pharmacokinetics and Tissue Distribution  
The POEG-b-PPPMP/DOX, POEG-b-POM/DOX or DOX·HCl was injected into tumor-
free mice at a DOX dose of 5mg/kg. The plasma concentrations of DOX were examined at 
different time points. The initial blood concentration of POEG-b-PPPMP was around 3 mg/mL, 
which was 100-fold higher than its CMC (0.03 mg/mL). The concentrations of DOX in the blood 
following i.v. injection of different DOX formulations as a function of time were illustrated in 
Figure 3-14A. Compared to DOX·HCl, the plasma concentrations of DOX for both POEG-b-
POM/DOX and POEG-b-PPPMP/DOX were significantly higher at early time points and 
maintained at relatively high levels until 12 h, which is attributed to the surface modification of 
PEG and stealth-shielding against RES system. With the same length of coated PEG, however, 
POEG-b-PPPMP/DOX provided higher levels of DOX in circulation than POEG-b-POM/DOX. 
This is likely due to a more effective interaction between POEG-b-PPPMP and DOX, which is 
also supported by the data from in vitro release study (Figure 3-9).  
 
Next, the DOX tissue distribution of the three formulations was investigated in tumor-
bearing mice. POEG-b-PPPMP/DOX, POEG-b-POM/DOX or DOX·HCl was injected into 
4T1.2 tumor-bearing mice at a DOX dose of 5mg/kg. Twenty-four hours following the injection, 
major organs and tumors were harvested for the quantification of DOX. As shown in Figure 
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3-14B, compared to free DOX, both micellar formulations exhibited significantly greater 
amounts of DOX in tumor tissue, which is attributed to the EPR effect of nanoparticles. In 
addition, DOX formulated in POEG-b-PPPMP was more effective in tumor accumulation than in 
POEG-b-POM. This is consistent with the PK data and is likely ascribed to the better stability in 
blood stream due to the increased carrier-drug interaction between DOX and POEG-b-PPPMP. 
The DOX uptake in other organs was lower for POEG-b-PPPMP/DOX compared to free DOX 
group, although it was not statistically significant. The decreased accumulation of DOX in 
normal tissues, particularly in heart shall help to decrease the DOX-associated toxicity and allow 
higher doses of DOX to be administered to maximize the therapeutic effect. 
 
Figure 3-14. Pharmacokenetics and biodistribution POEG-b-PPPMP/DOX micelles in 4T1.2 breast tumor 
model. 
(A) Pharmacokinetics of DOX·HCl, POEG-b-POM/DOX and POEG-b-PPPMP/DOX micelles in tumor-free female 
BALB/c mice. (B) Tissue distribution of DOX 24 h post injection in tumor-bearing female BALB/c mice treated 
with DOX·HCl, POEG-b-POM/DOX or POEG-b-PPPMP/DOX micelles at the same dose of 5mg DOX/kg. Values 
reported are the means ± SEM, n=5. P values were generated by two-way ANOVA using the Tukey test for multiple 
comparisons. *P < 0.05, *** P < 0.001 (POEG-b-PPPMP/DOX vs DOX·HCl; 
&
P < 0.05 (POEG-b-POM/DOX vs 
DOX·HCl); 
###
P < 0.001 (POEG-b-PPPMP/DOX vs POEG-b-POM/DOX). 
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Table 3-3. Pharmacokinetic Parameters of DOX in Different Formulations. 




















POEG-b-PPPMP/DOX 16.19 180.16 27.60 0.56 12.97 
 
3.4.10  In Vivo Therapeutic Study 
 The in vivo tumor growth inhibition efficiency of POEG-b-PPPMP/DOX micelles was 
investigated in a highly aggressive syngeneic murine breast cancer model (4T1.2, s.c. at 
mammary fat pad). As expected, the control carrier alone (POEG-b-POM) showed minimal 
antitumor activity (Figure 3-15A). POEG-b-PPPMP alone exhibited a modest but significant 
(P<0.05) tumor inhibition effect. Doxil formulation and POEG-b-POM/DOX showed 
comparable and enhanced tumor inhibitory effect. Among all treatment groups, POEG-b-
PPPMP/DOX was most effective in inhibiting the tumor growth. Figure 3-15 B&D show the 
weights and images of tumor tissues that were collected at the end of the experiment, which was 
consistent with data of tumor growth curves (Figure 3-15A). There were slight increases in body 
weights in all groups over the period of study, suggesting the negligible toxicity of POEG-b-
PPPMP/DOX micelles in vivo (Figure 3-15C).  
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Figure 3-15. Antitumor activity of blank POEG-b-POM, blank POEG-b-PPPMP micelles, Doxil, DOX loaded 
POEG-b-POM and DOX loaded POEG-b-PPPMP micelles in a syngeneic murine breast cancer model 
(4T1.2). 
Three injections were given on day 1, 4 and 7. (B) Weights of tumors collected from different groups at the end of 
experiment. (C) Changes of body weight in mice receiving different treatments. (D) Photographs of tumors collected 
from different treatment groups at the end of experiment. Values reported are the means ± SEM, n = 5. P values 
were generated by one-way ANOVA using the Tukey test for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 
0.001 (vs control). 
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3.4.11  Histochemical Staining 
Histological analysis was conducted to further evaluate the therapeutic effect of POEG-b-
PPPMP/DOX formulation. As shown in Figure 3-16, tumors treated with DPBS or POEG-b-
POM carrier alone exhibited abundant aggregates of neoplastic cells with conspicuous nucleoli 
and scant cytoplasm due to high proliferation rate. In contrast, tumors that were treated with 
POEG-b-PPPMP/DOX showed significantly altered morphology with shrunken nuclei and the 
lowest tumor cell density.  
 
Figure 3-16. Histological analyses of tumor tissues collected from different groups at the end of in vivo 
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3.5 Discussion 
As a primary approach in cancer treatment, various classes of chemotherapeutic drugs are 
available in clinic. Regardless of the differences in the structures of the agents, their molecular 
targets, and the major mechanisms of action, the eventual onset of apoptosis seems to be a 
common consequence in chemotherapy-induced cell death. Ceramide, the central molecule in 
sphingolipids family, has recently been identified as a key mediator of this process and has 
attracted tremendous attention in cancer therapy[133]. Mounting evidence shows that most 
chemotherapeutic agents are capable of inducing endogenous ceramide accumulation through 
either activation of sphingomyelin catabolism and/or increases in de novo synthesis[91]. 
 
Various strategies have been developed to increase the intracellular levels of ceramides in 
tumor cells including intracellular delivery of exogenous ceramides, enhancement of ceramide 
synthesis, and inhibition of ceramide catabolism[99]. As a stand-alone strategy, the first two 
approaches are insufficient as the increased levels of ceramides are only short-lived due to 
activation of the ceramide catabolism pathways[91]. Importantly, many of the ceramide 
metabolites have the opposite effects of ceramides, playing an important role in tumor cell 
survival and drug resistance[112, 134, 135]. 
 
A number of pathways are involved in the catabolism of ceramides inside cells with GCS 
being the dominant mechanism for ceramide catabolism[136]. Drugs that cause increases in the 
intracellular levels of ceramides such as DOX, PTX and C6-ceramide itself, also induce 
upregulation of GCS expression. However, different types of tumor cells respond differently to a 
ceramide-generating drug (e.g., DOX) with respect to the extent of GCS upregulation. Our data 
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(Figure 3-1) show that GCS upregulation was much more dramatic in MCF-7 cells than in 4T1.2 
cells following treatment of DOX, PTX or C6-ceramide. Nonetheless, combination of a 
ceramide-generating drug with an inhibitor of GCS shall represent an effective strategy to 
improve the therapeutic outcome.  
 
PPMP is a small molecule drug that was initially known to inhibit the enzymatic activity 
of GCS. PPMP was later shown to be also effective in downregulating the mRNA expression 
levels of GCS in tumor cells (Figure 3-13). Our data show that PPMP effectively downregulated 
both basal and DOX-induced GCS mRNA levels in MCF-7 and 4T1.2 cells, which is consistent 
with what was found in other tumor cells [42,43]. Interestingly, PPMP appears to selectively 
upregulate the proapoptotic ceramide species while having minimal impact on those species that 
have no effect in promoting the apoptosis or even enhance the tumor cell proliferation (Figure 
3-12). The underlying mechanism is unclear and requires more studies in the future.  
 
As a strategy to faciliate the codelivery of PPMP and another ceramide-genertaiung 
anticancer agent, we initially developed a dual-functional carreir that is based on PEG-PPMP2. 
One issue with this system is the low number (2) of PPMP units in the carrier, which will limit 
the amounts of PPMP that can be delivered to tumor tissues. This led us to the developemnt of an 
improved nanocarrier, which is a POEG-b-PPPMP-based copolymer with significantly increased 
number of PPMP units (7) in each molecule of polymer. A PPMP monomer was first 
synthesized, which allows the use of a simple and well-controlled polymerization protocol to 
obtain well-defined POEG-b-PPPMP polymers. This approach has an obvious advantage of 
simplicity compared to the strategy of post-conjugation of PPMP following the synthesis of a 
  93 
polymer scaffold. It also avoids the issue of the presence of some remaining reactive groups in 
polymers after conjugation of PPMP. After synthesis, the formulation of blank or drug-loaded 
POEG-b-PPPMP could be prepared through a very simple film hydration method. In addition, 
POEG-b-PPPMP was effective in formulating a wide range of hydrophobic anticancer drugs of 
different structures. 
 
POEG-b-PPPMP well retains the pharmacological activity of free PPMP. POEG-b-
PPPMP exhibited comparable activity in downregulation of basal GCS mRNA expression 
(Figure 3-13), and similarly reversed the DOX-induced GCS upregulation as free PPMP (Figure 
3-13). More importantly, like free PPMP, POEG-b-PPPMP also selectively increased the 
accumulation of pro-apoptotic ceramides with negligible effect on anti-apoptotic ceramides 
species.  
 
POEG-b-POM was synthesized as a control carrier that has the same units of hydrophilic 
POEG and hydrophobic oleic acid (POEG15-b-POM7) compared to POEG-b-POM. 
Interestingly, DOX formulated in POEG-b-POM showed a relatively slower kinetics of drug 
release (Figure 3-9), longer stay in blood (Figure 3-14A), and more effective accumulation at 
tumor tissues (Figure 3-14B) compared to DOX formulated in the control carrier. This is likely 
due to a more effective interaction between POEG-b-PPPMP and DOX. In addition to 
hydrophobic interaction as seen with POEG-b-POM/DOX, the aromatic rings of PPMPs in 
POEG-b-PPPMP further interact with DOX through π-π stacking, resulting in an enhancement in 
the overall carrier/drug interactions.   
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POEG-b-PPPMP demonstrated significant antitumor activity both in vitro and in vivo. 
This is likely due to the release of active PPMP following delivery of POEG-b-PPPMP to tumor 
cells. Importantly, codelivery of DOX via POEG-b-PPPMP led to effective growth inhibition of 
4T1.2 breast tumor, much more effectively than Doxil and POEG-b-PPPMP/DOX. The 
improved antitumor activity of POEG-b-PPPMP/DOX over POEG-b-POM /DOX might be 
largely attributed to the synergistic action between the released PPMP from POEG-b-PPPMP 
and the codelivered DOX. The improved delivery of DOX via POEG-b-PPPMP-based carrier 
(Figure 3-14) may also play a role. 
In summary, we have developed a well-characterized POEG-b-PPPMP prodrug-based 
micellar nanocarrier that consists of 7 units of PPMP and 15 units of POEG for efficient delivery 
of water insoluble anticancer drugs. POEG-b-PPPMP well retained the biological ability of 
PPMP. DOX loaded in POEG-b-PPPMP micelles exhibited slow release kinetics in vitro as well 
as a sustained PK profile in mice. Combination of DOX with POEG-b-PPPMP led to inhibition 
of DOX-induced upregulation of GCS, increased accumulation of pro-apoptotic ceramides, and 
enhanced cytotoxicity towards tumor cells. More importantly, systemic administration of DOX 
formulated in POEG-b-PPPMP micelles resulted in significant inhibition of 4T1.2 breast tumor, 
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4.0 Pendant HDAC Inhibitor SAHA Derivatized Polymer as a Novel Prodrug Micellar 
Carrier for Anticancer Drugs 
4.1 Abstract 
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDACI) 
approved by FDA for the treatment of cutaneous T cell lymphoma, is a promising anticancer 
drug for various cancers with a unique mode of action. However, it demonstrates limited clinical 
benefits in solid tumors as a single drug. In order to achieve enhanced and synergistic co-
delivery of SAHA and Doxorubicin (DOX), a cleavable SAHA-based prodrug polymer (POEG-
b-PSAHA), consisting of hydrophilic poly(oligo(ethylene glycol) methacrylate) (POEG) blocks 
and hydrophobic SAHA segments, has been developed. POEG-b-PSAHA prodrug polymer was 
able to form spherical micelles with a diameter around 60 nm, and well retained the 
pharmacological activity of SAHA in either inhibiting the proliferation of tumor cells or 
inducing histone acetylation. DOX formulated in POEG-b-PSAHA-based micelles showed a 
sustained release profile. DOX-loaded POEG-b-PSAHA exhibited more potent cytotoxicity 
towards tumor cells than free DOX and DOX loaded in a pharmacologically “inert” nanocarrier, 
POEG-b-POM. Consistently, DOX/POEG-b-PSAHA formulation resulted in an improved 
therapeutic effect in vivo compared to free DOX, Doxil, or DOX formulated in POEG-b-POM 
micelles. These results suggest that SAHA-based prodrug micelles may serve as a dual 
functional carrier for combination strategies in epigenetic-oriented anticancer therapy. 
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4.2 Background 
Cancer development and progression is not only confined to genetic changes, but also 
involves epigenetic changes, leading to alterations in gene expression and cell phenotypes. 
Epigenetics is concerned with the heritable phenotypes based on changes in chromosome, as 
opposed to genetics, whose realm is on the basis of alterations in the primary DNA sequence 
[137, 138]. Alterations in the structure and modification status of chromatin represent powerful 
regulatory mechanisms for gene expression and genome stability [137]. The major epigenetic 
modifications in mammals, and particularly in humans, are DNA methylation and post-
translational histone modifications (acetylation, methylation, phosphorylation etc.) [139]. In the 
context of histone modifications, the acetylation status of histones plays a crucial role in 
regulating gene expression by affecting the accessibility of DNA around them [140]. Acetylation 
levels are controlled by the balance of two enzymes families: histone acetyltransferase (HAT) 
and histone deacetylase (HDAC). HAT facilitates the acetylation of lysine in histone tails, which 
is associated with a more relaxed chromatin state, opening up access for transcription factors and 
polymerases, and therefore gene-transcription activation. In contrast, HDACs deacetylate the 
lysine residues thereby promoting a more condensed chromatin state and hence leading to 
transcriptional gene silencing [141, 142]. Specially, the removal of the acetyl groups by HDACs 
also exposes the protonated amino groups of lysine units of histones, thereby increasing ionic 
interactions between the positively charged histones and negatively charged phosphate backbone 
of DNA, which yields a more compact chromatin structure and represses gene transcription by 
limiting the accessibility of the transcription machinery [142].  
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A growing body of evidence indicates that the silence of tumor suppressor genes caused 
by HDAC overexpression could be a common phenomenon in tumor onset and progression [143-
145]. Therefore, there is growing interest in the development of HDAC inhibitors (HDACi) as 
anticancer agents and a large number of studies demonstrated the potential of HDACi in different 
cancer cell lines and in animal models of tumors [146-148]. The oral drug Vorinostat, also 
known as SAHA (from suberoylanilide hydroxamic acid) was the first HDAC inhibitor approved 
by the U.S.  FDA in 2006 for the treatment of cutaneous T cell lymphoma in patients who have 
progressive, persistent or recurrent disease or following failure of two systemic therapies. It was 
also approved for multiple myeloma with slight advantage over Velcade®. SAHA is a pan-
HDAC inhibitor and inhibits both classes I and II enzymes but does not inhibit HDACs 
belonging to class III [146, 149]. SAHA acts as a micromolar inhibitor of HDACs by chelating 
the zinc atoms in HDAC catalytic sites via its hydroxamic end, with the phenyl ring protruding 
out of the binding pocket and lying on the hydrophobic surface of HDAC [150]. SAHA blocks 
the proliferation of cultured tumor cells and suppresses tumor growth in a variety of tumor 
models including prostate cancer [151], breast cancer [152], leukemia [153], glioma [154] and 
lung cancer [155] with little or no toxicity. 
 
Although SAHA has significant anticancer activity as a monotherapy in hematological 
malignancies, it demonstrates limited clinical benefit for patients with solid tumors, prompting 
the investigation of novel combination treatments with existing neoplastic interventions [156]. 
Besides, the acceptable toxicity profile of SAHA permits a broad integration into currently 
approved chemotherapy regimens [157-159]. Based on a mechanistic rationale, SAHA has been 
shown to be additive or synergistic with a wide array of anticancer drugs, including conventional 
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chemotherapeutics (doxorubicin, paclitaxel, cisplatin, gemcitabine, 5-fluorouracil and etoposide) 
[160-163], targeted agents (imatinib, bevacizumab and trastuzumab) [164, 165] and 
transcriptional modulators (all-trans retinoic acid and the demethylating agent 5-aza-2′-
deoxycytidine) [166]. One of the most significant combinations is with DNA damage-inducing 
therapies, which occurs, in part, through a SAHA-mediated increase in chromatin accessibility 
and downregulation of DNA repair [156]. Doxorubicin induces DNA strand breaks by binding to 
DNA, stabilizing the Topo II-DNA complex, and inhibiting the re-ligation of DNA strands 
during replication [167]. SAHA potentiates DOX-induced Topo II-mediated DNA damage, 
growth inhibition and cell death through the chromatin decondensation, facilitating the access of 
topo II inhibitors to their DNA substrate [158, 159]. Moreover, the synergy is further intensified 
by the effect of SAHA on the expression, regulation and activation of a variety of DNA repair 
and DNA damage response genes, like Ku70 [168]. 
 
Although the combination of SAHA and other anticancer agents helps, to some extent, 
achieve better treatment of cancer, the triumph of simple physical mixture of multiple drugs is 
largely hindered as a result of poor solubility, minimal distribution to tumor tissue, and 
suboptimal dose ratio [169]. Carrier-mediated combination therapy could offer some advantages 
to overcome the above challenges, including improved solubility and bioavailability of each 
drug, increased accumulation at tumor sites through EPR effect, synchronized and controlled 
pharmacokinetics of each drug and ratiometric dosing, that is, the ability to tailor the relative 
ratios of each agent based on its pharmacological disposition [170].  
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Among the commonly used drug delivery systems, polymers with diverse structures have 
been widely selected as the nanocarriers for hydrophobic anticancer drugs, including SAHA, 
DOX, and others. Several nanoscopic formulations of SAHA have been developed for parenteral 
administrations to improve the solubility and overall disposition profile. For example, PEG-b-
PLA block copolymer-based micelles have been employed as a carrier to encapsulate SAHA, 
and it was found that SAHA loaded in micelles provided sustained exposure and improved 
pharmacokinetics characterized by a significant increase in serum t1/2, AUC and mean residence 
time [171]. However, the use of a large amount of pharmacologically inert carriers may not only 
add to the cost but also imposes safety issue [172]. Prodrug polymer nanocarriers represent an 
effective strategy to reduce the amount of inert materials. More importantly, amphiphilic prodrug 
polymers self-assemble in aqueous solution and serve as dual-functional carriers to achieve the 
additive or synergistic effect with co-delivered anticancer drugs.  
 
In this study, we designed and synthesized SAHA-based prodrug polymer, denoted as 
POEG-b-PSAHA. These amphiphilic polymers could self-assemble into prodrug micelles and 
serve as nanocarriers for DOX delivery. The size and structure of POEG-b-PSAHA were 
characterized. Moreover, the in vitro pharmacological activity of POEG-b-PSAHA prodrug 
micelles was examined and compared with free SAHA. Finally, the antitumor activity of DOX-
loaded POEG-b-PSAHA micelles was investigated in a syngeneic breast cancer model. 
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4.3 Experiment Procedures 
4.3.1  Materials 
Aniline, N,N′-dicyclohexylcarbodiimide, 4-(dimethylamino)pyridine, hydroxylamine 
hydrochloride, 1-hydroxybenzotriazole hydrate, potassium carbonate, potassium hydroxide,  
vinylbenzyl chloride, 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid, 
oligo(ethylene glycol) methacrylate OEGMA (average Mn = 500), 2,2-Azobis(isobutyronitrile) 
(AIBN), trypsin-EDTA solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) and Dulbecco’s Modified Eagle’s Medium (DMEM) were all purchased from Sigma-
Aldrich (MO, USA). AIBN was purified by recrystallization in anhydrous ethanol. Monomethyl 
suberate was purchased from TCI (OR, USA).  DOX.HCl was purchased from LC Laboratories 
(MA, USA). Fetal bovine serum (FBS) and penicillin-streptomycin solution were purchased 
from Invitrogen (NY, USA.). Cell culture and animals were similarly handled as described 
before [55]. 
4.3.2  Synthesis of SAHA-monomer 
SAHA was synthesized following a published method [173]. 
Vinylbenzyl chloride (1.0 g, 6.6 mmol), succinic acid (7.7 g, 66.0 mmol, 10 equiv) and 
K2CO3 (4.5 g, 32.8 mmol, 5 equiv) were dissolved in 30 mL DMF and immersed into an oil bath 
at 90 °C. After 4 h, the mixture was filtered through cottons to remove excess amount of salt. 
The reaction was quenched by addition of excess amount of pure water and centrifuged to 
remove DMF. The precipitate was dissolved in DCM, and the crude product was purified by 
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column chromatography on silica gel eluted with ethanol/DCM (v/v, 1: 9) to give the Compound 
1 (1.4 mg, 91%). 
 
For the synthesis of SAHA-monomer, CDI (69 mg, 0.43 mmol, 1.2 equiv) was added in 
portions to a stirred solution of Compound 1 (100 mg, 0.43 mmol, 1.2 equiv) in DCM. After 
stirring for 10 min, the reaction mixture turned into light yellow color. TLC showed that the 
intermediate was formed, and then SAHA (94 mg, 0.36 mmol) was added to the mixture in 
portions. After 2 h, the reaction was complete as confirmed by TLC, and the reaction was 
quenched by the addition of the saturated sodium bicarbonate. The aqueous layer was extracted 
with DCM, washed with brine, and dried over MgSO4. The crude product was chromatographed 
on silica gel (ethyl acetate/hexane =2:1) to give SAHA monomer (125 mg, 69%).  
4.3.3  Synthesis of POEG macroCTA 
POEG macroCTA was synthesized and purified following a published literature [43]. 
4.3.4  Synthesis of POEG-b-PSAHA 
POEG macroCTA (150 mg, 0.02 mmol), SAHA-monomer (125 mg, 0.26 mmol, 13 
equiv), AIBN (1 mg, 0.0061 mmol, 0.3 equiv) and 2 mL dried 1, 4-Dioxane were added into an 
Schlenk tube and deoxygenated by free-pump-thawing for three times. The mixture was then 
protected under N2 and immersed into an oil bath at 90 °C. After 24 h, the reaction was quenched 
by immersing the tube into liquid nitrogen. The mixture was purified through three cycles of 
dissolution/precipitation in DCM/hexane and dried in vacuum to afford POEG-b-PSAHA 
(260mg, 96%). 
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4.3.5  Preparation and Characterization of DOX-loaded POEG-b-PSAHA Micelles  
The blank or DOX-loaded POEG-b-PSAHA micelles were prepared through the film 
hydration method. First, DOX.HCl was neutralized with 3 equivalents of triethylamine in a 
mixture of DCM/methanol (1:1, v/v). DOX (5 mg/mL) was then mixed with POEG-b-PSAHA 
(50 mg/mL in DCM) at various carrier/drug weight ratios. After removing the solvent by 
nitrogen flow, the thin film was formed, which was further dried under vacuum for 2 h to remove 
any trace of remaining solvent. Then the thin film was hydrated with PBS followed by vortexing. 
The blank micelles were similarly prepared. The average diameter and the size distribution of 
micelles were examined via a Zetasizer (DLS). The morphology of blank or DOX-loaded POEG-
b-PSAHA micelles was observed using transmission electron microscopy (TEM).  
 
The drug loading efficiency of DOX was examined by Waters Alliance 2695 Separations 
Module combined with Waters 2475 Fluorescence Detector (excitation, 490 nm; emission, 590 
nm; gain, 3; sensitivity (FUFS), 10 000) and high performance liquid chromatography (HPLC) 
respectively as described in previous publications [56]. Drug loading capacity (DLC) and drug 
loading efficiency (DLE) were calculated according to the following equation: DLC %= [weight 
of drug loaded/(weight of polymer used + weight of drug used)]×100%, DLE %= (weight of 
loaded drug/weight of input drug)×100 %. The colloidal stability of drug-loaded micelles with 
various carrier/drug molar ratios at 4°C was evaluated by following the changes in sizes of the 
particles or visible precipitates every hour in the first 12 h and daily after 12 h following sample 
preparation. 
 
  103 
The CMC of POEG-b-PSAHA was measured by fluorescence spectrometry using nile 
red as a fluorescence probe. Briefly, thirty microliters of nile red (0.05 mg/mL in DCM) were 
added to each tube and the solvent was removed by nitrogen flow. POEG-b-PSAHA micelles 
ranging from 6.1× 10
−5
 to 5 ×10
−1
 mg/mL were prepared with serial dilution as described above 
and then added into the tubes with nile red. The final concentration of nile red was kept at 6.0 × 
10
−7
 M. The micelles were vortexed and kept overnight at room temperature to reach the 
equilibrium of solubilization. The samples were excited at an excitation wavelength of 550 nm 
and fluorescence intensities were recorded at an emission spectrum from 600 to 700 nm. The 
peak intensities at 647 nm were plotted versus polymer concentrations. The CMC value was 
calculated as the cross-point where a sharp increase in fluorescence intensity was observed.  
 
The in vitro release of DOX from DOX-loaded POEG-b-PSAHA micelles was examined 
using a dialysis method. Briefly, two hundred and fifty microliters of DOX/POEG-b-PSAHA 
micelles or free DOX·HCl (0.5 mg DOX/mL) were transferred to clamped dialysis bags 
(MWCO 3500 Da) in triplicate and incubated in 50 mL PBS as release medium, with gentle 
shaking at 100 rpm at 37 °C. One milliliter of medium was withdraw and same volume of fresh 
medium was supplemented at 10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 48 and 72 h. DOX release 
from micelles was measured by fluorescence spectrometry at the excitation wavelength of 480 
nm and emission wavelength of 590 nm by Synergy H1 Hybrid Multi-Mode Microplate Reader 
(Winooski, VT). 
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4.3.6  In vitro Cytotoxicity Assay 
Cytotoxicity assay was performed with 4T1.2 mouse breast cancer cells, MCF-7 human 
breast cancer cells, and HCT-116 human colon cancer cells. 4T1.2 (1×10
3
 cells/well), MCF-7 
(5×10
3
 cells/well), or HCT-116 (2×10
3
 cells/well) cells were seeded in 96-well plates followed 
by 24 h of incubation in DMEM with 10% FBS and 1% streptomycin/penicillin. To evaluate the 
combinational effect of SAHA with other anticancer drugs, various concentrations of free 
SAHA, free DOX·HCl, or the combination of both were added in triplicate to cells and incubated 
for 48 h. To study the cytotoxicity of blank POEG-b-PSAHA micelles, cells were challenged 
with various concentrations of POEG-b-PSAHA micelles or free SAHA (in DMSO) at 
equivalent SAHA concentrations for 48 h. The cytotoxicity of DOX-loaded POEG-b-PSAHA 
micelles was also examined, in comparison to DOX.HCl and DOX loaded in a biologically inert 
polymer POEG-b-POM. Cells were treated with different DOX formulations of varied 
concentrations. Blank POEG-b-PSAHA or POEG-b-POM at concentrations equivalent to those 
of carriers in the corresponding DOX formulation groups, was also added into cells. Cells were 
incubated for 48 h and cell viability was determined by MTT assay. Briefly, ten microliters of 3-
(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) (5mg/mL in PBS) were 
added to cells. Following incubation for 4 h, the medium was removed and MTT formazan was 
solubilized by DMSO. The absorbance was measured by a microplate reader with wavelength at 
590 nm and reference wavelength at 620 nm. Untreated cells were used as a control. Cell 
viability was calculated as [(ODtreat -ODblank)/(ODcontrol -ODblank )×100%]. 
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4.3.7  Western Blot 
Western immunoblotting was conducted with 4T1.2 cells. Cells were treated with 0.1% 
DMSO (control) or indicated concentrations (1 M or 5 M) of SAHA or POEG-b-PSAHA, 
respectively. After 24 h treatment, cells were rinsed twice with ice-cold PBS and lysed by RIPA 
buffer. The lysates were centrifuged at 12,500 rpm for 10 min. Samples with equal amounts of 
total cellular proteins were subjected to sodium dodecylsulfate polyacryl amide gel 
electrophoresis (SDS-PAGE), followed by transferring to nitrocellulose membranes. The 
membranes were first blocked in 5% nonfat dry milk dissolved in DPBS with 0.1% Tween 20 
(PBST) for 1 h at RT, and then incubated with primary antibody at a final dilution of 1:1,000 in 
5% BSA in PBST overnight at 4 °C. After washing three times with PBST, the membranes were 
incubated with secondary antibody at a final dilution of 1:5,000 in PBST for 1 h at room 
temperature. After washing three times with PBST, bound antibodies were detected by 
chemiluminescence. Beta-actin was used as the loading control. Primary antibodies for AC-H3 
and AC-H4 were from Cell Signaling Technology (MA, USA) and the antibody for beta-actin 
was from Sigma-Aldrich (MO, USA). 
4.3.8  Plasma Pharmacokinetics 
For plasma pharmacokinetics, DOX/POEG-b-PSAHA micelles or free DOX.HCl was 
injected intravenously into tumor-free female CD1 mice at a DOX dose of 5 mg/kg, with five 
mice in each group. Blood samples were collected in heparinized tubes at designated time points 
(3min, 10 min, 30 min, 1 h, 2 h, 4 h, 8 h and 12 h) post injection. The samples were centrifuged 
at 12,500 rpm for 10 min at 4 °C and 20 μL of the supernatant were collected. Then 200 μL 
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methanol, containing 500 ng/mL daunorubicin as the internal standard, was added and vortexed 
for 3 min. The samples were centrifuged at 12,500 rpm for 10 min at 4 °C and 150 μL of the 
clear supernatant was collected and injected into HPLC for DOX analysis. 
4.3.9  In vivo Therapeutic Study 
The in vivo antitumor efficacy of the DOX loaded in POEG-b-PSAHA prodrug 
nanocarrier was tested in a syngeneic 4T1.2 mouse breast cancer model. Female BALB/c mice 
were s.c. inoculated with 4T1.2 cells at right mammary fat pad with 2×10
5
 cells/mouse. When 
the tumor sizes reached around 50 mm
3
, mice were randomly divided into five groups (n=5), and 
treated via tail vein injection with PBS, DOX.HCl, Doxil, DOX/POEG-b-POM or DOX/POEG-
b-PSAHA micelles at a DOX dose of 5 mg/kg on days 1, 4 and 7, respectively. Tumor sizes were 
measured with the digital caliper every three days following the initiation of the treatment and 
calculated by the formula: (L×W
2
)/2, in which L is the longest and W is the shortest in tumor 
diameters (mm). Data were plotted as the actual tumor volume. Body weights were also 
monitored for the indication of toxicity. On day 23 post injection, all mice were sacrificed and 
tumor tissues were collected for measurement of weights and photography. 
4.3.10  Statistical Analysis 
In vitro or in vivo data are presented as mean ± standard deviation (SD) or mean 
± standard error of mean (SEM), respectively. Statistical analysis was performed with two-tailed 
Student’s T test or one-way analysis of variance (ANOVA) for two groups or multiple groups, 
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respectively, followed by Turkey simultaneous post hoc test. In all statistical analyses, P < 0.05 
was considered statistically significant.  
4.4 Results and Discussion 
4.4.1  Effect of Combination of SAHA and DOX on Tumor Cell Proliferation 
The proliferation inhibitory effect of SAHA and DOX was examined in 4T1.2 and HCT-
116 cell lines. As shown in Figure 4-1A, SAHA or DOX inhibited the proliferation of 4T1.2 
cells in a concentration-dependent manner. It was also apparent that combination of the two 
agents led to enhanced cytotoxicity. A similar combinational effect was found in HCT-116 cells 
(Figure 4-1B). Combination index (CI) was then calculated to assess a potential synergism 
between SAHA and DOX, by the equation CI=(d1/IC501) + (d2/IC502), with d1 or d2 being the 
concentration of SAHA or DOX required to achieve 50% killing effect in co-treatment, while 
IC501 or IC502 being IC50 of SAHA or DOX in single treatment, respectively. The CI of SAHA 
and DOX combination were 0.67 and 0.84 in 4T1.2 and HCT-116 cells respectively, suggesting 
a synergism between the two drugs.  
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Figure 4-1. Synergistic effect between SAHA and DOX in inhibiting the proliferation of tumor cells. 
4T1.2 (A) or HCT-116 (B) cells were treated with various concentrations of free SAHA, free DOX or the 
combination of SAHA and DOX. After 48 h, the cytotoxicity was determined by MTT assay. The experiments was 
performed in triplicate and repeated three times. Data are presented as means ± SD. 
4.4.2  Synthesis and Characterization of the POEG-b-PSAHA Polymer 
We initially designed and synthesized a SAHA-based monomer by directly conjugating 
SAHA with methacryloyl chloride. The macro-chain transfer agent POEG was then synthesized 
by RAFT polymerization of hydrophilic OEGMA monomer, which was further used to initiate 
the polymerization of hydrophobic SAHA monomer. However, micelles formed from this 
polymer had a size around 160 nm (data not shown), which is suboptimal for EPR effect. In 
order to decrease the hydrodynamic size, we re-designed a new SAHA monomer by introducing 
an additional 4 carbon hydrophobic chain and another benzyl ring to SAHA (Figure 4-2). 
Vinylbenzyl chloride was linked to succinic acid, followed by the condensation reaction with 
SAHA to form a hydrolysable diester bond. Then RAFT polymerization was similarly performed 
as described above, yielding the amphiphilic POEG-b-PSAHA block copolymer. The structure 
of POEG-b-PSAHA polymer was confirmed by 
1
H NMR (Figure 4-3), and the average degree of 
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polymerization of the SAHA monomer was calculated. Each POEG-b-PSAHA molecule 
contained 12 units of SAHA. 
 




H NMR spectra of POEG-b-PSAHA polymer in CDCl3. 
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4.4.3  Characterizations of DOX-loaded POEG-b-PSAHA Micelles 
Blank or DOX-loaded POEG-b-PSAHA micelles were prepared by a simple film 
hydration method. Unlike the initial SAHA polymer that formed relatively large-sized micelles 
(~160 nm), the size of drug-free POEG-b-PSAHA micelles was significantly smaller (63.7 nm). 
This is likely due to more effective carrier-carrier interaction as a result of incorporation of 
additional 4 carbon hydrophobic chain and another benzyl ring to SAHA monomer. Loading of 
DOX into POEG-b-PSAHA micelles at a carrier/drug weight ratio of 20:1 only led to a slight 
increase in the particle size (~70 nm) (Figure 4-4B). TEM showed sphere shape with a uniform 
size distribution, which was consistent with DLS (Figure 4-4C, D). The size, DLC, and 
formulation stability of drug-loaded POEG-b-PSAHA micelles were then examined and listed in 
Table 1. DOX could be loaded into POEG-b-PSAHA micelles at a carrier/drug ratio as low as 
5/1 (mg/mg), at which ratio DOX loading capacity was 14.9 % and DOX-loaded micelles were 
stable for 5 days at 4 °C. With an increase in the carrier/drug ratio, the drug encapsulation 
efficiency and colloidal stability were further improved. As shown in Table 4-1, at a carrier/drug 
ratio of 50:1, DOX-loaded micelles were stable for 50 days at 4 °C. A carrier/drug mass ratio of 
20:1 and 5:1 was used for in vitro and in vivo study, respectively.  
Figure 4-5 shows that the CMC of POEG-b-PSAHA micelles was around 0.004 mg/mL 
(0.33 μM) as determined by a rapid change of fluorescence intensity of loaded nile red probe 
during serial dilution. This low CMC of POEG-b-PSAHA shall provide a good stability for the 
micelles upon dilution in blood stream after i.v. injection. 
 
  111 
 
Figure 4-4. Particle size distribution of blank POEG-b-PSAHA micelles (A) and DOX-loaded POEG-b-
PSAHA micelles (B). TEM images of blank POEG-b-PSAHA micelles (C) and DOX-loaded POEG-b-PSAHA  
micelles (D). Scale bar is 100 nm. 
Table 4-1. Physicochemical characterizations of DOX-loaded POEG-b-PSAHA micelles. 





















POEG-b-PSAHA:   63.7 ± 0.7 0.14 ± 0.01    
POEG-b-PSAHA: 
DOX 
5:1 78.4 ± 0.4 0.22 ± 0.01 14.9 89.3 5 d 
POEG-b-PSAHA: 
DOX 
10: 1 75.9 ± 0.6 0.18 ± 0.01 8.2 90.6 9 d 
POEG-b-PSAHA: 
DOX 
20:1 73.9 ± 0.9 0.26 ± 0.01 4.5 93.5 17 d 
POEG-b-PSAHA: 
DOX 
30: 1 79.7 ± 0.3 0.23 ± 0.01 3.0 92.3 32 d 
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POEG-b-PSAHA: 
DOX 
50:1 86.6 ± 0.2 0.20± 0.01 1.9 96.7 50 d 
a) 
DOX concentration in micelles was kept at 0.5 mg/mL. 
b)
 Measured by dynamic light scattering particle sizer. 
c)
 
PDI = polydispersity index. 
d)
 DLC = drug loading capacity. 
e)
 DLE = drug loading efficiency. f) Data mean there 




Figure 4-5. CMC of POEG-b-PSAHA micelles using nile red as a fluorescence probe. 
4.4.4  In vitro Drug Release 
The release profile of DOX loaded in POEG-b-PSAHA micelles in PBS was investigated 
by a dialysis method and compared to that of free DOX. As shown in Figure 4-6, around 50% of 
DOX was released from DOX.HCl in the first two hours and 85% of total DOX was released 
within 12 h. In contrast, less than 1% of DOX was released from the DOX-loaded POEG-b-
PSAHA micelles in the first hour and a relatively sustained release continued for 72 hours, with 
only around 30% of total drug released. The slow release kinetics might be due to strong carrier-
drug interaction, including hydrophobic interaction and π-π stacking, which shall provide a good 
stability of DOX/POEG-b-PSAHA in blood stream.  
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Figure 4-6. Cumulative DOX release profile from POEG-b-PSAHA micelles with free DOX as a control. 
PBS was used as the release medium. DOX concentration was fixed at 0.5 mg/mL. Values reported are the means ± 
SD for triplicate samples. *** P < 0.001 (POEG-b-PSAHA/DOX vs. free DOX). 
4.4.5  In vitro Cytotoxicity of Drug-Free or DOX-Loaded POEG-b-PSAHA Micelles 
To evaluate whether POEG-b-PSAHA prodrug micelles maintained the ability of SAHA 
to inhibit tumor cell proliferation, 4T1.2, MCF-7 or HCT-116 cells were treated with POEG-b-
PSAHA micelles or free SAHA (in DMSO) for 48 h. As shown in Figure 4-7A, free SAHA 
inhibited the proliferation of 4T1.2 tumor cells in a dose-dependent manner, while POEG-b-
PSAHA showed a comparable cytotoxicity. Similar results were shown in MCF-7 and HCT-116 
tumor cells (Figure 4-7B & C), suggesting that SAHA could be effectively released from POEG-
b-PSAHA via the cleavage of carbamide bond. 
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Figure 4-7. MTT cytotoxicity of POEG-b-PSAHA prodrug micelles in 4T1.2 mouse breast cancer cell line (A), 
MCF-7 human breast cancer cell line (B), and HCT-116 human colon cancer cell line (C) in comparison to 
free SAHA. 
Cells were treated for 48 h and values reported are the means ± SD for triplicate samples. **P < 0.01, ***P<0.01 
(POEG-b-PSAHA vs. SAHA).  
 
The in vitro cytotoxicity of DOX-loaded POEG-b-PSAHA micelles was also tested, in 
comparison with DOX.HCl and DOX loaded in pharmacologically “inert” POEG-b-POM 
micelles. POEG-b-PSAHA and POEG-b-POM carrier alone were included as controls and were 
used at the same concentrations as those used in drug-loaded micelles. As shown in Figure 4-8A, 
POEG-b-POM blank micelles showed minimal cytotoxicity even at the highest concentration (20 
μg/mL). In contrast, blank POEG-b-PSAHA micelles exhibited significant cytotoxicity, which 
was comparable to that of DOX.HCl. DOX loaded in POEG-b-PSAHA was more potent in 
killing tumor cells than DOX.HCl and DOX/POEG-b-POM formulation. Similar results were 
observed in MCF-7 and HCT-116 cells (Figure 4-8B & C). It is likely that the improved 
cytotoxicity of DOX/POEG-b-PSAHA is attributed to a synergistic action between DOX and 
SAHA that was released from the carrier following intracellular delivery.  
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Figure 4-8. MTT cytotoxicity assay of DOX-loaded POEG-b-PSAHA micelles in 4T1.2 (A), MCF-7 (B) and 
HCT-116 (C) tumor cells after 48 h treatment. 
Data are presented as the means ± SD for triplicate samples. *P<0.05, **P<0.01, ***P<0.001 (POEG-b-













P<0.001 (POEG-b-PSAHA/DOX vs. POEG-b-PSAHA). 
4.4.6  Effect of POEG-b-PSAHA on Histone Acetylation 
To investigate if the POEG-b-PSAHA-mediated cytotoxicity is attributed to the specific 
action of released SAHA, we examined the efficiency of POEG-b-PSAHA in modulating the 
acetylation of histone in 4T1.2 breast cancer cells by Western blot. As shown in Figure 4-9, the 
basal levels of acetylated H3 and H4 were very low. SAHA treatment at submicromolar 
concentrations for 24 h led to significant increases in their levels in a dose-dependent manner. 
Interestingly, POEG-b-PSAHA was comparable to or even more potent than free SAHA in 
inducing acetylation of H3 or H4 at the same concentrations of SAHA. These data indicated that 
POEG-b-PSAHA well retained the bioactivity of SAHA in inhibiting HDAC, resulting in the 
hyperacetylation of histone H3 and H4 and subsequently inhibition of cancer cell proliferation. 
The possible mechanism for the comparable or even further enhanced efficacy in histone 
acetylation is that POEG-b-PSAHA protected the hydroxamic acid of SAHA from hydrolysis 
and pharmacologically active SAHA was slowly released from the polymer over a prolonged 
period of time. On the other hand, free SAHA with unprotected hydroxamic acid may be 
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subjected to rapid metabolic conversion to inactive metabolites, SAHA-glucuronide and 4-
anilino-4-oxobutanoic acid [174].  
 
Figure 4-9. Effect of POEG-b-PSAHA prodrug micelles on expression of acetylated histone 3 (Ac-H3) and 
acetylated histone 4 (Ac-H4) compared to free SAHA. 
4T1.2 cells were treated with various concentrations of SAHA or POEG-b-PSAHA at an equivalent concentration of 
SAHA for 24 h. Western blotting was performed with total protein extracts using antibodies against acetylated H3 
and H4. Equal loading and transfer were verified by reproving the membranes for β-actin. 
4.4.7  Plasma Pharmacokinetics 
The DOX/POEG-b-PSAHA or DOX.HCl was injected into tumor-free mice at a DOX 
dose of 5 mg/kg. The plasma concentrations of DOX were examined at different time points. The 
initial concentration of POEG-b-PSAHA was around 1 mg/mL, which was 250-fold higher than 
its CMC (0.004 mg/mL). The concentrations of DOX in the blood following i.v. injection of 
different treatments as a function of time were illustrated in Figure 4-10. Compared to DOX.HCl 
group, the plasma concentrations of DOX from the group treated with POEG-b-PSAHA/DOX 
were significantly higher at early time points and maintained at relatively high levels until 12 h, 
which is likely attributed to the surface modification of PEG and stealth-shielding against RES 
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system. These data demonstrated that DOX formulated in POEG-b-PSAHA prodrug micelles 
was able to circulate for a significantly longer period of time in the blood. 
 
Figure 4-10. Plasma pharmacokinetics of DOX.HCl and DOX/POEG-b-PSAHA micelles in tumor-free female 
CD1 mice at the same dose of 5 mg DOX/kg. 
Values reported are the means ± SEM, n =5. 
4.4.8  In vivo Therapeutic Study 
Following the demonstration of a potential synergistic effect between POEG-b-PSAHA-
based carrier and the co-delivered DOX in cultured cancer cells, we then evaluated the tumor 
growth inhibitory effect of DOX/POEG-b-PSAHA in a highly metastatic syngeneic murine 
breast cancer model (4T1.2, s.c.). As shown in Figure 4-11A, free DOX exhibited a modest 
antitumor activity at a dose of 5 mg/kg. Doxil and DOX/POEG-b-POM formulations were more 
effective than free DOX. At the same dose of DOX, DOX/POEG-b-PSAHA was most effective 
in inhibiting the tumor growth (Figure 4-11A). Figure 4-11 B & D show the weights and images 
of tumor tissues collected at the end of the experiment, which were consistent with the result of 
tumor growth curves (Figure 4-11A). The significantly improved anti-tumor activity of 
DOX/POEG-b-PSAHA is likely attributed to the effective accumulation of the nanocarrier at 
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tumor sites due to its small size (~70 nm). The synergistic effect between the released SAHA and 
co-delivered DOX may also play an important role in tumor inhibition. More studies are needed 
in the future to further delineate the underlying mechanism. There were slight increases in body 
weights in all groups over the period of study, suggesting the negligible toxicity of DOX/POEG-
b-PSAHA micelles in vivo.  
 
Figure 4-11. Antitumor activity of DOX-loaded POEG-b-PSAHA micelles in 4T1.2 breast tumor model. 
(A) Antitumor activity of DOX.HCl, Doxil, DOX-loaded POEG-b-POM and DOX-loaded POEG-b-PSAHA 
micelles in female BALB/c mice bearing 4T1.2 breast tumor. Three injections were given on days 1, 4, 7 and each 
point represents the mean of actual tumor volume. (B) Weights of tumors collected from different groups at the end 
of experiment. (C) Changes of body weight in mice receiving different treatments. (D) Photographs of tumors 
collected from different treatment groups at the end of experiment. Values reported are the means ± SEM, n = 5. *P 
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4.5 Discussion 
In summary, we have developed a well-characterized POEG-b-PSAHA prodrug micellar 
nanocarrier, which consists of a hydrophobic segment composed of 12 SAHA-based units, and a 
POEG hydrophilic segment for efficient entrapment of DOX. Our POEG-b-PSAHA prodrug 
micelles well retained the biological activity of SAHA in inhibiting the proliferation of tumor 
cells and promoting the acetylation of histone H3 and H4. Besides, POEG-b-PSAHA was 
effective in formulating DOX and demonstrated a slow kinetics of drug release. More 
importantly, in vivo delivery of DOX via POEG-b-PSAHA led to significant inhibition of 4T1.2 
tumor, much more effectively than DOX.HCl, Doxil and DOX/POEG-b-POM. 
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5.0 Creatine Based Polymer for Codelivery of Bioengineered MicroRNA and Chemodrugs 
against Breast Cancer Lung Metastasis 
5.1 Abstract 
Metastasis is the major cause for breast cancer related mortality. The combination of 
miRNA-based therapy and chemotherapy represents a promising approach against breast cancer 
lung metastasis.  The goal of this study is to develop an improved therapy that co-delivers a 
novel bioengineered miRNA prodrug (tRNA-mir-34a) and doxorubicin (DOX) via a 
multifunctional nanomicellar carrier that is based on a conjugate of amphiphilic copolymer 
POEG-VBC backbone with creatine, a naturally occurring cationic molecule. Co-delivery of 
DOX leads to more effective processing of tRNA-mir-34a into mature miR-34a and down-
regulation of target genes. DOX+tRNA-mir-34a/POEG-PCre exhibits potent synergistic anti-
tumor and anti-metastasis activity in vitro and in vivo. Interestingly, the enhanced immune 
response contributes to the overall antitumor efficacy. POEG-PCre may represent a safe and 
effective delivery system for an optimal chemo-gene combination therapy. 
5.2 Backgrounds 
Breast cancer is the most common type of cancer and second cause of cancer-related 
mortality in women worldwide[175]. The main cause of death from breast cancer is metastasis, 
with lung, liver and bones as the major secondary target sites[176, 177]. Among different 
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subtypes of breast cancer, triple-negative breast cancer (TNBC) is notorious for its aggressive 
behavior and resistance to endocrine and anti-HER2 therapies[178]. Other than chemotherapy, 
treatments for metastatic TNBC are very limited[179]. Therefore, new and improved therapeutic 
strategies for metastatic TNBC are highly demanded.  
 
MicroRNAs (miRNAs or miRs) are short endogenous non-coding RNAs, responsible for 
post-transcriptional regulation of many target genes that are involved in cancer cell proliferation 
and tumor progression[180]. Due to the imperfect complementarity with target mRNAs, miRs 
are capable of regulating a broad set of genes simultaneously, which benefits the treatment of 
cancer as a heterogenic disease[181]. Therefore, there has been growing interest in developing 
miR-based therapies. In particular, expression levels of tumor suppressive miR-34a is usually 
downregulated in cancerous tissues, which could be reintroduced into cancerous tissues to 
achieve replacement therapy[182]. Recent studies revealed that the introduction of exogenous 
miR-34a into cancer cells induced cell apoptosis and inhibited cell proliferation and migration 
through targeting Bcl-2, CD44, SIRT1, Rac1, Fra-1, Notch-1, and various cyclins[183, 184]. In 
addition, miR-34a has been reported to sensitize breast cancer cells to first-line chemotherapies, 
such as doxorubicin (DOX), paclitaxel and 5-FU[185]. Moreover, a liposome-formulated miR-
34a, namely “MRX34”, has entered Phase I clinical trials for the treatment of unresectable 
primary liver cancer[186]. 
 
One major limitation for miR-based therapies is that the source of miRs has been limited 
to synthetic RNAs with artificial modifications, which raises concerns over the stability, cost, 
specificity and safety of these RNA-based therapeutics[187]. To improve the miR-based therapy, 
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we have recently developed a novel miR-34a prodrug, pre-miR-34a fused to a transfer RNA 
(tRNA), namely tRNA-mir-34a[188]. These bioengineered miRs are produced and folded in 
Escherichia coli in large scale with high yield, which can effectively maintain the function and 
safety properties of natural RNAs and therefore represent a new class of more affordable and 
biocompatible miR-based agents for research and therapy. Indeed, this tRNA-carried pre-miR-
34a was selectively processed into mature miR-34a in human carcinoma cells, resulting in 
reduced expression of the target genes and consequently the inhibition of cancer cell 
proliferation in vitro and in vivo[188]. However, the use of tRNA-mir-34a alone only exhibited 
modest effect against human lung cancer or hepatocarcinoma. The combination of tRNA-mir-
34a with DOX-based chemotherapy might work synergistically to increase the antitumor 
efficacy while minimizing the toxicity associated with each single treatment. In this study, we 
aimed to develop a nanocarrier for systemic co-delivery of tRNA-mir-34a and DOX to treat 
metastatic TNBC. 
 
Currently, a variety of delivery systems have been developed for gene delivery including 
viral carriers, peptides, liposomes and cationic polymers. Despite the high efficiency in gene 
delivery, viral vector-based therapies are limited by their safety concerns such as 
immunogenicity, and the difficulty of large-scale production[189, 190]. In contrast, non-viral 
nanocarriers have attracted increasing attention in nucleic acid delivery due to their favorable 
safety profiles and the ease of production[191]. In addition to nanocarriers designed exclusively 
for genes, there are growing interests in developing multi-functional nanocarriers that can 
simultaneously deliver multiple types of therapeutic payloads to disease sites in a targeted and 
controlled manner for combination therapy[192]. It has been suggested that the use of naturally 
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occurring molecules as building blocks of the nanocarriers is superior in achieving the properties 
of non-toxic, biodegradable, biocompatible and non-immunogenic[193-196].  
 
We herein developed a multi-functional delivery system based on an amphiphilic 
polymer (POEG-PCre) with a naturally occurring cationic molecule creatine attached to the 
pendent side chain, for the co-delivery of bioengineered tRNA-mir-34a and small molecule 
chemodrugs. The backbone of POEG-PCre (POEG-PVBC), which consists of hydrophobic alkyl 
main chains and pendent benzyl rings, forms the core of micelles to load hydrophobic anticancer 
drugs through hydrophobic-hydrophobic interaction and π-π stacking. Creatine was post-
conjugated to the backbone to introduce the positive charges, which further formed complexes 
with the negatively charged nucleic acids. In addition, the cationic creatine groups in the polymer 
can also facilitate the accumulation of nanoparticles in the lung tissue and thereby promote the 
subsequent interaction with tumor cells. That is because the lung is the first capillary bed 
encountered by cationic NPs after intravenous (i.v.) injection and therefore acts as the most 
effective target organ.[197] Also,  the lung tissue has been reported to be endowed with a much 
higher polyamine active uptake system than any other major organs,[198] which may benefit the 
targeted delivery of creatine-based nanocarrier with amine groups to the lungs. The excess 
amount of positive charges on the nanocarrier was shielded by PEG to improve in vivo stability 
of the system. We hypothesized that the co-delivery of tRNA-mir-34a and DOX via our multi-
functional nanocarrier represents a safe and effective approach for the treatment of metastatic 
TNBC. We first examined the biophysical properties of the nanocarrier co-loaded with DOX and 
tRNA-mir-34a. The efficiency of delivery and transfection was then examined both in vitro and 
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in vivo. Finally, the antitumor effect of DOX+tRNA-mir-34a/polymer as well as the underlying 
mechanism was investigated. 
 
5.3 Experiment Procedures 
5.3.1  Reagents 
DOX·HCl was purchased from LC Laboratories (MA, U.S.A). Creatine, 4-Cyano-4 
[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid, vinylbenzyl chloride (VBC) monomer, 
and oligo(ethylene glycol) methacrylate (average Mn = 500, OEG500), 2- 
Azobis(isobutyronitrile) (AIBN), trypsin-EDTA solution, 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl tetrazolium bromide (MTT) and Dulbecco’s Modified Eagle’s Medium (DMEM) were 
purchased from Sigma-Aldrich (MO, U.S.A). AIBN was purified by recrystallization in 
anhydrous ethanol. Opti-MEM medium, fetal bovine serum (FBS), Dulbecco’s phosphate 
buffered saline (DPBS), penicillin-streptomycin solution and TRIzol lysis reagent were 
purchased from Invitrogen (NY, U.S.A.). QuantiTect Reverse Transcription Kit was purchased 
from Qiagen (MD, U.S.A). All solvents used in this study were HPLC grade.  
5.3.2  Animals 
Female BALB/c mice (4–6 weeks) were purchased from Charles River (CA, U.S.A). All 
animals were housed under pathogen-free conditions according to AAALAC (Association for 
Assessment and Accreditation of Laboratory Animal Care) guidelines. All animal-related 
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experiments were performed in full compliance with institutional guidelines and approved by the 
Animal Use and Care Administrative Advisory Committee at the University of Pittsburgh.  
5.3.3  Cell Culture 
Mouse triple negative breast cancer cells 4T1.2 and human triple negative breast cancer 
cells MDA-MB-231 were cultured in DMEM medium supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37 °C in a humidified atmosphere with 5% CO2. All cell lines used in 
this work were obtained from ATCC (VA. U.S.A).  
5.3.4  Production of MiR-34a Prodrug 
The expression and purification of tRNA-mir-34a and control tRNA-MSA was carried 
out using a novel RNA bioengineering technology as described recently[188]. Briefly, 
recombinant RNAs were produced in HST08 E. coli and verified by denaturing urea (8 M) 
polyacrylamide (8%) gel electrophoresis (PAGE) analysis of total bacterial RNA isolated by 
phenol extraction. Target RNAs were isolated by an anion exchange fast protein liquid 
chromatography (FPLC) method[199] on a NGC QUEST 10PLUS FPLC system (Bio-Rad, CA, 
U.S.A). RNA concentrations were determined with a NanoDrop 2000 Spectrophotometer 
(Thermo Fisher Scientific, MA, U.S.A), and RNA purity was further determined by a high 
performance liquid chromatography (HPLC) assay. [188, 200] RNAs over 98% pure (by HPLC) 
were used in this study. 
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5.3.5  Synthesis of POEG-PVBC Polymer 
OEG500 (550 mg, 1.1 mmol), VBC monomer (600 μL, 4.27 mmol), 4-Cyano-4-
(phenylcarbonothioylthio) pentanoic acid (8 mg, 0.0286mmol), AIBN (3 mg, 0.0186 mmol), and 
1 mL of dried tetrahydrofuran were added into a Schlenk tube, and deoxygenated by free-pump-
thawing for three times. Then the mixture was filled with N2 and immersed into an oil bath 
thermostated at 82 °C to start the polymerization. After 16 h, the reaction was quenched, and the 
mixture was precipitated in hexane for 3 times. The product POEG-PVBC was obtained after 
vacuum drying. Conversion of OEG500 monomer was 66.0% and conversion of VBC monomer 
was 80.0%. 
5.3.6  Synthesis of POEG-PCre Polymer 
The POEG-PVBC polymer (270 mg) and creatine (1 g) were mixed in 15 mL anhydrous 
DMF with K2CO3 (1 g). After stirring at 80 °C for 36 h, the reaction mixture was cooled down 
and transferred into a dialysis bag (MWCO=3500 Da). After dialysis against a dilute 
hydrochloric acid solution for 1 day and deionized water for 3 days, the solution in the dialysis 
bag was centrifuged at 4,500 rpm for 12 min and the supernatant was lyophilized to give the 
POEG-PCre polymer.
 1
H NMR spectra were examined on a 600.0 MHz Bruker spectrometer 
using DMSO-d6 as the solvent. 
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5.3.7  Preparation of DOX+tRNA-mir-34a Co-formulated Micelles 
DOX solution was first prepared by dissolving DOX·HCl in DMSO containing 
triethylamine (5 equiv) overnight to remove HCl. DOX-loaded POEG-PCre micelles were 
prepared by the dialysis method. Briefly, 2 mg of polymer was dissolved in 200 L DMSO and 
mixed with 20 L of DOX solution (10 mg/mL). The mixture was then dialyzed against distilled 
deionized (DD) water using a dialysis bag (MWCO=3500) overnight to remove the unloaded 
free DOX. Drug-free micelles were similarly prepared without adding DOX solution. For tRNA-
mir-34a complexation, polymeric micelles were diluted to different concentrations in DD water 
and mixed with the equivalent volume of tRNA-mir-34a (in 10% of glucose) to obtain the 
desired N/P ratios. This nanocomplexes was allowed to incubate at RT for 20 min prior to further 
characterization. In vitro studies were performed with freshly prepared nanocomplexes. For in 
vivo studies, micelles and tRNA-mir-34a were first mixed in DD water for 20 min, and then 
lyophilized with glucose as a cryoprotectant.  
5.3.8  Physical Characterization of DOX+tRNA-mir-34a Co-formulated Micelles 
The particle size and zeta potential of different POEG-PCre micellar formulations were 
assessed by dynamic light scattering (DLS) via a Zetasizer (Nano-ZS 90, Malvern Instruments, 
Malvern, UK). The morphology of POEG-PCre blank micelles and gene-drug-coloaded micelles 
was observed by transmission electron microscopy (TEM). The micelles were mounted on a 
copper grid with nitrocellulose supporting film. The samples were negatively stained with 
phosphotungstic acid and dried at room temperature before examination. 
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To quantify the incorporated DOX, the fluorescence intensity (λex/λem= 480 nm/590 
nm) of DOX-loaded micelles and various known amounts of DOX dissolved in DMSO was 
measured with a SpectraMax M3 microplate reader (Molecular Devices, CA, U.S.A). The 
colloidal stability of POEG-PCre micellar formulations with various carrier/drug mass ratios at 
room temperature and 4°C was evaluated by following the changes in sizes of the particles or 
visible precipitates every hour in the first 12 h and daily after 12 h following sample preparation. 
 
The CMC of POEG-PCre micelles was determined by using nile red as a fluorescence 
probe as described previously[201].  
5.3.9  Gel Retardation Assay and Dextran Sulfate Replacement Assay 
tRNA-mir-34a/polymer complexes were prepared at different N/P ratios, ranging from 1 
to 40 (tRNA-mir-34a concentration was fixed at 0.02 mg/ml). The resulting nanocomplexes were 
then electrophoresed on a 2% agarose gel. The gels were prepared with 2% agarose in Tris-
acetate-EDTA (TAE) buffer containing 0.5 μg/mL ethidium bromide (Biotium, CA, U.S.A). For 
electrophoretic mobility shift analysis, samples were incubated at room temperature for 20 min; 
BlueJuice™ Gel Loading Buffer (10X) (Invitrogen, NY, U.S.A) was then added to the samples. 
Gel electrophoresis was carried out at 120 V for 20 min and the gel was subsequently visualized 
using a UV illuminator. Free tRNA-mir-34a was served as a control. The gel retardation of 
plasmid/polymer complexes and siRNA/polymer complexes at different N/P ratios were 
performed similarly. 
 
  129 
For replacement assay, tRNA-mir-34a/polymer complexes of various N/P ratios were 
first prepared. Dextran sulfate was then added to the samples with various S/P ratios (molar ratio 
between the sulfur from dextran sulfate and the phosphate from nucleic acid). The samples were 
then electrophoresed similarly as described above.  
5.3.10  Stability of DOX+tRNA-mir-34a Co-formulated Micelles 
Nanocomplexes were suspended in Dulbecco's phosphate-buffered saline (DPBS) of 
pH=7.4, BSA (30 mg/mL in DPBS) and RMPI 1640 with 10% FBS, respectively. The stability 
of nanocomplexes at various time periods (0, 1, 2, 4, 6, 8, 24 and 48 hours) was followed by 
examining their sizes via DLS. 
5.3.11  Release of DOX from POEG-PCre Micelles In Vitro 
The kinetics of DOX release from DOX/POEG-PCre or DOX+ tRNA-mir-34a/POEG-
PCre was performed according to a previous report[202].  
5.3.12  Cellular Uptake of DOX+tRNA-miR-34a/Polymer Complexes 
tRNA-mir-34a was labeled with fluorescent dye MFP488 using Label IT® miRNA 
Labeling Kits (Mirus Bio, WI, U.S.A). Cellular uptake of nanocomplexes carrying tRNA-mir-
34a
MFP488
 (green fluorescence) and DOX (red fluorescence) was evaluated by using confocal 
laser scanning microscopy (CLSM, FluoView 1000, Olympus, Japan). 4T1.2 cells were seeded 
in 6-well plates at a density of 2×10
4 
cells/well followed by 24 h of incubation in DMEM 
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/POEG-PCre, or DOX/POEG-PCre in 
Opti-MEM medium at a dose of 100 nM and 10 M for tRNA-mir-34aMFP488 and DOX 
respectively. Free DOX.HCl and naked tRNA-mir-34a
MFP488
 were used as controls. Four h later, 
the cells were washed three times with cold DPBS to remove the remaining nanocomplexes. Cell 
nuclei were then stained with Hoechst 33342 (1 μg/mL) at room temperature for 15 min. Cells 
were then washed with cold DPBS three times before observation under a confocal scanning 
microscope.  
5.3.13  Real-Time PCR 
Real-Time PCR (RT-PCR) was applied to evaluate the expression level of mature miR-
34a and its target genes Bcl-2 and PD-L1. Total RNA was extracted from cultured cells or frozen 
tumor tissues using Trizol reagent (Invitrogen, NY, U.S.A) following the protocols of the 
manufacturer.  
 
For miRNA expression analysis, 1 μg of total RNA was applied for reverse transcription 
to synthesize cDNA of miRNA using miScript PCR starter kit (Qiagen, MD, U.S.A). 
Quantitative real-time PCR was performed using miScript SYBR Green PCR Kit (Qiagen, MD, 
U.S.A) containing miScript Universal Primer (reverse primer) and QuantiTect SYBR Green PCR 
Master Mix on a 7900HT Fast Real-time PCR System. Relative miRNA levels were analyzed 
using delta-delta-Ct calculations and normalized to U6. Each sample was analyzed in triplicate. 
The primers were as follows: miR-34a: 5'-TGGCAGTGTCTTAGCTGGTTGT-3'’; U6: 5'- 
CGCAAGGATGACACGCAAATTC-3'; chimeric ncRNAs forward 5’-
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GGCTACGTAGCTCAGTTGGT-3’, chimeric ncRNAs reverse 5’-
TGGTGGCTACGACGGGATTC-3’; pre-miR-34a forward 5’-
GGCCAGCTGTGAGTGTTTCTTTGG-3’, pre-miR-34a reverse 5’-
GGGCCCCACAACGTGCAG-3’. 
 
For mRNA expression analysis, cDNA was generated from the 1 μg of total RNA using 
QuantiTect Reverse Transcription Kit (Qiagen, MD, U.S.A) according to the manufacturer’s 
instructions. Quantitative real-time PCR was performed using SYBR Green Mix on a 7900HT 
Fast Real-time PCR System. Relative target mRNA levels were analyzed using delta-delta-Ct 
calculations and normalized to GAPDH. The primers were as follows: mouse Bcl-2 forward 5'-
GTCGCTACCGTCGTGACTTC-3', mouse Bcl-2 reverse 5'-CAGACATGCACCTACCCAGC-
3'; human Bcl-2 forward 5'-GGTGGGGTCATGTGTGTGG-3', human Bcl-2 reverse 5'-
CGGTTCAGGTACTCAGTCATCC-3'; mouse Dicer forward 5'-
GGTCCTTTCTTTGGACTGCCA-3', mouse Dicer reverse 5'-GCGATGAACGTCTTCCCTGA-
3'; human Dicer forward 5'-CGAGCCTCCATTGTTGGTCCAC-3', human Dicer reverse 5'-
CCAGTTCGCCAATTTTGTGCAG-3'; mouse PD-L1 forward 5'-
GCATTATATTCACAGCCTGC-3', mouse PD-L1 reverse 5'-CCCTTCAAAAGCTGGTCCTT-
3'. 
5.3.14  Western Blot Assay 
Cultured cells or frozen tumors were harvested and lysed with RIPA lysis buffer (Thermo 
Fisher Scientific, MA, U.S.A) by gently shaking on ice for 30 min. After centrifugation at 12,500 
g for 10 min, the supernatants were collected and the concentrations of proteins were measured 
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using Pierce BCA Protein Assay Kit (ThermoFisher Scientific, MA, U.S.A). The protein samples 
were denatured by boiling for 5 min and loaded onto 10% SDS-PAGE gel for electrophoresis. 
The proteins were then incubated in blocking buffer (5% non-fat dry milk in TBST) at RT for 1 h 
after being transferred onto PVDF membranes (Bio-Rad, CA, U.S.A). The membranes were then 
incubated with anti-Bcl-2 or anti-PD-L1 antibody (Cell Signaling Technology, MA, U.S.A) in 
antibody dilution buffer (5% BSA in TBST) with gentle agitation overnight at 4°C. After 
washing with TBST for three times, the membranes were subsequently incubated with the 
secondary HRP-linked goat anti-rabbit IgG antibody (Cell Signaling Technology, MA, U.S.A) 
for 1 h at RT. After another three washes washing with TBST, the membranes were incubated 
with Pierce™ ECL Western Blotting Substrate (Thermo Fisher Scientific, MA, U.S.A) for 1 min, 
wrapped in plastic and exposed to X-ray film. Protein expression was normalized against 
GAPDH or β-Actin expression.  
5.3.15  In Vitro Cytotoxicity 
4T1.2 (1×10
3
 cells/well) or MDA-MB-231 (5×10
3
 cells/well) cells were seeded in 96-
well plates followed by incubation in DMEM with 10% FBS and 1% streptomycin/penicillin for 
24 h. Cells were then treated with various formulations including free DOX.HCl, DOX-loaded 
POEG-PCre micelles, DOX+ tRNA-MSA/POEG-PCre micelles, DOX+ tRNA-mir-34a/POEG-
PCre micelles, blank POEG-PCre micelles, tRNA-MSA/POEG-PCre micelles and tRNA-mir-
34a/POEG-PCre micelles. The former four DOX-containing groups were compared at various 
equivalent concentrations of DOX. The concentrations of POEG-PCre carrier in the last three 
DOX-free micelles were same as those of the carrier in DOX-loaded groups. After 48 h, MTT 
assay was performed as described before[202]. 
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5.3.16  Cell Apoptosis 
4T1.2 cells were seeded in 6-well plates at a density of 2×10
4 
cells/well followed by 24 h 
of incubation in DMEM containing 10% FBS and 1% streptomycin/penicillin. Cells were then 
treated with blank POEG-PCre micelles, tRNA-MSA/POEG-PCre micelles, tRNA-mir-
34a/POEG-PCre micelles, free DOX.HCl, DOX/POEG-PCre micelles, DOX+ tRNA-
MSA/POEG-PCre micelles or DOX+ tRNA-mir-34a/POEG-PCre micelles. All DOX-loaded 
groups contained the equivalent DOX concentration of 100 nM while the dose of tRNA-mir 
was100 nM of in all tRNA-miR complexed groups. After 48 h, cells were harvested, processed 
by using AnnexinV/propidium iodide (PI) apoptosis detection kit (BD), and subjected to flow 
cytometric analysis (FACSCalibur, BD, U.S.A).  
5.3.17  In Vivo Biodistribution 
Female Balb/c mice bearing 4T1.2 tumor lung metastasis were used to investigate the 
biodistribution of nanocomplexes. tRNA-mir-34a was labeled with MFP488 similarly as 
described above. Mice were injected with free DOX.HCl, DOX-loaded POEG-PCre micelles, 
tRNA-mir-34a
 MFP488
 loaded POEG-PCre micelles or DOX+ tRNA-mir-34a
 MFP488
-co-loaded 
POEG-PCre micelles through tail vein. Major organs including lung, liver, heart, spleen and 
kidney were harvest from mice at 1h post injection. Tissues were then embedded in OCT and 
frozen in liquid nitrogen. The specimens were cryosectioned into 5 μm sections. The signals of 
DOX and tRNA-mir-34a
 MFP488
 in different tissues were examined under a confocal microscope.  
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5.3.18  In Vivo Anti-tumor Efficacy and Safety Profile 
Female Balb/c mice at age of 4-6 weeks were injected with 4T1.2 cells (2×10
5
 in 100 μL 
DPBS) through the tail vein. Five days after tumor cell injection, mice were randomly divided 
into 7 groups (n=5). Mice were treated intravenously with DPBS, tRNA-MSA-complexed 
POEG-PCre micelles, tRNA-mir-34a-complexed POEG-PCre micelles, free DOX.HCl, DOX-
loaded POEG-PCre micelles, DOX+tRNA-MSA-co-loaded POEG-PCre micelles or 
DOX+tRNA-mir-34a-co-loaded POEG-PCre micelles, at a DOX dose of 5 mg/kg and a 
tRNA/mirs dose of 30 µg per mouse, respectively. The treatments were conducted every three 
days for a total of three times. Sixteen days after the first injection, all mice were sacrificed, and 
lung tissues were harvested, weighted and photographed. Pulmonary metastases were 
enumerated by intra-tracheal injection of India ink solution. India ink-injected lungs were 
washed in Feket’s solution (300 ml 70% EtOH, 30 ml 37% formaldehyde and 5 ml glacial acetic 
acid) and white tumor nodules against a dark blue lung background were counted. In addition, 
blood sample was collected, and serum was isolated after centrifuging at 12,500 rpm for 10 min. 
ALT, AST and creatinine levels in serum were measured. 
5.3.19  Histopathological Analysis 
Major organs including lung, liver, heart, spleen and kidney were harvested and fixed in 
10% formalin at the end of above treatments. The fixed samples were then embedded in paraffin 
and the tissue sections were performed with immunohistochemical analysis including H&E and 
Ki67 staining. H&E staining were performed for histological evaluation of the tumor nodules in 
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lungs, and Ki67 staining was carried out to evaluate the cell proliferation rate of the tumor cells. 
The toxicity of formulations was also assessed by H&E staining of several major organs. 
5.3.20  Immune Cell Infiltration Profile in Tumor-Bearing Lungs 
The immune cell population in tumor-bearing lungs with various treatments was 
conducted in an independent in vivo study. Mice received similar treatments as described in the 
therapeutic study. Twenty-four hours after the last injection, lungs and spleens were collected in 
serum free RPMI medium. Lungs were cut mechanically with scissors and digested with 
Liberase TL and DNase I. Tissues were further grinded and filtered through a 70 mm cell 
strainer with red blood cells lysed by ACK lysis buffer. TILs and MDSC cells were further 
purified and stained with fluorescence-labeled antibody for flow cytometry analysis using a 
FACS flow cytometer according to a previous report[203]. 
 
 
5.3.21  Statistics 
In vitro or in vivo data are presented as mean ± standard deviation (SD) or 
mean± standard error of mean (SEM), respectively. Two-tailed Student’s T test or analysis of 
variance (ANOVA) was used to compare two groups or multiple groups, respectively. 
Significance was determined with Tukey simultaneous post hoc test. In all statistical analyses, 
P < 0.05 is considered statistically significant.  
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5.4 Results 
5.4.1  Synthesis of POEG-PCre Polymers 
The POEG-PCre polymer was synthesized by RAFT co-polymerization of OEG500 
monomer and VBC monomer, followed by conjugation with creatine (Figure 5-1). The 
1
H 
nuclear magnetic resonance (NMR) spectra of the POEG-PVBC and POEG-PCre were shown in 
Figure 5-2. The units of OEG and VBC were calculated to be 25 and 118, respectively, 
according to the monomer conversion. The conjugated units of creatine were calculated to be 47 
by comparing the characteristic signals at 4.12-4.8 (f), 5.07 (e), and 5.95-7.88 (c and d) ppm 
(Figure 5-2b). 
 
Figure 5-1. Synthesis of POEG-PCre polymer via RAFT co-polymerization of OEG500 monomer and VBC 
monomer, followed by conjugation with creatine. 




H NMR spectra of the a) POEG-PVBC and b) POEG-PCre polymers in DMSO-d6. 
 
5.4.2  Characterization of Micellar Nanoparticles 
POEG-PCre micelles were prepared by dialysis. As shown in Figure 5-3a, POEG-PCre 
copolymer self-assembled into spherical nanoparticles with a size around 180 nm as indicated by 
dynamic light scattering (DLS) and transmission electron microscopy (TEM). The critical 
micellar concentration (CMC) of POEG-PCre copolymer, determined using nile red as a 
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fluorescence probe,[202] was as low as approximately 0.05 mg/mL (3.0 μM) ((Figure 5-3b). The 
low CMC indicated the stability of POEG-PCre micelles upon dilution in the blood stream after 
i.v. injection. The DOX-loaded POEG-PCre micelles were similarly prepared. DOX could be 
incorporated into POEG-PCre micelles at a carrier/drug ratio of 5:1 (w/w) or higher (data not 
shown). A carrier/drug ratio of 10:1 was chosen for the subsequent studies due to the relatively 
high drug loading capacity and the excellent colloidal stability (stable for one month and two 
months at RT and 4°C, respectively). DOX-loaded POEG-PCre micelles were comparable to 
blank POEG-PCre micelles in size and morphology (Figure 5-3a).  
 
The surface zeta potential of POEG-PCre micelles was approximately +40 mV (Figure 
5-3e). We then tested whether the cationic micelles could form stable complexes with tRNA-mir-
34a via gel retardation assay. POEG-PCre micelles were mixed with tRNA-mir-34a at various 
N/P ratios (the number of nitrogen residues (N) in the cationic polymer per phosphate (P) of 
nucleic acids) from 1:1 to 40:1. As shown in Figure 5-3c, complete complexation of tRNA-mir-
34a by POEG-PCre polymer was achieved at an N/P ratio of 5:1 or greater. Accordingly, in 
Figure 5-3e, at N/P ratios of below 5, the net charges of nanocomplexes were negative with the 
particle sizes similar to that of blank micelles. At an N/P ratio of 5, a significant increase in 
particle size was observed with particle charges close to neutral. Interestingly, further increases 
in N/P ratios led to continuous increases in zeta potentials and decreases in particle sizes, 
suggesting gradual condensation of nucleic acid by POEG-PCre cationic polymer. In order to 
form more compact POEG-PCre/tRNA-mir-34a complexes as well as to overcome the 
neutralization by serum proteins, an N/P ratio of 20 was chosen for all subsequent studies. At this 
N/P ratio, the average size of the nanocomplexes decreased to around 120 nm (Figure 5-3a). In 
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addition, DOX loading had negligible effect on the size distribution, zeta-potential and nucleic 
acid binding ability of POEG-PCre micelles (Figure 5-3a, 1c, 1e). 
 
The binding ability of POEG-PCre to plasmid or siRNA was also investigated. Compared 
to complexation with tRNA-mir-34a, POEG-PCre polymer could form stable complexes with 
plasmid at a lower N/P ratio of 2.5:1 (Figure 5-4a). However, POEG-PCre polymer was not 
effective in complexing with siRNA at an N/P ratio as high as 80:1 (Figure 5-4b), suggesting that 
our POEG-PCre carrier was unique in forming complexes with nucleic acids with appropriate 
sizes and secondary structures including tRNA-mirs. To further investigate the interaction 
between POEG-PCre nanocarrier and tRNA-mirs, a competitive binding gel-shift assay with 
dextran sulfate was performed. As shown in Figure 5-3d, at an N/P ratio of 5:1, substantial 
amounts of tRNA-mir-34a began to be released from POEG-PCre nanocarrier or PEI at an S/P 
ratio (molar ratio between the sulfur from dextran sulfate and the phosphate from tRNA-mir-34a) 
of 5 or greater. When the N/P ratios reached 10:1 or higher, tRNA-mir-34a could not be replaced 
by dextran sulfate even at an S/P ratio as high as 80. In contrast, an obvious release of tRNA-
mir-34a was observed from PEI carrier at the corresponding N/P ratios. These data suggest that, 
in addition to electrostatic interaction as seen with PEI, other interactions, such as π-π stacking 
between the pendent benzyl rings of our polymer and the base π-systems of nucleic acids, might 
also contribute to a more stable nanocomplexing system.  
 
The release kinetics of DOX from DOX-loaded POEG-PCre micelles was investigated by 
dialysis against DPBS of pH 7.4 at 37 °C. As shown in Figure 5-3f, more than 80% of free DOX 
was diffused out of dialysis bag (MWCO=3500) in the first 4 h. On the contrary, only 16 % of 
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DOX was released from DOX/POEG-PCre micelles in first 4 h, and less than 40 % of DOX was 
released for an extended period of 96 h. POEG-PCre micelles co-loaded with DOX and tRNA-
mir-34a exhibited a comparable but slightly slower release profile compared with micelles 
loaded with DOX alone. 
 
We further examined the stability of our nanocomplexes in various solutions that mimic 
commonly used buffer, routine cell culture medium or serum (i.e. DPBS of pH 7.4, DMEM 
medium with 2% FBS or 30 mg/mL of BSA), respectively. As shown in Figure 5-3g, no 
aggregation of nanoparticles was observed in all tested solutions and all of the nanocomplexes 
showed minimal changes in sizes for up to 48 h. 
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Figure 5-3. In vitro biophysical characterizations of micelles. 
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a) Size distribution and morphology of blank micelles, tRNA-mir-34a complexed micelles, DOX-loaded micelles 
and micelles co-loaded with tRNA-mir-34a and DOX (carrier: drug = 10: 1, w/w; carrier: tRNA-mir-34a = 20: 1, 
N/P) were examined by DLS and TEM, respectively. Scale bar, 100 nm. b) CMC of POEG-PCre polymers 
determined from the plot of nile red fluorescence intensity. c) Gel retardation assay of tRNA-mir-34a/polymer and 
tRNA-mir-34a+DOX/polymer complexes at different N/P ratios. Samples were incubated for 20 min at room 
temperature before being loaded onto a 2% (w/v) agarose gel (120 V, 20 min). d) Dextran sulfate competitive 
binding gel electrophoresis assay for tRNA-mir-34a/vector complexes (N/P=5, N/P=10 and N/P=20) at various S/P 
ratios. The experiments were repeated three times. e) Particle sizes and zeta potentials of tRNA-mir-34a/polymer 
and tRNA-mir-34a+DOX/polymer complexes formed at different N/P ratios. f) In vitro drug release profiles of 
DOX from DOX/POEG-PCre and DOX+tRNA-mir-34a/POEG-PCre in comparison with free DOX diffusion in 
DPBS at 37°C. g) The stability of blank micelles, tRNA-mir-34a complexed micelles, DOX-loaded micelles and 
micelles co-loaded with tRNA-mir-34a and DOX was examined by incubating nanocomplexes with DPBS 
(pH=7.4), DMEM with 2% FBS or BSA (30mg/mL) at room temperature. Changes in sizes of the complexes were 
followed by DLS. Data are means ± SD (n=3). 
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Figure 5-4. a) Gel retardation assay of EGFP plasmid/POEG-PCre complexes at different N/P ratios. b) Gel 
retardation assay of siRNA/ POEG-PCre complexes at different N/P ratios. The experiments were repeated 
three times. 
5.4.3  Cellular Internalization of Nanocomplexes 
To monitor intracellular co-delivery of DOX and tRNA-mir-34a, tRNA-mir-34a was 
labeled with MFP488 fluorescent dye in order to visualize the cell uptake of tRNA-mir-34a 
along with red fluorescence of DOX. 4T1.2 cells were incubated for 4 h with micelle complexes 
carrying DOX and/or MFP488-labeled tRNA-mir-34a and then observed under a confocal 
microscope. Naked tRNA-mir-34a without any transfection agent was used as a negative control. 
As shown in Figure 5-5, DOX/POEG-PCre showed more DOX fluorescence signal compared to 
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free DOX at the same dose of DOX. Interestingly, the DOX+tRNA-mir-34a
MFP488
 co-loaded 
POEG-PCre micelles showed even more uptake of DOX than that of the DOX/POEG-PCre 
micelles, which might be due to a more condensed structure after complexation with tRNA-mir-
34a, leading to higher endocytosis efficiency. Overlay of DOX (red) and tRNA-mir-34a
MFP488
 
(green) generated the yellow signals in the merged channel, suggesting the co-localization of 
DOX and tRNA-mir-34a
MFP488
 inside tumor cells. In addition, fluorescence signals of both DOX 
and tRNA-mir-34a
MFP488
 were present in the perinuclear regions of the cytoplasm in 
nanocomplexes treated groups, while the DOX fluorescence signals in free DOX treated group 
were profoundly observed in the nucleus overlapping with Hoechst staining (blue).  These data 
suggest different cellular uptake routes of free DOX and DOX-loaded micelles, through passive 
diffusion and endocytosis, respectively. 
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Figure 5-5. Internalization and colocalization of DOX+tRNA-mir-34a
MFP488
/POEG-PCre in 4T1.2 breast 
cancer cells at 4h post incubation was monitored by confocal microscope. 
From left to right: MFP488-labeled tRNA-mir-34a (green); DOX (red); nuclear staining with Hoechst 33342 (blue); 
an overlay of MFP488, DOX and Hoechst. The experiments were repeated three times. 
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5.4.4  Generation of Mature MiR-34a and Suppression of Target Gene Expression 
The processing of tRNA-mir-34a into mature tumor suppressor miR-34a was evaluated 
by quantitative RT-PCR. As shown in Figure 5-6a, there was over a 200-fold increase in the 
amount of mature miR-34a in 4T1.2 cells after treatment with tRNA-mir-34a/POEG-PCre 
nanocomplexes. Interestingly, significantly greater amounts of mature miR-34a (~1200-fold 
increase) were found in cells treated with the DOX+tRNA-mir-34a co-loaded POEG-PCre 
micelles. This is unlikely due to the differences in the amounts of tRNA-mir-34a delivered 
intracellularly since comparable levels of MFP488 fluorescence were found for the two groups 
(Figure 5-6). Consistently, Figure 3b shows that the amounts of chimeric ncRNA scaffold inside 
4T1.2 cells were similar after treatment with either POEG-PCre/tRNA-mirs or POEG-
PCre/DOX+tRNA-mirs, suggesting comparable efficiency of delivery of the two formulations. 
Rather it might be due to a more efficient processing of tRNA-mir-34a in cells following co-
delivery of DOX. Figure 5-7 shows that treatment with free DOX or DOX-loaded POEG-PCre 
micelles led to the induction of Dicer, an RNase III enzyme involved in pre-miRs cleavage, in a 
dose-dependent manner. As a result, the level of pre-miR-34a in DOX+tRNA-mir-34a/POEG-
PCre-treated cells was significantly lower than that in cells treated with tRNA-mir-34a/POEG-
PCre, suggesting a more complete processing of pre-miR-34a into mature miR-34a as a result of 
the co-delivered DOX (Figure 5-6c).  Similar trends were observed in MDA-MB-231 cells 
(Figure 5-6a-c; Figure 5-7).  
 
The anti-apoptotic Bcl-2 has been previously identified as a downstream target of miR-
34a.[204] The expression of Bcl-2 was then evaluated at both the transcript and protein levels 
after intracellular delivery of tRNA-mir-34a. tRNA-MSA (Sephadex aptamer tagged methionyl-
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tRNA), the sole tRNA scaffold, was used as a control. As shown in Figure 5-6d, the mRNA 
expression levels of Bcl-2 in cells treated with blank POEG-PCre micelles, tRNA-MSA/POEG-
PCre micelles, free DOX, DOX/POEG-PCre micelles or DOX+tRNA-MSA/POEG-PCre 
micelles were similar to that of untreated control cells, suggesting that POEG-PCre carrier, 
tRNA-MSA and DOX had minimal regulatory effects on the expression of Bcl-2. In contrast, 
significant down-regulation of Bcl-2 expression was observed in the tumor cells treated with 
POEG-PCre/tRNA-mir-34a or the co-loaded formulation. Consistently, the downregulation of 
Bcl-2 was reaffirmed at the protein level by Western blotting (Figure 5-6e). Importantly, the 
down-regulation of Bcl-2 was more significant in cells treated with the co-loaded formulation 
than cells treated with POEG-PCre/tRNA-mir-34a. Similar results were found in MDA-MB-231 
cells (Figure 5-6d and e).  
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Figure 5-6. Restoration of mature miR-34a down-regulates Bcl-2 expression in 4T1.2 and MDA-MD-231 
cancer cells after treatment with different formulations. 
Cells were harvested at 48 h after treatment. a-c) Mature miR-34a (a), chimeric ncRNA 
(b) and pre-miR-34a (c) expression levels were detected by RT-PCR. d) The mRNA expression 
of Bcl-2 was quantitatively analyzed by RT-PCR. e) The protein expression of Bcl-2 was 
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evaluated by Western blot. Data are means ± SD (n=3). P values were generated by one-way 
ANOVA using the Tukey test for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Figure 5-7. The mRNA expression of Dicer in a) 4T1.2 and b) MDA-MB-341 cells after treatment with 
various doses of DOX-containing formulations evaluated by RT-PCR. 
5.4.5  MTT Assay, Apoptosis Assay and Cell Migration 
The in vitro cytotoxicity of DOX+tRNA-mir-34a co-loaded POEG-PCre micelles was 
evaluated by MTT assay. Tumor cells were treated with various formulations for 48 h, with the 
doses of DOX, tRNA-mirs, and POEG-PCre carrier ranging from 7.8 to 1,000 ng/mL, 0.78 nM 
to 100 nM, and 78 ng/mL to 10000 ng/mL, respectively. As shown in Figure 5-8a, no obvious 
cell growth inhibition was noticed in cells treated with POEG-PCre nanocarrier alone or tRNA-
MSA loaded POEG-PCre micelles, even at the concentration of the polymer as high as 10 
μg/mL. TRNA-mir-34a/POEG-PCre micelles showed a moderate level of cytotoxicity at high 
concentrations. Free DOX inhibited the proliferation of tumor cells in a dose-dependent manner 
and the cytotoxicity of DOX/POEG-PCre was comparable to that of free DOX. Incorporation of 
tRNA-MSA into DOX/POEG-PCre micelles showed minimal impact on the overall cytotoxicity 
of the co-loaded formulation.  In contrast, incorporation of tRNA-mir-34a into DOX/POEG-
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PCre micelles led to a significant enhancement in the cytotoxicity of nanocomplexes on 4T1.2 
cells, indicating the synergistic effect between co-delivered tRNA-mir-34a and DOX via our 
POEG-PCre system. A similar trend was also observed in MDA-MB-231 breast cancer cells 
(Figure 5-8a). 
 
We then assessed the enhanced cytotoxicity of DOX+tRNA-mir-34a-co-loaded 
nanocomplexes via apoptosis assay. Cell apoptosis was evaluated quantitatively by Annexin 
V/propidium iodide flow cytometry. As shown in Figure 5-8b, few apoptotic cells were detected 
in control cells or cells treated with POEG-PCre carrier alone or tRNA-MSA loaded 
nanocomplexes, which was in agreement with the results of MTT assay. An increase in cell 
apoptosis (~21%) was observed in cells treated with tRNA-mir-34a loaded nanoparticles, 
suggesting that increased expression of mature miR-34a after delivery of tRNA-mir-34a into 
tumor cells can trigger the apoptosis of breast cancer cells due to the tumor suppressor functions 
of miR-34a. Free DOX, DOX/POEG-PCre and DOX+tRNA-MSA/POEG-PCre were 
comparable in inducing cell apoptosis to a significantly higher level (~31%). Importantly, a 
significantly higher percentage of necrosis (~ 13%), in addition to much greater degree of late 
apoptosis (~20%) and comparable level of early apoptosis, was obtained in cells treated with 
DOX+tRNA-mir-34a co-loaded formulation, which confirms a potent synergy between tRNA-
mir-34a and DOX in inducing apoptosis and necrosis.  
 
Besides cancer cell viability, cell migration is a critical process for tumor progression and 
metastasis. MiR-34a was reported to be functional as an anti-metastatic miRNA by directly 
targeting CD44 and NOTCH-1.[184, 205] Therefore, we investigated the effects of tRNA-mir-
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34a and DOX co-loaded nanocomplexes on the cell migration using the wound closure assay. As 
shown in Figure 5-8c and Figure 5-9, the wounded area was substantially repopulated by highly 
aggressive 4T1.2 cancer cells after 24 h in groups with no treatment or treated with POEG-PCre 
nanocarrier alone or tRNA-MSA loaded nanocomplexes. Significant inhibition (~75%) of cell 
migration was observed in cells treated with tRNA-mir-34a/POEG-PCre.  Three DOX-containing 
formulations (free DOX, DOX/POEG-PCre or DOX+tRNA-MSA/POEG-PCre) had comparable 
potency with a modest inhibition of ~40 %. In contrast, the DOX/tRNA-mir-34a-co-loaded 
group was most effective in inhibiting the migration of cancer cells; the denuded area was well 
retained with only 4.9 % of repopulated cells. 
  152 
 
Figure 5-8. In vitro antitumor efficacy. 
a) Cell cytotoxicity of 4T1.2 and MDA-MD-231 cancer cells treated with different formulations after 48 h. Data are 
means ± SD (n=3).  b) Cell apoptosis of 4T1.2 cells detected by flow cytometry using an AnnexinV-FITC/PI 
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apoptosis detection kit after 48 h. c) Inhibition migration of 4T1.2 cells examined by wound healing assay after 24 h. 
The experiments were repeated three times. 
 
Figure 5-9. Quantitative determination of cell migration of 4T1.2 cells after 24 h. 
Data are means ± SD (n=3). P values were generated by one-way ANOVA using the Tukey test for multiple 
comparisons. **P < 0.01, ***P < 0.001. 
5.4.6  In Vivo Biodistribution 
To gain insight into the biodistribution of nanocomplexes, the fluorescence signals of 
DOX and MFP488-labeled tRNA-mir-34a in tissue sections were examined by confocal 
microscopy. As shown in Figure 5-10, substantial amounts of fluorescent signals of both DOX 
and MFP488 were detected in lungs treated with DOX+tRNA-mir-34aMFP488 co-loaded 
micelles. The yellow color in the merged channel indicated the co-localization of DOX and 
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signals were observed in other major organs (Figure 5-11), suggesting that POEG-PCre 
nanocarrier is particularly suitable for targeted co-delivery of DOX and tRNA-mir-34a to lungs, 
which may benefit the prevention and treatment of breast cancer lung metastasis.  
 
Figure 5-10. Biodistribution of nanocomplexes in tumor-bearing lungs. Balb/c mice bearing 4T1.2 lung 
metastatic tumors were i.v. injected with DOX+tRNA-mir-34a
MFP488
/POEG-PCre nanocomplexes. 
Fluorescent signals in tumor-bearing lungs were examined after 1 h. The experiments were repeated three times. 
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Figure 5-11. Biodistribution of nanocomplexes in a) heart, b) spleen, c) liver and d) kidney. 
Balb/c mice bearing 4T1.2 lung metastatic tumors were i.v. injected with DOX+tRNA-mir-34aMFP488/POEG-PCre 
nanocomplexes. Fluorescent signals in major organs were examined after 1 h. The experiments were repeated three 
times. 
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5.4.7  In Vivo Therapeutic Study 
The in vivo anti-tumor efficacy of DOX+tRNA-mir-34a co-loaded nanocomplexes was 
evaluated in a breast cancer lung metastasis model, generated by tail-vein injection of 4T1.2 
tumor cells into female Balb/c mice. Five days after tumor inoculation, various treatments were 
applied to each group of mice (n=5) via i.v. administration every 3 days for 3 times (Figure 
5-12a). The tumor burdens in the lungs were analyzed 5 days after the last treatment. As shown 
in Figure 5-12b, c and h, tRNA-MSA loaded in POEG-PCre micelles showed negligible 
therapeutic effect compared to the control group. tRNA-mir-34a/POEG-PCre nanocomplexes 
exhibited a moderate inhibition of lung metastasis (P<0.05). Dramatic reduction in the number of 
tumor nodules in lungs was found in groups treated with free DOX, DOX/POEG-PCre or 
DOX+tRNA-MSA/POEG-PCre micelles. More importantly, POEG-PCre micelles co-loaded 
with DOX and tRNA-mir-34a was significantly superior to all other treatments in the inhibition 
of 4T1.2 tumor metastasis.  
 
Figure 5-12e showed that the levels of mature miR-34a was significantly and selectively 
upregulated in tumors treated with tRNA-mir-34a loaded micelles. In consistency to in vitro 
data, codelivery of tRNA-mir-34a and DOX via POEG-PCre micelles led to a further increase in 
the amounts of mature miR-34a likely due to the upregulation of Dicer expression by DOX-
containing formulations in vivo (Figure 5-13). Figure 5-12f, g showed that the expression levels 
of Bcl-2 in tumor tissues were significantly suppressed at both mRNA and protein levels 
following treatment with tRNA-mir-34a, particularly for the co-loaded formulation. To further 
evaluate the anticancer efficacy, H&E staining and immunohistochemical analysis of Ki67 were 
performed in tumor-bearing lungs. As shown in Figure 5-12i, H&E staining of lung tissues 
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showed clearly infiltration of tumor cells (with large nuclei) in all of the groups except the 
DOX/tRNA-mir-34a co-delivery group. In addition, DOX/tRNA-mir-34a co-delivery group 
showed the lowest number of Ki67-positive tumor cells (Figure 5-12j). Together, the above data 
clearly demonstrate a synergy between DOX and tRNA-mir-34a in the overall antitumor activity 
in the lung metastasis model.  
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Figure 5-12. Synergistic antitumor activity of tRNA-mir-34a and DOX co-delivered by POEG-PCre micelles 
in a mouse model of breast cancer (4T1.2) lung metastasis. 
a) Experimental scheme for the establishment of lung metastasis and treatment. b-c) Quantification of tumor nodules 
(b) and lung weights (c). d) Changes in mouse body weights during the treatment period. e-f) Quantification of 
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mature miR-34a (e) and Bcl-2 mRNA (f) in tumor-bearing lungs by RT-PCR.  g) Bcl-2 protein level was evaluated 
by Western blot. h) Representative images of lungs collected from mice receiving various treatments. i-j) H&E (i) 
and Ki67 (j) staining of lung tissues. Data are means ± SEM (n=5). P values were generated by one-way ANOVA 
using the Tukey test for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Figure 5-13. Quantification of Dicer mRNA expression in tumor-bearing lungs harvested the end of in vivo 
therapeutic study by RT-PCR.   
Data are means ± SEM (n=5). P values were generated by one-way ANOVA using the Dunnett test for multiple 
comparisons to one control. ***P < 0.001. 
5.4.8  Safety Profile 
Compared to control or monotherapy, co-delivery of DOX and tRNA-mir-34a did not 
cause loss of body weight (Figure 5-12d) or any other signs of stress such as hunched posture 
and labored movement. In addition, blood chemistry tests were performed to evaluate the effect 
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measured blood biomarkers including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and creatinine were significantly altered by our therapies, indicating the 
absence of hepatic and renal toxicity. Moreover, the H & E staining of major organs was carried 
out to further evaluate the potential toxicity of different treatments. As shown in Figure 5-14d, 
there were signs of myocytolysis and myofibrillolysis with fibrils dearrangement in the heart 
sections in free DOX group. In addition, hepatocellular vacuolation was found in this group, 
suggesting possible cardiac and liver toxicities despite no significant alterations in ALT and AST 
levels. In contrast, no significant pathological changes were observed in the major organs in the 
groups treated with single-loaded or co-loaded nanocomplexes. These results suggested that 
POEG-PCre based formulations were well tolerated at the doses tested. 
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Figure 5-14. Safety profile of tRNA-mir-34a and DOX codelivered by POEG-PCre micelles in a mouse model.   
a-c) ALT (a), AST (b) and creatinine (c) level detected at the end of therapy. (d) H & E staining of major organs 
harvested at the end of therapy. Data are means ± SEM (n=5). 
 
5.4.9  Immune Cell Infiltration Profile in Tumor-Bearing Lungs 
Figure 5-15a, b and g showed that DOX treatment led to a significant increase in the 
numbers of CD4 and CD8 cells in the tumor-bearing lungs. DOX treatment also led to an 
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increase in the numbers of functional CD8 (IFN-γ+ CD8) cells (Figure 5-15c, h). However, the 
above changes were much more significant following the tRNA-mir-34a/DOX combination 
treatment (Figure 5-15a-c, g, h). Treatment with tRNA-mir-34a alone or tRNA-mir-34a/DOX 
combination reduced the numbers of PD1+ CD8 cells (Figure 5-15d, i) and T-regulatory cells 
(Tregs) (Figure 5-15e, j). Figure 5-15f and k show that the numbers of MDSC were significantly 
decreased following the tRNA-mir-34a/DOX combination treatment. There was a trend of 
decreases in the numbers of MDSC following the treatment with DOX alone.  
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Figure 5-15. Flow analysis of infiltration of immune cells in tumor-bearing lungs following various 
treatments. 




cells via tail vein. Five days later, mice were treated with tRNA-
MSA/POEG-PCre, tRNA-mir-34a/POEG-PCre, free DOX, DOX/POEG-PCre, DOX+tRNA-MSA /POEG-PCre and 
DOX+tRNA-mir-34a/POEG-PCre respectively for three times. T lymphocyte subsets isolated from lung tissues with 




 (b), IFN-γ positive 
intratumoural CD8 T cells (c), PD-1 positive intratumoural CD8 T cells (d), FoxP3+ Treg cells (e) and MDSC cells 





 (g), IFN-γ positive intratumoural CD8 T cells (h), PD-1 positive intratumoural CD8 T cells (i), 
FoxP3+ Treg cells (j) and CD11b+/Gr-1+ MDSC cells (k). The results are shown as the means ± SEM with 3 mice 
in each group. The experiments were repeated two times. P values were generated by one-way ANOVA using the 
Tukey test for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 5-16. PD-L1 mRNA and protein expression in tumor-bearing lungs harvested the end of in vivo 
therapeutic study. 
a) Quantification of PD-L1 mRNA expression in tumor-bearing lungs harvested the end of in vivo therapeutic study 
by RT-PCR.  Data are means ± SEM (n=5). P values were generated by one-way ANOVA using the Dunnett test for 
multiple comparisons to one control. *P < 0.05. b) PD-L1 protein level was evaluated by Western blot. 
5.5 Discussion 
We have developed a novel co-delivery system for DOX and miR-34a, which is based on 
a natural and endogenous cationic molecule—creatine. A primary function of creatine is to 
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athletes as an ergogenic aid to enhance anaerobic exercise performance[206]. Typically, creatine 
is produced endogenously or obtained through the diet at a rate of 1 g per day in young 
adult[207]. Excess amounts of creatine could be metabolized to creatinine and excreted through 
kidney[208]. Our carrier is a polymeric system in which creatine was post-conjugated to the 
polymer backbone via ester bond. The biodegradability of the polymer and the nontoxic nature 
of creatine may account for the excellent safety profile of our new nanocarrier as shown in 
Figure 5-12d and Figure 5-14. We further improved our DOX/miR-34a combination therapy via 
employing a bioengineered miR-34a prodrug that will be processed into mature miR-34a upon 
intracellular delivery. Currently miRNA replacement therapy is limited to the use of synthetic 
RNAs that are chemically modified to improve their stability[209]. Such modifications may alter 
the folding, biologic activities, and more importantly the safety profiles, such as the 
proinflammatory cytokine response.[210] In contrast, bioengineered miR-34a prodrug is folded 
in living cells, which may better maintain the functions and safety properties of natural miR-
34a[188].  
Besides the favorable safety, our creatine-based nanocarrier is also noted for its ability in 
co-delivery of both small molecule drugs and nucleic acid-based therapeutics. Generally, most 
chemotherapeutic drugs are poorly water-soluble, while miRNAs are polyanionic molecules with 
high water-solubility, instability and high molecular weight[211]. Most carriers reported so far 
are designed for delivery of either small molecule drugs or nucleic acid therapeutics alone[52, 
53]. Some carriers were developed for codelivery of the two different types of therapeutics but 
they often involved complicated preparation process[54]. POEG-PCre represents a simple 
nanocarrier for effective co-loading of small molecule drugs and nucleic acids-based 
therapeutics.  POEG-PCre readily self-assembles to form a hydrophobic core that allows 
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effective loading of hydrophobic drugs such as DOX. At the same time, the multiple positive 
charges from creatine at the interface of the POEG-PCre micelles facilitate the interaction with 
the negatively charged nucleic acids. Interestingly, the multivalent charge-charge interactions 
between the cationic polymer and nucleic acids may also serve as a simple approach to cross-link 
and stabilize the micelles[212, 213]. As a result, the size of tRNA-mir-34a complexed micelles 
(~120 nm) was much smaller than that of blank micelles or DOX-loaded micelles (~180 nm) 
(Figure 5-3a). In addition, DOX/tRNA-mir-34a-coloaded nanoparticles exhibited a slightly 
slower release kinetics compared to that of micelles loaded with DOX only (Figure 5-3f). 
 
Complexation of cationic polymers with large-sized nucleic acids such as plasmid DNA 
is known to lead to formation of compact particles, which involves structure arrangement and 
condensation of DNA[214]. On the other hand, cationic polymers tend to form loose complexes 
with short oligonucleotides due to their small lengths[215]. Accordingly, our POEG-PCre 
polymer readily formed stable complexes with plasmid DNA at N/P ratios above 2.5 but failed to 
do so with short siRNA at N/P ratio as high as 80 (Figure 5-4). Interestingly, tRNA-mir-34a 
appears to have an appropriate size (~ 200 nt) to form stable complexes with POEG-PCre 
polymer. It should be noted that POEG-PCre/tRNA-mir-34a complexes were more stable than 
PEI/tRNA-mir-34a complexes as evidenced by the fact that tRNA-mir-34a in POEG-
PCre/tRNA-mir-34a complexes was more resistant to the replacement by the negatively charged 
dextran sulphate compared to PEI/tRNA-mir-34a (Figure 5-3d). This is likely due to additional 
mechanisms of interactions between POEG-PCre and nucleic acids in addition to charge 
interactions.[216]  The backbone of POEG-PCre consists of hydrophobic alkyl main chains and 
pendent benzyl rings that can interact with the base π-systems of nucleic acids through 
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hydrophobic interaction and π–π stacking[217]. The enhanced interaction of our polymer with 
nucleic acids may help to improve the stability of polymer/nucleic acid complexes in the blood 
circulation.  
  
POEG-PCre was highly effective in mediating codelivery of tRNA-mir-34a and DOX to 
cultured tumor cells in vitro and pulmonary circulation in vivo. Creatine is a derivative of the 
guanidinium cation. Positively charged guanidinium group is able to form electrostatic 
association and bidentate hydrogen bond with anionic cell surface phosphates, carboxylates 
and/or sulfates to initiate the event of cellular entry[218]. This feature has been widely utilized to 
design several new guanidinium-rich transporter scaffolds to improve the performance of cell 
penetration for small molecules, peptides and genes[219]. The efficient intracellular delivery of 
tRNA-mir-34a and DOX (Figure 5-5) shall likely benefit from this multivalent effect. Following 
systemic administration, the creatine-based polymer may take advantage of the lung-enriched 
polyamine transporters to guide the targeted accumulation of nanocomplexes to lung 
tissues[198]. Indeed, a more predominant distribution of the nanocomplexes in the lungs was 
observed (Figure 5-10, Figure 5-11), which should be beneficial to the prevention and treatment 
of lung metastasis.  
 
Codelivery of DOX and tRNA-mir-34a via POEG-PCre-based nanoparticles led to an 
enhanced combinational effect both in vitro and in vivo. It is interesting to note that codelivery of 
DOX facilitates the processing of tRNA-mir-34a, resulting in increased levels of mature miR-
34a (P<0.001) (Figure 5-6a). The underlying mechanism is not clearly understood; however, our 
data suggest that DOX induced the expression of RNase III enzyme Dicer (Figure 5-7). It has 
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been reported that Dicer is required for activating the DNA damage response when double-strand 
DNA breaks and non-coding RNA is synthesized at the site of DNA damage[220]. Therefore, 
DOX may enhance the expression of Dicer through the DNA damage response. More studies are 
needed to better understand the underlying mechanism for the DOX-mediated enhancement of 
tRNA-mir-34a processing.  
 
The improved antitumor activity of DOX/tRNA-mir-34a-based therapy is likely 
attributed to various factors. Overexpression of miR-34a is effective in inhibiting the 
proliferation of cancer cells and inducing apoptosis. In addition, miR-34a sensitizes cancer cells 
to chemotherapeutic agents such as DOX. Our data further suggest a role of immune response in 
the overall antitumor activity of DOX/tRNA-mir-34a combination therapy. DOX was reported to 
trigger immunogenic cell death by promoting tumor infiltration of IL-17-secreting γδ T cells and 
enhancing the proliferation and activation of IFNγ-secreting CD8+ T cells in tumor draining 
lymph nodes[221]. Similar results were shown in our studies with a lung metastatic tumor model. 
However, treatment with DOX+tRNA-mir-34a co-loaded nanocomplexes resulted in even 
greater numbers of tumor-infiltrating CD4+, CD8+ and CD8+ IFN-γ+ CD8+ T cells (Figure 
5-15), which may be attributed to the effect of miR-34a on the down-regulation of PD-L1 
expression (Figure 5-16). In addition, the co-treatment led to significantly reduced numbers of 
MDSCs that are highly immunosuppressive and play an important role in suppressing the 
antitumor immunity. Therefore, our combination therapy helps to create an active tumor immune 
microenvironment that likely contributes to the overall antitumor activity.  
In summary, we have developed a novel nanocarrier (POEG-PCre) for co-delivery DOX 
and bioengineered miR-34a prodrug, based on the built-in blocks of naturally occurring cationic 
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molecule—creatine. Stable and nanosized micelles co-loaded with DOX and tRNA-mir-34a 
could be readily prepared and were highly effective in targeted delivery of payloads to lungs. 
Significantly improved antitumor activity was demonstrated with codelivery of DOX and miR-
34a prodrug in comparison with other control groups in a 4T1.2 lung metastasis model. POEG-
PCre may represent a simple and effective delivery system for an optimal chemo-gene 
combination therapy. 
 
  171 
6.0  Summary and Perspectives  
During my graduate study, I worked on several projects to develop multi-functional 
nanomicellar system for the combinational co-delivery of anticancer agents. We first improved 
our previous PEG-FTS conjugates dual-functional micellar system, through the incorporation of 
both reduction-responsive disulfide bond and drug-interactive motif Fmoc, to form a simple 
PEG5k-Fmoc-S-S-FTS2 system. Compared with PEG5k-Fmoc-FTS2, our novel system exhibited 
further strengthened drug loading capacity and colloidal stability. More FTS was freed from 
PEG5k-Fmoc-S-S-FTS2 in treated tumor cells compared to PEG5k-Fmoc-FTS2. After loading 
Paclitaxel (PTX) into PEG5k-Fmoc-S-S-FTS2 micelles, it showed more potent efficiency in 
inhibition of 4T1.2 tumor cell proliferation in vitro and in vivo than Taxol® and PTX-loaded 
PEG5k-Fmoc-FTS2.  
In order to increase the drug content from the prodrug-based carrier, we modified the 
structure and synthesis route of prodrug-based nanocarrier, from the conjugation of limited 
amount of hydrophobic drug with PEG to the polymerization of drug-based monomer. The 
increased units of hydrophobic drugs in each prodrug polymer could not only decrease the 
amounts of carrier materials in in vivo application by increase the drug loading capacity and 
micelle stability, but also provide better synergistic effect with loaded anticancer drugs. We 
applied this strategy to other two targeted therapeutics: PPMP (GCS inhibitor) and SAHA 
(HDAC inhibitor), and developed POEG-b-PPPMP and POEG-b-PSAHA respectively. POEG15-
b-PPPMP7 consists of 7 units of PPMP and well retained the biological ability of PPMP. 
Combination of DOX with POEG-b-PPPMP led to inhibition of DOX-induced upregulation of 
GCS, increased accumulation of pro-apoptotic ceramides, and enhanced cytotoxicity towards 
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tumor cells. More importantly, systemic administration of DOX formulated in POEG-b-PPPMP 
micelles resulted in significant inhibition of 4T1.2 breast tumor, much more effectively than 
Doxil and POEG-b-POM/DOX.  
POEG-b-PSAHA prodrug micellar nanocarrier consists of a hydrophobic segment 
composed of 12 SAHA-based units, and a POEG hydrophilic segment for efficient entrapment of 
DOX. Our POEG-b-PSAHA prodrug micelles well retained the biological activity of SAHA in 
inhibiting the proliferation of tumor cells and promoting the acetylation of histone H3 and H4. 
More importantly, in vivo delivery of DOX via POEG-b-PSAHA led to significant inhibition of 
4T1.2 tumor, much more effectively than DOX.HCl, Doxil and DOX/POEG-b-POM. 
To further improve the combination cancer therapy, we developed multifunctional 
cationic polymer for the co-delivery of small molecule drugs (for known targets) and nucleic 
acid therapeutics (for “undruggable” targets). we have developed POEG-PCre cationic polymer 
for co-delivery DOX and bioengineered miR-34a prodrug, based on the built-in blocks of 
naturally occurring cationic molecule—creatine. Significantly improved antitumor activity was 
demonstrated with codelivery of DOX and miR-34a prodrug in comparison with other control 
groups in a 4T1.2 lung metastasis model. POEG-PCre may represent a simple and effective 
delivery system for an optimal chemo-gene combination therapy. 
Although the biophysical property and antitumor efficacy of multifunctional nanocarriers 
for combination cancer therapy has improved progressively by the continuous creation and 
modification from previous systems, there still some issues remain unsolved.  
Firstly, Despite the passive targeting of nanoparticles to the tumor tissues, the majority of 
nanoparticles were still cleared by the RES system, resulting in short half-lives and unwanted 
micelle deposition in the liver and spleen. More accumulation of nanoparticles to the tumor sites 
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could be achieved by coating active targeting ligand to the surface of the micelles, such as folic 
acid[222], transferrin[223], RGD[224], whose receptors are highly expressed on tumor cells 
compared to normal cells. These modifications can potentially increase the targeting of micelles 
to tumor sites, as well as boost the binding to cells and subsequent internalization. Alternatively, 
stimuli-responsive polymeric micelles offer promising opportunities to trigger the micellar 
dissociation and drug release at tumor sites in response to specific external or internal stimuli, 
such as temperature, pH, ultrasound or enzymes, by including thermo- or pH-sensitive 
components.  
In addition, the size of polymeric micelles developed in my graduate research is still 
relatively large (60~200 nm). Further decrease the size of nanoparticles might contribute to 
better tumor penetration. It has been reported that the accumulation of sub-100 nm polymeric 
micelles in poorly permeable tumors largely depended on size, with only 30 nm micelles could 
penetrate tumors with hypovascular and hypopermeable characteristics (such as intractable 
pancreatic tumors)[225].  To further reduce the size of nanomicelles, the effort might be made to 
decrease the ratio of hydrophobic segment in the polymer molecule. However, more subtle 
modification is demanded to keep the balance between the smaller size and lower drug loading 
capacity.  
Moreover, in spite of shielding by PEG, there are a significant number of unanswered 
questions related to micelle stability. Generally, the overall stability of micelles formulation is 
suboptimal compared to other formulations. Crosslinking the core or the corona might be a 
promising strategy to enhance the colloid stability. Besides, our micelles were not fully evaluated 
in physiologically relevant media but only in water or aqueous buffer, which limited the 
predictability of the in vitro assay to the complex in vivo microenvironment. More stability 
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related tests should be done in serum, major protein constituents (e.g. albumin, globulins), blood 
or cells.  Additional questions relate to micelle stability during freeze-drying and re-constitution. 
These impact scalability and development of micelles for clinical use. Selection of suitable 
lyoprotectants and optimization of freeze-dry process cycles might be helpful to enhance the 
stability during the formulation and storage.  
Furthermore, due to limited time, sophisticated design and systemic optimization of each 
system was not fully explored before moving to the pharmacologic evaluation. More systematic 
studies on the structure-activity relationship of polymeric micellar systems are needed to better 
understand the mechanism of drug-carrier interaction and establish a stable micellar system with 
a high drug loading capacity.  
Last but not least, all systems developed in my graduate study have not been evaluated in 
human tumor cell line xenograft model or patient-derived xenograft (PDX) cancer models, which 
might compromise the translation from preclinical into clinical study[226, 227]. In addition, 
survival studies should also be performed to better evaluate therapeutic benefit of our systems. 
the These studies shall lead to the development of further improved micellar systems with 
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